{"articles": [{"pubmed_id": "33224541", "title": "Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections.", "authors": "J. Labrador, GJ. Hermida, R. Alvarez, V. Anso, P. de Vicente, M. Go\u00f1i, TJ. Gonzalez-Lopez", "publication_date": "2020-11-24", "keywords": ""}, {"pubmed_id": "33207600", "title": "The New ELN Recommendations for Treating CML.", "authors": "R. Hehlmann", "publication_date": "2020-11-20", "keywords": "ELN recommendations, blast crisis, chronic myeloid leukemia, diagnosis, monitoring, treatment, treatment-free remission"}, {"pubmed_id": "33180106", "title": "Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.", "authors": "E. Atallah, CA. Schiffer, JP. Radich, KP. Weinfurt, MJ. Zhang, J. Pinilla-Ibarz, V. Kota, RA. Larson, JO. Moore, MJ. Mauro, MWN. Deininger, JE. Thompson, VG. Oehler, M. Wadleigh, NP. Shah, EK. Ritchie, RT. Silver, J. Cortes, L. Lin, A. Visotcky, A. Baim, J. Harrell, B. Helton, M. Horowitz, KE. Flynn", "publication_date": "2020-11-13", "keywords": ""}, {"pubmed_id": "33162495", "title": "[Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].", "authors": "T. Takaku", "publication_date": "2020-11-10", "keywords": "Chronic myeloid leukemia, Tyrosine kinase inhibitor, Vascular adverse events"}, {"pubmed_id": "33157925", "title": "Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report.", "authors": "D. Pilalas, T. Koletsa, G. Arsos, G. Panselinas, P. Exadaktylou, G. Polychronopoulos, C. Savopoulos, GD. Kaiafa", "publication_date": "2020-11-08", "keywords": ""}, {"pubmed_id": "33085860", "title": "Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.", "authors": "R. Fo\u00e0, R. Bassan, A. Vitale, L. Elia, A. Piciocchi, MC. Puzzolo, M. Canichella, P. Viero, F. Ferrara, M. Lunghi, F. Fabbiano, M. Bonifacio, N. Fracchiolla, P. Di Bartolomeo, A. Mancino, MS. De Propris, M. Vignetti, A. Guarini, A. Rambaldi, S. Chiaretti, ", "publication_date": "2020-10-22", "keywords": ""}, {"pubmed_id": "33074527", "title": "Precision medicine in acute lymphoblastic leukemia.", "authors": "CH. Pui", "publication_date": "2020-10-20", "keywords": "CAR T-cell therapy, acute lymphoblastic leukemia, immunotherapy, molecular therapeutics, targeted therapy, tyrosine kinase inhibitors"}, {"pubmed_id": "33068232", "title": "Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.", "authors": "UN. Karakulak, E. Aladag, V. Hekimsoy, ML. Sahiner, EB. Kaya, N. Ozer, S. Aksu, H. Demiroglu, H. Goker, Y. Buyukasik, O. Ozcebe, N. Sayinalp, IC. Haznedaroglu", "publication_date": "2020-10-18", "keywords": "Chronic myeloid leukaemia, Strain, Systolic functions, Tyrosine kinase inhibitor"}, {"pubmed_id": "33050945", "title": "The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.", "authors": "HR. Samimagham, M. Hassani Azad, M. Haddad, M. Arabi, D. Hooshyar, M. KazemiJahromi", "publication_date": "2020-10-15", "keywords": "COVID-19, Efficacy, Famotidine, Hospitalized, Randomised controlled trial, protocol"}, {"pubmed_id": "33050924", "title": "Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).", "authors": "A. Duvignaud, E. Lhomme, T. Pistone, R. Onaisi, R. Sitta, V. Journot, D. Nguyen, N. Peiffer-Smadja, A. Cr\u00e9mer, S. Bouchet, T. Darnaud, D. Poitrenaud, L. Piroth, C. Binquet, JF. Michel, B. Lef\u00e8vre, D. Lebeaux, J. Lebel, J. Dupouy, C. Roussillon, A. Gimbert, L. Wittkop, R. Thi\u00e9baut, J. Orne-Gliemann, JP. Joseph, L. Richert, X. Anglaret, D. Malvy, ", "publication_date": "2020-10-15", "keywords": ""}, {"pubmed_id": "33032772", "title": "Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.", "authors": "JT. Nguyen, AL. Cole, AA. Leech, WA. Wood, SB. Dusetzina", "publication_date": "2020-10-10", "keywords": "chronic myeloid leukemia, economic evaluation, tyrosine kinase inhibitor"}, {"pubmed_id": "33021721", "title": "Chronic myeloid leukemia in solid organ transplant patients: a case series.", "authors": "I. Amitai, AS. Abulafia, P. Raanani, JH. Lipton", "publication_date": "2020-10-07", "keywords": "Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Solid organ transplant"}, {"pubmed_id": "33008453", "title": "Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.", "authors": "G. Lancman, J. Mascarenhas, M. Bar-Natan", "publication_date": "2020-10-04", "keywords": "COVID-19, Cytarabine, Reactivation, Rituximab, SARS-CoV-2"}, {"pubmed_id": "32972178", "title": "Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.", "authors": "K. Slez\u00e1kov\u00e1, M. Mistr\u00edk, A. B\u00e1torov\u00e1", "publication_date": "2020-09-26", "keywords": "bosutinib, chronic myeloid leukemia, dasatinib, hematopoietic stem cell transplantation, imatinib, nilotinib, ponatinib, remission, tyrosine kinase inhibitors"}, {"pubmed_id": "32958432", "title": "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.", "authors": "H. Bostan, T. Toptas, FP. Tanrikulu, K. Kut, F. Arikan, F. Yilmaz, I. Atagunduz, T. Firatli-Tuglular", "publication_date": "2020-09-23", "keywords": "CML, Dasatinib, Generic imatinib, Imatinib mesylate, Nilotinib"}, {"pubmed_id": "32927513", "title": "[Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor \u03b1-mutant gastrointestinal stromal tumor].", "authors": "XF. Sun, XD. Gao, W. Yuan, JY. Sun, M. Fu, AW. Xue, H. Li, P. Shu, Y. Fang, YY. Hou, KT. Shen, YH. Sun, J. Qin, XY. Qin", "publication_date": "2020-09-16", "keywords": "Gastrointestinal stromal tumor, Platelet-derived growth factor alpha (PDGFRA), Prognosis"}, {"pubmed_id": "32908560", "title": "YQFM Alleviates Side Effects Caused by Dasatinib through the ROCK/MLC Pathway in Mice.", "authors": "Y. Liu, Y. Dai, H. Xu, Q. Zhou, F. Li, B. Yu, Y. Zhang, J. Kou", "publication_date": "2020-09-11", "keywords": ""}, {"pubmed_id": "32878823", "title": "Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.", "authors": "U. Markovic, A. Bulla, S. Leotta, S. Stella, ML. Consoli, L. Tamb\u00c8, C. Conticello, F. DI Raimondo, F. Stagno", "publication_date": "2020-09-04", "keywords": "BCR-ABL1, Imatinib, TKI, chronic myeloid leukemia, dasatinib, second-line treatment"}, {"pubmed_id": "32871908", "title": "Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.", "authors": "QJ. Yang, J. Zheng, FT. Dang, YM. Wan, J. Yang", "publication_date": "2020-09-03", "keywords": ""}, {"pubmed_id": "32855397", "title": "Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation.", "authors": "J. Iske, M. Seyda, T. Heinbokel, R. Maenosono, K. Minami, Y. Nian, M. Quante, CS. Falk, H. Azuma, F. Martin, JF. Passos, CU. Niemann, T. Tchkonia, JL. Kirkland, A. Elkhal, SG. Tullius", "publication_date": "2020-08-29", "keywords": ""}, {"pubmed_id": "32839263", "title": "Evaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital.", "authors": "I. Marquinez-Alonso, V. Escudero-Vilaplana, S. Osorio, CG. Rodriguez-Gonzalez, E. Gonz\u00e1lez-Haba, M. Sanjurjo-S\u00e1ez", "publication_date": "2020-08-26", "keywords": "chronic myelogenous leukemia, dasatinib, effectiveness, imatinib, nilotinib, real world data, safety, tyrosine-kinase inhibitors"}, {"pubmed_id": "32779849", "title": "How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults.", "authors": "WB. Slayton, KR. Schultz, LB. Silverman, SP. Hunger", "publication_date": "2020-08-12", "keywords": "Philadelphia chromosome, clinical trial, hematopoietic stem cell transplant, minimal residual disease, tyrosine kinase inhibitor"}, {"pubmed_id": "32719607", "title": "The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.", "authors": "H. Haguet, C. Bouvy, AS. Delvigne, E. Modaffari, A. Wannez, P. Sonveaux, JM. Dogn\u00e9, J. Douxfils", "publication_date": "2020-07-29", "keywords": "BCR-ABL tyrosine kinase inhibitor, atherosclerosis, cardiovascular, chronic myeloid leukemia, endothelial cells"}, {"pubmed_id": "32699984", "title": "Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.", "authors": "M. Tiribelli, AE. Eskazan", "publication_date": "2020-07-24", "keywords": "Bosutinib, Chronic myeloid leukemia, Dasatinib, Imatinib, Ponatinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "32695366", "title": "Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.", "authors": "MD. Lundholm, GA. Charnogursky", "publication_date": "2020-07-23", "keywords": "acute lymphoblastic leukemia, adverse effect, diabetes, hypoglycemia, tyrosine kinase inhibitor"}, {"pubmed_id": "32686430", "title": "Dasatinib-induced colitis: discovering the side effects of immunotherapy.", "authors": "V. Jim\u00e9nez Beltr\u00e1n, A. Berm\u00fadez Alarc\u00f3n, O. Casta\u00f1o Fern\u00e1ndez", "publication_date": "2020-07-21", "keywords": ""}, {"pubmed_id": "32681739", "title": "Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.", "authors": "Y. Abaza, H. Kantarjian, Y. Alwash, G. Borthakur, R. Champlin, T. Kadia, G. Garcia-Manero, N. Daver, F. Ravandi, S. Verstovsek, J. Burger, Z. Estrov, M. Ohanian, M. Lim, N. Pemmaraju, E. Jabbour, J. Cortes", "publication_date": "2020-07-19", "keywords": ""}, {"pubmed_id": "32678032", "title": "Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor \u03b2.", "authors": "V. Bellat, A. Verch\u00e8re, SA. Ashe, B. Law", "publication_date": "2020-07-18", "keywords": "Cell signaling pathway, Estrogen receptor \u03b2 (ESR2), Synergistic drug combination, Transcriptome and proteomic analysis, Triple negative breast cancer (TNBC)"}, {"pubmed_id": "32677196", "title": "A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.", "authors": "Y. Zhou, X. Zhang, X. Wu, Y. Zhou, B. Zhang, X. Liu, X. Wu, Y. Li, L. Shen, J. Li", "publication_date": "2020-07-18", "keywords": "dasatinib, gastrointestinal stromal tumor, next-generation sequencing"}, {"pubmed_id": "32675015", "title": "A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.", "authors": "N. Spetsieris, M. Boukovala, JA. Weldon, A. Tsikkinis, A. Hoang, A. Aparicio, SM. Tu, JC. Araujo, AJ. Zurita, PG. Corn, L. Pagliaro, J. Kim, J. Wang, SK. Subudhi, NM. Tannir, CJ. Logothetis, P. Troncoso, X. Wang, S. Wen, E. Efstathiou", "publication_date": "2020-07-18", "keywords": "Androgen-signaling inhibition, Neoangiogenesis, Src pathway, Targeted agents, Tumor microenvironment"}, {"pubmed_id": "32664269", "title": "Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.", "authors": "L. Piscitani, V. Sirolli, L. Di Liberato, M. Morroni, M. Bonomini", "publication_date": "2020-07-16", "keywords": "VEGF, aflibercept, anti-VEGF agents, cancer, dasatinib, immune checkpoint inhibitor, kidney, nephrotoxicity, nivolumab"}, {"pubmed_id": "32657579", "title": "Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.", "authors": "Y. Yang, H. Gao, X. Sun, Y. Sun, Y. Qiu, Q. Weng, Y. Rao", "publication_date": "2020-07-14", "keywords": ""}, {"pubmed_id": "32611965", "title": "Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.", "authors": "H. Inoue, H. Taji, K. Yamada, C. Iriyama, T. Saito, H. Kato, M. Yanada, K. Yamamoto, N. Matsukawa", "publication_date": "2020-07-03", "keywords": "chronic myelogenous leukemia, dasatinib, demyelinating peripheral neuropathy, nilotinib, tyrosine kinase inhibitor"}, {"pubmed_id": "32603316", "title": "Everolimus improves the efficacy of dasatinib in PDGFR\u03b1-driven glioma.", "authors": "Z. Miklja, VN. Yadav, RT. Cartaxo, R. Siada, CC. Thomas, JR. Cummings, B. Mullan, S. Stallard, A. Paul, AK. Bruzek, K. Wierzbicki, T. Yang, T. Garcia, I. Wolfe, M. Leonard, PL. Robertson, HJ. Garton, DR. Wahl, H. Parmar, JN. Sarkaria, C. Kline, S. Mueller, T. Nicolaides, C. Glasser, SE. Leary, S. Venneti, C. Kumar-Sinha, AM. Chinnaiyan, R. Mody, MP. Pai, TN. Phoenix, BL. Marini, C. Koschmann", "publication_date": "2020-07-01", "keywords": "Brain cancer, Molecular biology, Oncology, Pharmacology"}, {"pubmed_id": "32590107", "title": "Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.", "authors": "FY. Zheng, AD. Lu, YX. Zuo, YP. Jia, J. Wu, LP. Zhang", "publication_date": "2020-06-27", "keywords": "Acute lymphoblastic leukaemia, Children, Growth, Tyrosine kinase inhibitors"}, {"pubmed_id": "32586039", "title": "Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.", "authors": "F. Carofiglio, A. Lopalco, A. Lopedota, A. Cutrignelli, O. Nicolotti, N. Denora, A. Stefanachi, F. Leonetti", "publication_date": "2020-06-27", "keywords": "chronic myeloid leukemia, dasatinib, formulation, imatinib, nilotinb, pediatric age, ponatinib, tyrosine kinase inhibitors"}, {"pubmed_id": "32572057", "title": "Signaling Inhibitors Accelerate the Conversion of mouse iPS Cells into Cancer Stem Cells in the Tumor Microenvironment.", "authors": "J. Du, Y. Xu, S. Sasada, AKK. Oo, G. Hassan, H. Mahmud, AC. Khayrani, MJ. Alam, K. Kumon, R. Uesaki, SM. Afify, HM. Mansour, N. Nair, MH. Zahra, A. Seno, N. Okada, L. Chen, T. Yan, M. Seno", "publication_date": "2020-06-24", "keywords": ""}, {"pubmed_id": "32569380", "title": "Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.", "authors": "DM. Moujalled, DT. Hanna, S. Hediyeh-Zadeh, G. Pomilio, L. Brown, V. Litalien, R. Bartolo, S. Fleming, M. Chanrion, S. Banquet, AL. Maragno, L. Kraus-Berthier, M. Schoumacher, CG. Mullighan, A. Georgiou, CA. White, G. Lessene, DCS. Huang, AW. Roberts, O. Geneste, L. Rasmussen, MJ. Davis, PG. Ekert, A. Wei, AP. Ng, SL. Khaw", "publication_date": "2020-06-23", "keywords": ""}, {"pubmed_id": "32559295", "title": "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.", "authors": "C. Vener, R. Banzi, F. Ambrogi, A. Ferrero, G. Saglio, G. Pravettoni, M. Sant", "publication_date": "2020-06-20", "keywords": ""}, {"pubmed_id": "32558423", "title": "The remarkable response to ponatinib therapy in a child with blastic phase of chronic myeloid leukemia.", "authors": "T. Aksu, \u015e. \u00dcnal, F. G\u00fcmr\u00fck", "publication_date": "2020-06-20", "keywords": "blastic phase, chronic myeloid leukemia, ponatinib"}, {"pubmed_id": "32547383", "title": "Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome.", "authors": "AM. Abdalhadi, A. Alshurafa, M. Alkhatib, M. Abou Kamar, MA. Yassin", "publication_date": "2020-06-18", "keywords": "Acute respiratory distress syndrome, COVID-19, Chronic myelogenous leukemia, Febrile neutropenia, Pneumonia"}, {"pubmed_id": "32533516", "title": "Vascular events may predict the prognosis of patients with chronic myeloid leukemia.", "authors": "H. Ureshino, K. Kamachi", "publication_date": "2020-06-14", "keywords": ""}, {"pubmed_id": "32480168", "title": "Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation.", "authors": "Y. Zhang, SL. Diamond", "publication_date": "2020-06-02", "keywords": "Collagen, GPVI, Kinase, Platelet, Thrombosis"}, {"pubmed_id": "32470534", "title": "Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.", "authors": "AP. Singh, P. Umbarkar, S. Tousif, H. Lal", "publication_date": "2020-05-30", "keywords": "Cardio-oncology, Cardiotoxicity, Ponatinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "32450920", "title": "Eliminating senescent chondrogenic progenitor cells enhances chondrogenesis under intermittent hydrostatic pressure for the treatment of OA.", "authors": "H. Dai, R. Chen, C. Gui, T. Tao, Y. Ge, X. Zhao, R. Qin, W. Yao, S. Gu, Y. Jiang, J. Gui", "publication_date": "2020-05-27", "keywords": "Apoptosis, Arthroplasty, Cartilage, Inflammation, Mechanics, Osteoarthritis, Senescence, Senolytics, Stem cell"}, {"pubmed_id": "32449208", "title": "Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors.", "authors": "AA. Abu Rmilah, G. Lin, KH. Begna, PA. Friedman, J. Herrmann", "publication_date": "2020-05-26", "keywords": "QTc prolongation, sudden cardiac death, torsade de pointes, tyrosine kinase inhibitors, ventricular tachycardia"}, {"pubmed_id": "32447937", "title": "[Efficacy and safety of domestic dasatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase].", "authors": "WJ. Yu, X. Du, WG. Wang, J. Lou, P. Liu, L. Meng, J. Jin", "publication_date": "2020-05-26", "keywords": ""}, {"pubmed_id": "32399015", "title": "A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.", "authors": "O. Imataki, T. Ishida, H. Kubo, M. Uemura, Y. Nanya, K. Kawakami, S. Ogawa, N. Kadowaki", "publication_date": "2020-05-14", "keywords": "Chronic myeloid leukemia, Clonal evolution, Drug resistance, Leukemia oncogenesis, Tyrosine kinase inhibitor"}, {"pubmed_id": "32380976", "title": "The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.", "authors": "HJ. G Lindstr\u00f6m, R. Friedman", "publication_date": "2020-05-10", "keywords": "Allosteric inhibitor, Drug combination, Targeted therapy"}, {"pubmed_id": "32366389", "title": "ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.", "authors": "M. Massimino, S. Stella, E. Tirr\u00f2, MS. Pennisi, SR. Vitale, A. Puma, C. Romano, S. DI Gregorio, C. Tomarchio, F. DI Raimondo, L. Manzella", "publication_date": "2020-05-06", "keywords": "BCR-ABL1, CML, TKI, efficacy, resistance, review"}, {"pubmed_id": "32348984", "title": "Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.", "authors": "G. Novo, D. Di Lisi, E. Bronte, F. Macaione, V. Accurso, G. Badalamenti, G. Rinaldi, S. Siragusa, S. Novo, A. Russo", "publication_date": "2020-04-30", "keywords": "Arterial stiffness, Cardio-oncology, Cardiotoxicity, Chronic myeloid leukemia, Tyrosine kinase inhibitors"}, {"pubmed_id": "32347770", "title": "Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.", "authors": "L. Triche, A. Yarbrough, M. Roth, A. Ying, R. Wells", "publication_date": "2020-04-30", "keywords": "Chronic myeloid leukemia, growth hormone, major molecular remission, tyrosine kinase inhibitor"}, {"pubmed_id": "32326001", "title": "Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors.", "authors": "G. Caocci, M. Deidda, A. Noto, M. Greco, MP. Simula, O. Mulas, D. Cocco, C. Fattuoni, G. Mercuro, G. La Nasa, C. Cadeddu Dessalvi", "publication_date": "2020-04-25", "keywords": "Chronic myeloid leukemia, GC-MS metabolomics, cardiovascular adverse events, tyrosine kinase inhibitors"}, {"pubmed_id": "32319737", "title": "How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).", "authors": "M. Breccia, PP. Olimpieri, O. Olimpieri, F. Pane, A. Iurlo, P. Foggi, A. Cirilli, A. Colatrella, M. Cuomo, L. Gozzo, V. Summa, P. Corradini, P. Russo, ", "publication_date": "2020-04-23", "keywords": "chronic myeloid leukemia, failure, intolerance, second-generation TKIs"}, {"pubmed_id": "32306183", "title": "Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.", "authors": "S. Okamoto, H. Ureshino, A. Kawaguchi, M. Miyazono, Y. Ikeda, S. Kimura", "publication_date": "2020-04-20", "keywords": "Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Renal toxicities"}, {"pubmed_id": "32279331", "title": "Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.", "authors": "J. Schwaab, N. Naumann, J. Luebke, M. Jawhar, TCP. Somervaille, MS. Williams, R. Frewin, PJ. Jost, FS. Lichtenegger, P. La Ros\u00e9e, N. Storch, T. Haferlach, HP. Horny, A. Fabarius, C. Haferlach, A. Burchert, WK. Hofmann, NCP. Cross, A. Hochhaus, A. Reiter, G. Metzgeroth", "publication_date": "2020-04-13", "keywords": ""}, {"pubmed_id": "32265500", "title": "Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.", "authors": "JE. Cortes, Q. Jiang, J. Wang, J. Weng, H. Zhu, X. Liu, A. Hochhaus, DW. Kim, J. Radich, M. Savona, P. Martin-Regueira, O. Sy, R. Gurnani, G. Saglio", "publication_date": "2020-04-09", "keywords": ""}, {"pubmed_id": "32248338", "title": "Dasatinib-induced chylothorax: report of a case and review of the literature.", "authors": "B. Chen, Z. Wu, Q. Wang, W. Li, D. Cheng", "publication_date": "2020-04-06", "keywords": "Chylothorax, Dasatinib, Medication withdrawal"}, {"pubmed_id": "32239758", "title": "Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.", "authors": "E. Jabbour, H. Kantarjian", "publication_date": "2020-04-03", "keywords": ""}, {"pubmed_id": "32235443", "title": "Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).", "authors": "S. Cirmi, A. El Abd, L. Letinier, M. Navarra, F. Salvo", "publication_date": "2020-04-03", "keywords": "FAERS, adverse drug reaction, cardiovascular toxicity, chronic myeloid leukemia, tyrosine kinase inhibitors"}, {"pubmed_id": "32196424", "title": "Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.", "authors": "AL. Cole, WA. Wood, B. Muluneh, JL. Lund, J. Elston Lafata, SB. Dusetzina", "publication_date": "2020-03-21", "keywords": ""}, {"pubmed_id": "32190647", "title": "Prediction of Side Effects Using Comprehensive Similarity Measures.", "authors": "S. Seo, T. Lee, MH. Kim, Y. Yoon", "publication_date": "2020-03-20", "keywords": ""}, {"pubmed_id": "32169913", "title": "First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.", "authors": "S. Krebs, DR. Veach, LM. Carter, M. Grkovski, M. Fornier, MJ. Mauro, MH. Voss, DC. Danila, E. Burnazi, M. Null, K. Staton, C. Pressl, BJ. Beattie, P. Zanzonico, WA. Weber, SK. Lyashchenko, JS. Lewis, SM. Larson, MPS. Dunphy", "publication_date": "2020-03-15", "keywords": "18F-SKI-249380, PET imaging, Src kinase, dasatinib"}, {"pubmed_id": "32152879", "title": "Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease.", "authors": "J. Mori, K. Oshima, T. Tanimoto, H. Ishizuka, S. Kimura, M. Miura, N. Takahashi", "publication_date": "2020-03-11", "keywords": "CML, Cardiotoxicity, Dasatinib, Hemodialysis, Pharmacokinetics"}, {"pubmed_id": "32152877", "title": "Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.", "authors": "Y. Koutake, J. Taniguchi, N. Yasumori, H. Nagaishi, T. Eto, K. Nakashima, M. Fukazawa, T. Hayashi", "publication_date": "2020-03-11", "keywords": "Chronic myeloid leukemia, Dasatinib, Drug\u2013drug interactions, H2-receptor antagonists, Proton pump inhibitors"}, {"pubmed_id": "32152351", "title": "Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines.", "authors": "R. Kotaki, M. Kawashima, Y. Yamamoto, H. Higuchi, E. Nagashima, N. Kurosaki, M. Takamatsu, YY. Kikuti, KI. Imadome, N. Nakamura, A. Kotani", "publication_date": "2020-03-11", "keywords": ""}, {"pubmed_id": "32139432", "title": "Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.", "authors": "Y. Shi, MC. Beckett, HJ. Blair, R. Tirtakusuma, S. Nakjang, A. Enshaei, C. Halsey, J. Vormoor, O. Heidenreich, A. Krippner-Heidenreich, FW. van Delft", "publication_date": "2020-03-07", "keywords": "Adult Acute Lymphoblastic Leukemia, Functional genomics, Glucocorticoid resistance, Pediatric Acute Lymphoblastic Leukemia, Randomized murine Phase II-like Trial"}, {"pubmed_id": "32135623", "title": "[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].", "authors": "T. Yuan, YY. Lai, YZ. Qin, HX. Shi, XJ. Huang, Y. Hou, Q. Jiang", "publication_date": "2020-03-07", "keywords": "Dasatinib, Imatinib, Leukemia, myeloid, chronic, BCR-ABL positive, Nilotinib"}, {"pubmed_id": "32127639", "title": "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.", "authors": "A. Hochhaus, M. Baccarani, RT. Silver, C. Schiffer, JF. Apperley, F. Cervantes, RE. Clark, JE. Cortes, MW. Deininger, F. Guilhot, H. Hjorth-Hansen, TP. Hughes, JJWM. Janssen, HM. Kantarjian, DW. Kim, RA. Larson, JH. Lipton, FX. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, JP. Radich, D. Rea, J. Richter, G. Rosti, P. Rousselot, G. Saglio, S. Sau\u00dfele, S. Soverini, JL. Steegmann, A. Turkina, A. Zaritskey, R. Hehlmann", "publication_date": "2020-03-05", "keywords": ""}, {"pubmed_id": "32117790", "title": "Senolytics (DQ) Mitigates Radiation Ulcers by Removing Senescent Cells.", "authors": "H. Wang, Z. Wang, Y. Huang, Y. Zhou, X. Sheng, Q. Jiang, Y. Wang, P. Luo, M. Luo, C. Shi", "publication_date": "2020-03-03", "keywords": "SASP, apoptosis, oral mucositis, radiation ulcer, senescence, skin ulcer"}, {"pubmed_id": "32107574", "title": "T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.", "authors": "S. Ting, X. Mixue, Z. Lixia, L. Xueying, X. Wanzhuo, Y. Xiujin", "publication_date": "2020-02-29", "keywords": "Acute lymphoblastic leukemia, CAR-T cell, Chemotherapy, Donor lymphocyte infusion, Ponatinib, T315I mutation, Transplantation"}, {"pubmed_id": "32095296", "title": "Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports.", "authors": "X. Liao, Y. Guo, Y. Shen, J. Xiao", "publication_date": "2020-02-26", "keywords": ""}, {"pubmed_id": "32092139", "title": "Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.", "authors": "G. Marcucci, S. Geyer, K. Laumann, W. Zhao, D. Bucci, GL. Uy, W. Blum, AK. Eisfeld, TS. Pardee, ES. Wang, W. Stock, JE. Kolitz, J. Kohlschmidt, K. Mr\u00f3zek, CD. Bloomfield, RM. Stone, RA. Larson", "publication_date": "2020-02-25", "keywords": ""}, {"pubmed_id": "32086760", "title": "Chronic Myeloid Leukemia in Children: Challenges and Opportunities : Based on 7th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 29th Sept. 2019.", "authors": "D. Bansal", "publication_date": "2020-02-23", "keywords": "Dasatinib, Developing country, Nilotinib, Pediatric, Pioglitazone, Survival"}, {"pubmed_id": "32029318", "title": "Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report.", "authors": "K. Shinoda, S. Morita, S. Tamaki, R. Takahashi, S. Kitaoka, H. Asanuma, T. Yoshida, M. Okayama, H. Kasahara, S. Okamoto, M. Oya", "publication_date": "2020-02-08", "keywords": ""}, {"pubmed_id": "32027247", "title": "[Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia].", "authors": "Y. Li, BJ. Wang, W. Liu, ZY. Liang, Y. Yin, YJ. Dong, Q. Wang, YH. Sun, WL. Xu, HY. Ren", "publication_date": "2020-02-07", "keywords": ""}, {"pubmed_id": "31999839", "title": "Long-term results of frontline dasatinib in chronic myeloid leukemia.", "authors": "A. Maiti, JE. Cortes, KP. Patel, L. Masarova, G. Borthakur, F. Ravandi, S. Verstovsek, A. Ferrajoli, Z. Estrov, G. Garcia-Manero, TM. Kadia, GM. Nogueras-Gonz\u00e1lez, J. Skinner, R. Poku, S. DellaSala, R. Luthra, EJ. Jabbour, S. O'Brien, HM. Kantarjian", "publication_date": "2020-01-31", "keywords": "chromic myeloid leukemia, dasatinib, early chronic phase, frontline"}, {"pubmed_id": "31978329", "title": "Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.", "authors": "S. Kimura, J. Imagawa, K. Murai, M. Hino, T. Kitawaki, M. Okada, H. Tanaka, M. Shindo, T. Kumagai, T. Ikezoe, N. Uoshima, T. Sato, R. Watanabe, S. Kowata, M. Hayakawa, T. Hosoki, K. Ikeda, T. Kobayashi, Y. Kakinoki, T. Nishimoto, N. Takezako, H. Shibayama, A. Takaori-Kondo, H. Nakamae, A. Kawaguchi, H. Ureshino, J. Sakamoto, Y. Ishida, ", "publication_date": "2020-01-25", "keywords": ""}, {"pubmed_id": "31944221", "title": "Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.", "authors": "S. Shen, X. Chen, J. Cai, J. Yu, J. Gao, S. Hu, X. Zhai, C. Liang, X. Ju, H. Jiang, R. Jin, X. Wu, N. Wang, X. Tian, K. Pan, H. Jiang, L. Sun, Y. Fang, CK. Li, Q. Hu, M. Yang, Y. Zhu, H. Zhang, C. Li, D. Pei, S. Jeha, JJ. Yang, C. Cheng, J. Tang, X. Zhu, CH. Pui", "publication_date": "2020-01-17", "keywords": ""}, {"pubmed_id": "31933265", "title": "Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (\u2265\u200975 years) with Cancer.", "authors": "V. Clapes, V. Rousseau, F. Despas, JL. Montastruc, P. Olivier", "publication_date": "2020-01-15", "keywords": ""}, {"pubmed_id": "31931069", "title": "Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era.", "authors": "Y. Akahoshi, H. Nakasone, K. Kawamura, M. Kusuda, S. Kawamura, J. Takeshita, N. Yoshino, Y. Misaki, K. Yoshimura, A. Gomyo, A. Tanihara, M. Tamaki, SI. Kimura, S. Kako, Y. Kanda", "publication_date": "2020-01-14", "keywords": ""}, {"pubmed_id": "31923860", "title": "Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations.", "authors": "AR. Abduelkarem, HS. Anbar, SO. Zaraei, AA. Alfar, OS. Al-Zoubi, EG. Abdelkarem, MI. El-Gamal", "publication_date": "2020-01-11", "keywords": "Anticancer, Dasatinib, Diarylamide, Imatinib, Kinase inhibitor, Nilotinib"}, {"pubmed_id": "31900888", "title": "Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.", "authors": "D. Pushpam, S. Bakhshi", "publication_date": "2020-01-05", "keywords": "Gene polymorphism and imatinib, Pharmacology of tyrosine kinase inhibitors, Selection of tyrosine kinase inhibitors, Tyrosine kinase inhibitors in chronic myeloid leukemia"}, {"pubmed_id": "31885779", "title": "Antagonizing Effects of ", "authors": "SE. Lee, SH. Park, JA. Yoo, K. Kwon, JW. Kim, SW. Oh, SJ. Park, J. Kim, E. Yu, BS. Han, JY. Cho, J. Lee", "publication_date": "2019-12-31", "keywords": ""}, {"pubmed_id": "31848452", "title": "Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.", "authors": "K. Somers, K. Evans, L. Cheung, M. Karsa, T. Pritchard, A. Kosciolek, A. Bongers, A. El-Ayoubi, H. Forgham, S. Middlemiss, C. Mayoh, L. Jones, M. Gupta, UR. Kees, O. Chernova, L. Korotchkina, AV. Gudkov, SW. Erickson, B. Teicher, MA. Smith, MD. Norris, M. Haber, RB. Lock, MJ. Henderson", "publication_date": "2019-12-19", "keywords": ""}, {"pubmed_id": "31848139", "title": "Chylothorax: complication attributed to dasatinib use.", "authors": "A. Al-Abcha, MH. Iftikhar, F. Abu Rous, H. Laird-Fick", "publication_date": "2019-12-19", "keywords": "dasatinib, haematology (drugs and medicines), respiratory medicine, unwanted effects / adverse reactions"}, {"pubmed_id": "31816725", "title": "Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring.", "authors": "D. Koller, V. Vaitsekhovich, C. Mba, JL. Steegmann, P. Zubiaur, F. Abad-Santos, A. Wojnicz", "publication_date": "2019-12-11", "keywords": "Caffeine, Liquid chromatography-tandem mass spectrometry, Phospholipids, Solid phase extraction, Therapeutic drug monitoring, Tyrosine kinase inhibitors"}, {"pubmed_id": "31779971", "title": "Can Ph-like ALL be effectively targeted?", "authors": "L. Maese, EA. Raetz", "publication_date": "2019-11-30", "keywords": "ALL, Acute lymphoblastic leukemia, CRLF2, Cytokine receptor-like factor 2, Dasatinib, Ph-like ALL, Philadelphia chromosome-like, Ruxolitinib, TKI, Tyrosine kinase inhibitor"}, {"pubmed_id": "31779969", "title": "Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?", "authors": "BA. Derman, RA. Larson", "publication_date": "2019-11-30", "keywords": "AML, Acute myeloid leukemia, CBF, Core binding factor, FLT3, HiDAC, High-dose cytarabine, IDAC, IDH1, IDH2, Intermediate-dose cytarabine, LDAC, Low-dose cytarabine, MRD, Measurable residual disease, Post-remission"}, {"pubmed_id": "31772301", "title": "Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.", "authors": "L. Yu, J. Liu, X. Huang, Q. Jiang", "publication_date": "2019-11-28", "keywords": ""}, {"pubmed_id": "31760572", "title": "Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.", "authors": "F. Rabian, E. Lengline, D. Rea", "publication_date": "2019-11-25", "keywords": "Chronic myeloid leukemia, Personalized medicine, Tyrosine kinase inhibitors"}, {"pubmed_id": "31748496", "title": "[A Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieving Complete Molecular Response with Ponatinib Therapy despite the Development of Hemorrhagic Stroke during Remission Induction Chemotherapy].", "authors": "T. Fujii, N. Ohno, A. Doi, T. Matsui, N. Sahara, T. Matsunaga", "publication_date": "2019-11-22", "keywords": ""}, {"pubmed_id": "31733802", "title": "Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report.", "authors": "H. Yamane, K. Ide, A. Tanaka, S. Hashimoto, H. Nagoshi, H. Tahara, M. Ohira, A. Seidakhmetov, D. Marlen, Y. Tanaka, H. Ohdan", "publication_date": "2019-11-18", "keywords": ""}, {"pubmed_id": "31714021", "title": "Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?", "authors": "S. Deb, N. Bokn\u00e4s, C. Sj\u00f6str\u00f6m, A. Tharmakulanathan, K. Lotfi, S. Ramstr\u00f6m", "publication_date": "2019-11-13", "keywords": "chronic myeloid/myelogenous leukemia, coagulation, hemostasis, personalized medicine, platelets, tyrosine kinase inhibitors"}, {"pubmed_id": "31711851", "title": "Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.", "authors": "G. Caocci, O. Mulas, M. Annunziata, L. Luciano, E. Abruzzese, M. Bonifacio, EM. Orlandi, F. Albano, S. Galimberti, A. Iurlo, P. Pregno, N. Sgherza, B. Martino, G. Binotto, F. Castagnetti, A. Gozzini, M. Bocchia, C. Fozza, F. Stagno, MP. Simula, F. De Gregorio, MM. Trawinska, L. Scaffidi, C. Elena, I. Attolico, C. Barat\u00e8, D. Cattaneo, F. Pirillo, G. Gugliotta, A. Sicuranza, M. Molica, G. La Nasa, R. Fo\u00e0, M. Breccia", "publication_date": "2019-11-13", "keywords": "Cardiovascular toxicity, Chronic myeloid leuk, Ischemic heart disease, TKI, a, emia"}, {"pubmed_id": "31709128", "title": "Development of molecular and pharmacological switches for chimeric antigen receptor T cells.", "authors": "BX. Wu, NJ. Song, BP. Riesenberg, Z. Li", "publication_date": "2019-11-12", "keywords": ""}, {"pubmed_id": "31676669", "title": "Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia.", "authors": "N. Hijiya, CM. Zwaan, C. Rizzari, R. Fo\u00e0, F. Abbink, D. Lancaster, J. Landman-Parker, F. Millot, J. Moppett, B. Nelken, M. Caterina Putti, X. Tian, K. Sinclair, H. Santanastasio, A. Buchbinder, P. Kearns", "publication_date": "2019-11-05", "keywords": ""}, {"pubmed_id": "31670839", "title": "Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity.", "authors": "J. Liu, X. Jin, F. Zhou, H. Chen, W. Wang, Y. Liu, G. Wang, K. Hao, J. Zhang", "publication_date": "2019-11-02", "keywords": ""}, {"pubmed_id": "31647335", "title": "Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.", "authors": "NP. Shah, V. Garc\u00eda-Guti\u00e9rrez, A. Jim\u00e9nez-Velasco, S. Larson, S. Saussele, D. Rea, FX. Mahon, MY. Levy, MT. G\u00f3mez-Casares, F. Pane, FE. Nicolini, MJ. Mauro, O. Sy, P. Martin-Regueira, JH. Lipton", "publication_date": "2019-10-28", "keywords": "CML-CP, Dasatinib, deep molecular response, imatinib, major molecular response, treatment-free remission"}, {"pubmed_id": "31640889", "title": "Dasatinib-induced colitis: a case report.", "authors": "AG. Tamilarasan, P. Katelaris, R. Gasiorowski, R. Liyanasuriya", "publication_date": "2019-10-24", "keywords": ""}, {"pubmed_id": "31619990", "title": "Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential.", "authors": "J. Rivera-Torres, E. San Jos\u00e9", "publication_date": "2019-10-18", "keywords": "LGLs, Src tyrosine kinase inhibitors, dasatinib, immunotherapy, progeria, senescence, senolytics, \u03b3\u03b4 T cells"}, {"pubmed_id": "31597837", "title": "[Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].", "authors": "M. Miura, N. Takahashi", "publication_date": "2019-10-11", "keywords": "Target concentration intervention, Therapeutic drug monitoring, Tyrosine kinase inhibitor"}, {"pubmed_id": "31590985", "title": "Dasatinib-Induced Pulmonary Arterial Hypertension.", "authors": "E. Orlikow, J. Weatherald, N. Hirani", "publication_date": "2019-10-09", "keywords": ""}, {"pubmed_id": "31563565", "title": "Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.", "authors": "HY. Seo, TH. Ko, SY. Hyun, H. Song, ST. Lim, KY. Shim, JI. Lee, JH. Kong", "publication_date": "2019-09-30", "keywords": "Adverse event, Drug dosage, Medication adherence, National Health Information Database, Overall survival"}, {"pubmed_id": "31553487", "title": "Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.", "authors": "K. Naqvi, E. Jabbour, J. Skinner, K. Anderson, S. Dellasala, M. Yilmaz, A. Ferrajoli, P. Bose, P. Thompson, Y. Alvarado, N. Jain, K. Takahashi, J. Burger, Z. Estrov, G. Borthakur, N. Pemmaraju, S. Paul, J. Cortes, HM. Kantarjian", "publication_date": "2019-09-26", "keywords": "chronic myeloid leukemia, complete cytogenetic response, dasatinib, major molecular response"}, {"pubmed_id": "31530245", "title": "The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.", "authors": "L. Jiang, H. Wang, X. Zhu, W. Liu, S. Zhou, Z. Geng, Y. Xiao, P. Zou, Y. You, Q. Li, X. Zhu", "publication_date": "2019-09-19", "keywords": "chronic myeloid leukemia, discontinuation, leukemia stem cell, mitochondria oxidative phosphorylation, tyrosine kinase inhibitors"}, {"pubmed_id": "31529281", "title": "Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.", "authors": "M. Tiribelli, E. Abruzzese, I. Capodanno, F. Sor\u00e0, E. Trabacchi, A. Iurlo, L. Luciano, G. Binotto, M. Bonifacio, M. Annunziata, M. Crugnola, R. Fanin", "publication_date": "2019-09-19", "keywords": ""}, {"pubmed_id": "31520926", "title": "Discovery of a potent p38\u03b1/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies.", "authors": "MI. El-Gamal, HS. Anbar, H. Tarazi, CH. Oh", "publication_date": "2019-09-15", "keywords": "Antiinflammatory, Kinase inhibition, MAPK14, Pyrazole, p38\u03b1"}, {"pubmed_id": "31514197", "title": "Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.", "authors": "P. Pan, L. Wang, Y. Wang, L. Shen, P. Zheng, C. Bi, A. Zhang, Y. Lv, Z. Xue, M. Sun, C. Sun, J. Li, L. Jin, Y. Yao", "publication_date": "2019-09-13", "keywords": "Chronic myeloid leukemia, Imatinib, Meta-analysis, Tyrosine kinase inhibitor"}, {"pubmed_id": "31511239", "title": "Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.", "authors": "N. Hijiya, A. Maschan, C. Rizzari, H. Shimada, C. Dufour, H. Goto, HJ. Kang, T. Guinipero, Z. Karakas, F. Bautista, S. Ducassou, KH. Yoo, CM. Zwaan, F. Millot, P. Aimone, A. Allepuz, S. Quenet, F. Hourcade-Potelleret, S. Hertle, D. Sosothikul", "publication_date": "2019-09-13", "keywords": ""}, {"pubmed_id": "31462241", "title": "Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.", "authors": "L. Tang, H. Zhang, YZ. Peng, CG. Li, HW. Jiang, M. Xu, H. Mei, Y. Hu", "publication_date": "2019-08-30", "keywords": "Chronic myeloid leukemia, Efficacy, Network meta-analysis, Tolerability, Tyrosine kinase inhibitors"}, {"pubmed_id": "31433948", "title": "Intercostal Herniation of Pleural Fluid.", "authors": "TA. Newman, AK. Brady, JE. Shriki, JE. Takasugi, R. Adamson", "publication_date": "2019-08-23", "keywords": ""}, {"pubmed_id": "31416783", "title": "The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.", "authors": "R. Aoyama, J. Ishikawa, K. Harada", "publication_date": "2019-08-17", "keywords": "Chronic myeloid leukemia, Heart failure, Onco-cardiology, Tolvaptan, Tyrosine kinase inhibitors"}, {"pubmed_id": "31409168", "title": "Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.", "authors": "J. Cortes, L. Huynh, E. Mendelson, P. Brandt, D. Dalal, M. DerSarkissian, D. Cortina, S. Narkhede, M. Sheng Duh", "publication_date": "2019-08-15", "keywords": "Chronic myeloid leukemia, deep molecular response, nilotinib, targeted therapies, tyrosine kinase inhibitor"}, {"pubmed_id": "31402561", "title": "Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "Y. Akahoshi, S. Nishiwaki, S. Mizuta, K. Ohashi, N. Uchida, M. Tanaka, T. Fukuda, Y. Ozawa, S. Takahashi, M. Onizuka, S. Shiratori, H. Nakamae, Y. Kanda, T. Ichinohe, Y. Atsuta, S. Kako, ", "publication_date": "2019-08-14", "keywords": "Philadelphia chromosome-positive acute lymphoblastic leukemia, dasatinib, imatinib, minimal residual disease, post-transplant tyrosine kinase inhibitor"}, {"pubmed_id": "31376170", "title": "UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions.", "authors": "NZ. Alzoman, HM. Maher, SM. Shehata, NO. Abanmy", "publication_date": "2019-08-04", "keywords": "dandelion, dasatinib, drug interactions, imatinib, nilotinib, pharmacokinetics"}, {"pubmed_id": "31373213", "title": "Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?", "authors": "NO. Yurttas, AE. Eskazan", "publication_date": "2019-08-03", "keywords": "bleeding diathesis, chronic myeloid leukemia, dasatinib, imatinib, platelet dysfunction, tyrosine kinase inhibitor"}, {"pubmed_id": "31359838", "title": "Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.", "authors": "S. Maral, SM. Bakanay, O. Kucuksahin, I. Dilek", "publication_date": "2019-07-31", "keywords": "Dasatinib, lupus, pleural effusion, pulmonary arterial hypertension"}, {"pubmed_id": "31340935", "title": "CAR T Cells: Hitting the Pause Button.", "authors": "", "publication_date": "2019-07-26", "keywords": ""}, {"pubmed_id": "31334123", "title": "Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.", "authors": "V. Garc\u00eda-Guti\u00e9rrez, JC. Hern\u00e1ndez-Boluda", "publication_date": "2019-07-25", "keywords": "chronic myeloid leukemia, efficacy, patients, safety, treatment"}, {"pubmed_id": "31311724", "title": "Interstitial pneumonitis associated with dasatinib: two case reports and literature review.", "authors": "Y. Ito, M. Tanigawa, K. Iwamoto, A. Nigi, H. Itani, S. Kondo, T. Tokui, E. Usui, S. Tamaki", "publication_date": "2019-07-18", "keywords": "Chronic myeloid leukaemia, Dasatinib, Interstitial lung disease, Interstitial pneumonitis"}, {"pubmed_id": "31292394", "title": "Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine \"Goreisan\".", "authors": "H. Sasaki, Y. Kimizuka, H. Ogata, Y. Okada, S. Ota, T. Sano, C. Watanabe, Y. Maki, T. Yamamoto, Y. Tagami, J. Miyata, N. Hayashi, Y. Fujikura, A. Kawana", "publication_date": "2019-07-12", "keywords": "Goreisan, aquaporin, chronic myeloid leukemia, chylothorax, dasatinib"}, {"pubmed_id": "31290996", "title": "A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.", "authors": "E. Galanis, SK. Anderson, EL. Twohy, XW. Carrero, JG. Dixon, DD. Tran, SA. Jeyapalan, DM. Anderson, TJ. Kaufmann, RW. Feathers, C. Giannini, JC. Buckner, PZ. Anastasiadis, D. Schiff", "publication_date": "2019-07-11", "keywords": "Src family kinase inhibitors, bevacizumab, dasatinib, phase 2 trial, recurrent glioblastoma"}, {"pubmed_id": "31280457", "title": "Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.", "authors": "H. Izumi-Nakaseko, M. Fujiyoshi, M. Hagiwara-Nagasawa, A. Goto, K. Chiba, R. Kambayashi, AT. Naito, K. Ando, Y. Kanda, I. Ishii, A. Sugiyama", "publication_date": "2019-07-08", "keywords": "Dasatinib, Halothane-anesthetized dogs, Human induced pluripotent stem cell-derived cardiomyocytes, Safety pharmacology"}, {"pubmed_id": "31271217", "title": "Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.", "authors": "MG. Berger, B. Pereira, P. Rousselot, P. Cony-Makhoul, M. Gardembas, L. Legros, M. Escoffre-Barbe, FE. Nicolini, S. Saugues, C. Lambert, D. R\u00e9a, A. Guerci-Bresler, S. Giraudier, J. Guilhot, S. Saussele, FX. Mahon, ", "publication_date": "2019-07-05", "keywords": "CML, TKI, stopping trial, withdrawal syndrome"}, {"pubmed_id": "31270411", "title": "The Route to 'Chemobrain' - Computational probing of neuronal LTP pathway.", "authors": "A. Fahim, Z. Rehman, MF. Bhatti, N. Virk, A. Ali, A. Rashid, RZ. Paracha", "publication_date": "2019-07-05", "keywords": ""}, {"pubmed_id": "31246142", "title": "Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.", "authors": "H. Rafei, EJ. Jabbour, H. Kantarjian, KD. Sinicrope, C. Kamiya-Matsuoka, RS. Mehta, NG. Daver, TM. Kadia, K. Naqvi, J. Cortes, M. Konopleva", "publication_date": "2019-06-28", "keywords": ""}, {"pubmed_id": "31245199", "title": "Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury.", "authors": "N. Lopina, I. Dmytrenko, D. Hamov, D. Lopin, I. Dyagil", "publication_date": "2019-06-28", "keywords": "acute liver failure, acute toxic hepatitis, chronic myeloid leukemia, chronic myeloid leukemia second-line therapy, dasatinib, drug-induced liver disease, imatinib, nilotinib, ponatinib, tyrosine kinase inhibitors"}, {"pubmed_id": "31240558", "title": "Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.", "authors": "T. Kondo, M. Fujioka, S. Fujisawa, K. Sato, M. Tsuda, T. Miyagishima, A. Mori, H. Iwasaki, Y. Kakinoki, S. Yamamoto, Y. Haseyama, S. Ando, M. Shindo, S. Ota, M. Kurosawa, Y. Ohba, T. Teshima, ", "publication_date": "2019-06-27", "keywords": "BCR-ABL, Chronic myeloid leukemia (CML), Drug sensitivity test, F\u00f6rster resonance energy transfer (FRET), Tyrosine kinase inhibitor"}, {"pubmed_id": "31223555", "title": "Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature.", "authors": "H. Martinez-Cordero, B. Pati\u00f1o-Escobar, LJ. Enciso, DM. Otero, P. Spirko", "publication_date": "2019-06-22", "keywords": "central nervous system (cns) complications, chronic myeloid leukemia, hypercalcemia, intracranial bleed, leukemia, mast cell leukemia, mast cells, myeloid blast crisis"}, {"pubmed_id": "31218883", "title": "TKI-Related Platelet Dysfunction Does Not Correlate With Bleeding in Patients With Chronic Phase-Chronic Myeloid Leukemia With Complete Hematological Response.", "authors": "Y. Sener, M. Okay, S. Aydin, Y. Buyukasik, F. Akbiyik, ZG. Dikmen", "publication_date": "2019-06-21", "keywords": "chronic-phase myeloid leukemia, dasatinib, imatinib mesylate, platelet aggregation"}, {"pubmed_id": "31189810", "title": "[Investigation and Measurement of Hypophosphatemia Induced by Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia].", "authors": "H. Sakurada, Y. Kawase, S. Asano, H. Teramachi, M. Yamamura", "publication_date": "2019-06-14", "keywords": ""}, {"pubmed_id": "31189750", "title": "[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].", "authors": "Y. Nishimoto, H. Yasuda, K. Masuko, Y. Usui, K. Ueda, G. Kimura, K. Ito, Y. Kizawa", "publication_date": "2019-06-14", "keywords": "Src, corticosteroid resistance, lipopolysaccharide"}, {"pubmed_id": "31187953", "title": "Dasatinib-induced nephrotic syndrome: a case of phenoconversion.", "authors": "I. Mandac Rogulj, V. Mati\u0161i\u0107, B. Arsov, L. Boban, A. Juginovi\u0107, V. Molnar, D. Primorac", "publication_date": "2019-06-13", "keywords": ""}, {"pubmed_id": "31168745", "title": "Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.", "authors": "C. Hirt, S. Iannazzo, S. Chiroli, LJ. McGarry, P. le Coutre, L. Stenke, T. Dahl\u00e9n, JH. Lipton", "publication_date": "2019-06-07", "keywords": ""}, {"pubmed_id": "31163431", "title": "Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.", "authors": "T. Devos, G. Verhoef, E. Steel, D. Mazure, P. Lewalle, D. Bron, Z. Berneman, FS. Benghiat, P. Mineur, K. Theunissen, P. Zach\u00e9e, C. Doyen, N. Put, M. Lejeune, K. Van Eygen, V. Havelange, M. Reusens, W. Pluymers, K. Peeters", "publication_date": "2019-06-05", "keywords": " Treatment interruption/discontinuation, Chronic myeloid leukaemia, Dasatinib, Imatinib, Molecular response, Nilotinib, Ponatinib, Tyrosine kinase inhibitor\u00a0"}, {"pubmed_id": "31108179", "title": "Successful oral desensitization with dasatinib in delayed cutaneous hypersensitivity reactions.", "authors": "B. Karaatmaca, S. Aytac, UM. Sahiner, BE. Sekerel, O. Soyer", "publication_date": "2019-05-21", "keywords": ""}, {"pubmed_id": "31104438", "title": "[Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy].", "authors": "L. Yu, YZ. Qin, YY. Lai, HX. Shi, XJ. Huang, Q. Jiang", "publication_date": "2019-05-21", "keywords": "Hematologic toxicity, Leukemia, myeloid, chronic, BCR-ABL (+), Tyrosine kinase inhibitors"}, {"pubmed_id": "31089794", "title": "Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.", "authors": "X. Ren, Y. Qin, X. Huang, L. Zuo, Q. Jiang", "publication_date": "2019-05-16", "keywords": "Chronic myeloid leukemia, Chronic renal injury, Tyrosine kinase inhibitors"}, {"pubmed_id": "31079659", "title": "Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center.", "authors": "AC. Moura, MT. Delamain, GBO. Duarte, I. Lorand-Metze, CA. Souza, KBB. Pagnano", "publication_date": "2019-05-14", "keywords": "Chronic myeloid leukemia, Dasatinib, Hydroxyurea, Imatinib, Interferon-alpha, Pregnancy"}, {"pubmed_id": "31079415", "title": "Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.", "authors": "A. Hamadi, AP. Grigg, G. Dobie, KL. Burbury, AP. Schwarer, FA. Kwa, DE. Jackson", "publication_date": "2019-05-13", "keywords": ""}, {"pubmed_id": "31053734", "title": "Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.", "authors": "RC. Calizo, S. Bhattacharya, JGC. van Hasselt, C. Wei, JS. Wong, RJ. Wiener, X. Ge, NJ. Wong, JJ. Lee, CM. Cuttitta, G. Jayaraman, VH. Au, W. Janssen, T. Liu, H. Li, F. Salem, EA. Jaimes, B. Murphy, KN. Campbell, EU. Azeloglu", "publication_date": "2019-05-06", "keywords": ""}, {"pubmed_id": "31044260", "title": "Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.", "authors": "G. Caocci, O. Mulas, E. Abruzzese, A. Iurlo, M. Annunziata, EM. Orlandi, S. Galimberti, G. Binotto, N. Sgherza, L. Luciano, B. Martino, A. Russo Rossi, M. Bonifacio, C. Fozza, MM. Trawinska, D. Cattaneo, C. Elena, C. Barat\u00e8, F. De Gregorio, M. Molica, G. La Nasa, R. Fo\u00e0, M. Breccia", "publication_date": "2019-05-03", "keywords": "Acetylsalicylic acid, Bosutinib, Cardiovascular risk, Chronic myeloid leukemia"}, {"pubmed_id": "31036317", "title": "Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.", "authors": "A. Kizilors, E. Cris\u00e0, N. Lea, R. Passera, S. Mian, J. Anwar, S. Best, FE. Nicolini, R. Ireland, M. Aldouri, C. Pocock, T. Corbett, R. Gale, E. Bart-Smith, S. Weston-Smith, C. Wykes, A. Kulasekararaj, S. Jackson, P. Harrington, D. McLornan, K. Raj, A. Pagliuca, GJ. Mufti, H. de Lavallade", "publication_date": "2019-05-01", "keywords": ""}, {"pubmed_id": "31036057", "title": "Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway.", "authors": "WC. Huang, KT. Kuo, CH. Wang, CT. Yeh, Y. Wang", "publication_date": "2019-05-01", "keywords": "Cancer stemness, Cisplatin resistance, Lung cancer, M2 tumor-associated macrophages (M2-TAMs), Multiple kinase inhibitor, Src signaling"}, {"pubmed_id": "31029498", "title": "Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.", "authors": "G. Caocci, O. Mulas, M. Bonifacio, E. Abruzzese, S. Galimberti, EM. Orlandi, A. Iurlo, M. Annunziata, L. Luciano, F. Castagnetti, A. Gozzini, F. Stagno, G. Binotto, P. Pregno, F. Albano, B. Martino, C. Fozza, L. Scaffidi, MM. Trawinska, C. Barat\u00e8, C. Elena, D. Cattaneo, E. Scalzulli, G. La Nasa, R. Fo\u00e0, M. Breccia", "publication_date": "2019-04-29", "keywords": "Chronic myeloid leukemia, Recurrent arterial occlusive event, Secondary prophylaxis"}, {"pubmed_id": "31020267", "title": "Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.", "authors": "T. Toya, Y. Nagatomo, K. Kagami, T. Adachi", "publication_date": "2019-04-26", "keywords": "BCR-ABL tyrosine kinase inhibitor, Case report, Dasatinib, Pulmonary arterial hypertension , Scleroderma"}, {"pubmed_id": "31016870", "title": "Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.", "authors": "J. Chang, D. Douer, I. Aldoss, G. Vahdani, AR. Jeong, Z. Ghaznavi, S. Zhang, G. Yaghmour, KJ. Lee, A. Weissman, M. Akhtari", "publication_date": "2019-04-25", "keywords": "Dasatinib, Philadelphia chromosome, acute lymphoblastic leukemia, stem cell transplantation, survival"}, {"pubmed_id": "31008998", "title": "Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study.", "authors": "T. Iwamoto, F. Monma, K. Ohishi, A. Umino, K. Suzuki, K. Oka, K. Kawakami, T. Sekine, M. Okuda, N. Katayama", "publication_date": "2019-04-23", "keywords": ""}, {"pubmed_id": "30935343", "title": "Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.", "authors": "S. Janjetovic, AM. Asemissen, F. Dicker, M. Binder, J. Dierlamm, C. Bokemeyer, P. Schafhausen", "publication_date": "2019-04-03", "keywords": "11q23 rearrangements, BCR-ABL, Chronic myeloid leukemia, blast crisis, tyrosine kinase"}, {"pubmed_id": "30932238", "title": "Sweet syndrome in a patient with chronic myelogenous leukemia under dasatinib treatment.", "authors": "T. Matsuda, I. Ueda-Hayakawa, N. Kambe, S. Fujita, H. Okamoto", "publication_date": "2019-04-02", "keywords": ""}, {"pubmed_id": "30925742", "title": "Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway.", "authors": "CH. Chang, MC. Chen, TH. Chiu, YH. Li, WC. Yu, WL. Liao, M. Oner, CR. Yu, CC. Wu, TY. Yang, CJ. Teng, KY. Chiu, KC. Chen, HY. Wang, CH. Yue, CH. Lai, JT. Hsieh, H. Lin", "publication_date": "2019-03-31", "keywords": "Arecoline, EGFR, FAK, SRC, lung cancer cells, mAchR3"}, {"pubmed_id": "30916583", "title": "Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.", "authors": "MK. Bratt\u00e5s, H. Reikvam, THA. Tvedt, \u00d8. Bruserud", "publication_date": "2019-03-28", "keywords": "Acute lymphoblastic leukemia, BCR-ABL, chemotherapy, clinical studies, dasatinib, imatinib, immunomodulation"}, {"pubmed_id": "30907446", "title": "Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.", "authors": "MM. Fachi, FS. Tonin, LP. Leonart, I. Rotta, F. Fernandez-Llimos, R. Pontarolo", "publication_date": "2019-03-26", "keywords": "chronic myeloid leukaemia, drug-related side effects and adverse reactions, network meta-analysis, tyrosine kinase inhibitors"}, {"pubmed_id": "30901283", "title": "Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach.", "authors": "SKR. Adena, M. Upadhyay, H. Vardhan, B. Mishra", "publication_date": "2019-03-23", "keywords": "chronic myeloid leukemia, cytotoxicity study, dasatinib, full factorial design, gold nanoparticles, quality by design, risk assessment"}, {"pubmed_id": "30895346", "title": "A phase I study of gemcitabine\u2009+\u2009dasatinib (gd) or gemcitabine\u2009+\u2009dasatinib\u2009+\u2009cetuximab (GDC) in refractory solid tumors.", "authors": "NB. Mettu, D. Niedzwiecki, C. Rushing, AB. Nixon, J. Jia, S. Haley, W. Honeycutt, H. Hurwitz, JC. Bendell, H. Uronis", "publication_date": "2019-03-22", "keywords": "Cetuximab, Dasatinib, Gemcitabine, Pancreatic cancer, Phase I"}, {"pubmed_id": "30885996", "title": "Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.", "authors": "P. Jain, H. Kantarjian, PC. Boddu, GM. Nogueras-Gonz\u00e1lez, S. Verstovsek, G. Garcia-Manero, G. Borthakur, K. Sasaki, TM. Kadia, P. Sam, H. Ahaneku, S. O'Brien, Z. Estrov, F. Ravandi, E. Jabbour, JE. Cortes", "publication_date": "2019-03-20", "keywords": ""}, {"pubmed_id": "30880334", "title": "Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.", "authors": "BC. Creelan, JE. Gray, T. Tanvetyanon, AA. Chiappori, T. Yoshida, MJ. Schell, SJ. Antonia, EB. Haura", "publication_date": "2019-03-19", "keywords": ""}, {"pubmed_id": "30879266", "title": "Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.", "authors": "H. Sasaki, S. Mitani, S. Kusumoto, Y. Marumo, A. Asano, T. Yoshida, T. Narita, A. Ito, H. Yano, M. Ri, T. Ishida, H. Komatsu, S. Iida", "publication_date": "2019-03-18", "keywords": "Allogeneic bone marrow transplantation, Chronic myeloid leukemia, Cord blood transplantation, Megakaryoblastic blast phase, Ponatinib"}, {"pubmed_id": "30875349", "title": "Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib.", "authors": "DJ. Hermel, A. Nael, YT. Lu, J. Kim, RK. Brynes, M. Vergara-Lluri, M. Akhtari", "publication_date": "2019-03-16", "keywords": ""}, {"pubmed_id": "30846469", "title": "Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.", "authors": "L. Cornet, C. Khouri, M. Roustit, C. Guignabert, MC. Chaumais, M. Humbert, B. Revol, F. Despas, D. Montani, JL. Cracowski", "publication_date": "2019-03-09", "keywords": ""}, {"pubmed_id": "30845905", "title": "Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.", "authors": "S. Ochiai, Y. Sato, A. Minakawa, A. Fukuda, S. Fujimoto", "publication_date": "2019-03-09", "keywords": "Dasatinib, Drug-related nephrotic syndrome, Fibrillary glomerulonephritis, Nephrotic syndrome, Tyrosine kinase inhibitor, Vascular endothelial growth factor"}, {"pubmed_id": "30831623", "title": "[Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].", "authors": "YL. Chen, L. Wang, GL. Yan, ZZ. Yang, ZP. Huang, YS. Zhang, Z. Zhao, CC. Wan, Y. Bao, H. Xiang, H. Yin, LF. Chen, YY. Xiong, L. Meng, WM. Li", "publication_date": "2019-03-05", "keywords": "Domestic dasatinib, Efficiency, Leukemia, myeloid, chronic, Safety"}, {"pubmed_id": "30831480", "title": "Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.", "authors": "AC. King, JJ. Pappacena, MS. Tallman, JH. Park, MB. Geyer", "publication_date": "2019-03-05", "keywords": "Acute lymphoblastic leukemia, Blinatumomab, Minimal residual disease, Tyrosine kinase inhibitor"}, {"pubmed_id": "30797908", "title": "Dasatinib Reinitiation After Poststroke Thrombolysis Associated with Symptomatic Intracerebral Hemorrhage.", "authors": "RA. Hamilton, M. Hathidara, SD. Shujaat, AE. Strickland, BN. Bohnstedt, B. Ray", "publication_date": "2019-02-25", "keywords": "Acute ischemic stroke, Dasatinib, Symptomatic intracranial hemorrhage, Thrombolytic therapy, Tissue plasminogen activator"}, {"pubmed_id": "30785770", "title": "Tyrosine Kinase Inhibitor-associated Fibrothorax.", "authors": "AM. Adrianza, CA. Jimenez, GL. Aldana, L. Pozo, JE. Cortes, AES. Sagar", "publication_date": "2019-02-21", "keywords": ""}, {"pubmed_id": "30762219", "title": "Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.", "authors": "M. Kizaki, N. Takahashi, N. Iriyama, S. Okamoto, T. Ono, N. Usui, K. Inokuchi, C. Nakaseko, M. Kurokawa, M. Sumi, F. Nakamura, T. Kawaguchi, R. Suzuki, K. Yamamoto, K. Ohnishi, I. Matsumura, T. Naoe, ", "publication_date": "2019-02-15", "keywords": "BCR-ABL1, Chronic myeloid leukemia (CML), Early molecular response (EMR), Overall survival (OS), Tyrosine kinase inhibitor (TKI)"}, {"pubmed_id": "30761815", "title": "Current perspectives for the treatment of chronic myeloid leukemia", "authors": "E. Alada\u011f, \u0130C. Haznedaro\u011flu", "publication_date": "2019-02-15", "keywords": "Chronic, myeloid, leukemia, tyrosine, kinase, inhibitors"}, {"pubmed_id": "30759203", "title": "Coronary epicardic vasospasm in patient treated with desatinib for lymphoblastic leukaemia: the other side of the medal.", "authors": "G. Scalone, L. Mariani, A. Aimi, P. Grossi", "publication_date": "2019-02-14", "keywords": ""}, {"pubmed_id": "30728276", "title": "Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.", "authors": "AP. Mitchell, AN. Winn, JL. Lund, SB. Dusetzina", "publication_date": "2019-02-08", "keywords": "Antineoplastic agents, Conflict of interest, Drug industry, Drug prescriptions, Physicians, Practice patterns"}, {"pubmed_id": "30715668", "title": "Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.", "authors": "T. Toya, Y. Nagatomo, K. Kagami, M. Yukino, R. Yasuda, T. Namba, Y. Ido, S. Kobayashi, N. Masaki, H. Yada, F. Kimura, T. Adachi", "publication_date": "2019-02-05", "keywords": "CT, Dasatinib, EUTOS score, Pulmonary arterial hypertension"}, {"pubmed_id": "30711891", "title": "A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1", "authors": "KV. Gleixner, I. Sadovnik, M. Schneeweiss, G. Eisenwort, K. Byrgazov, G. Stefanzl, D. Berger, H. Herrmann, E. Hadzijusufovic, T. Lion, P. Valent", "publication_date": "2019-02-04", "keywords": "BCR-ABL1 T315I, Bosutinib, Drug combinations, Drug resistance"}, {"pubmed_id": "30705677", "title": "NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.", "authors": "MC. Chang, HI. Cheng, K. Hsu, YN. Hsu, CW. Kao, YF. Chang, KH. Lim, CG. Chen", "publication_date": "2019-02-02", "keywords": "BCR-ABL, CML, NKG2A, deep molecular response (DMR), major molecular response (MMR), natural killer cell, p38 mitogen-activated protein kinase"}, {"pubmed_id": "30675645", "title": "Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.", "authors": "I. Abou Dalle, E. Jabbour, NJ. Short, F. Ravandi", "publication_date": "2019-01-25", "keywords": "Acute lymphoblastic leukemia, Allogeneic stem cell transplantation, BCR-ABL, Blinatumomab, Inotuzumab, Tyrosine kinase inhibitor"}, {"pubmed_id": "30660512", "title": "Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.", "authors": "PM. Assun\u00e7\u00e3o, TP. Lana, MT. Delamain, GO. Duarte, R. Zulli, I. Lorand-Metze, CA. de Souza, EV. de Paula, KB. Barbosa Pagnano", "publication_date": "2019-01-21", "keywords": "Cardiovascular adverse events, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib"}, {"pubmed_id": "30657460", "title": "Integrative identification of unexpected kinase-inhibitor interactions in the MAPK-mediated proliferation and differentiation of Mc3T3-E1 osteoblasts.", "authors": "L. Zhao, Q. Huang, S. Tian, J. Ge, H. Zhu, Q. Dong", "publication_date": "2019-01-19", "keywords": ""}, {"pubmed_id": "30616998", "title": "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.", "authors": "JN. Justice, AM. Nambiar, T. Tchkonia, NK. LeBrasseur, R. Pascual, SK. Hashmi, L. Prata, MM. Masternak, SB. Kritchevsky, N. Musi, JL. Kirkland", "publication_date": "2019-01-09", "keywords": "Aging, Cellular senescence, Clinical trial, Idiopathic pulmonary fibrosis, Interstitial lung disease, Senolytics, Translation"}, {"pubmed_id": "30612898", "title": "Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis.", "authors": "M. Ogrodnik, Y. Zhu, LGP. Langhi, T. Tchkonia, P. Kr\u00fcger, E. Fielder, S. Victorelli, RA. Ruswhandi, N. Giorgadze, T. Pirtskhalava, O. Podgorni, G. Enikolopov, KO. Johnson, M. Xu, C. Inman, AK. Palmer, M. Schafer, M. Weigl, Y. Ikeno, TC. Burns, JF. Passos, T. von Zglinicki, JL. Kirkland, D. Jurk", "publication_date": "2019-01-08", "keywords": "aging, anxiety, anxiety-like behavior, brain, high-fat diet, lipid droplets, neurogenesis, obesity, senescence, stem cells"}, {"pubmed_id": "30607629", "title": "Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.", "authors": "A. Ocana, M. Gil-Martin, S. Antol\u00edn, M. Atienza, \u00c1. Monta\u00f1o, N. Ribelles, A. Urruticoechea, A. Falc\u00f3n, S. Pernas, J. Orlando, JC. Montero, MJ. Escudero, S. Benito, R. Caballero, E. Carrasco, F. Rojo, A. Pandiella, M. Ruiz-Borrego", "publication_date": "2019-01-05", "keywords": "Dasatinib, HER2-positive breast cancer, Metastatic breast cancer, Phase II, SRC kinase inhibitor, Trastuzumab resistance"}, {"pubmed_id": "30536062", "title": "Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.", "authors": "LF. Chen, GL. Yuan, ZD. Zhong, P. Zou, DJ. Li, Y. Bao, HB. Ren, L. Meng, WM. Li", "publication_date": "2018-12-12", "keywords": "chronic myeloid leukemia, generic dasatinib, safety, second-line treatment efficacy"}, {"pubmed_id": "30531140", "title": "[Agranulocytosis during therapy of chronic myeloid leukemia lymphoid blast crisis with dasatinib].", "authors": "M. Hatsuse, Y. Taminishi, S. Maegawa-Matsui, SI. Fuchida, A. Okano, S. Murakami, T. Inaba, C. Shimazaki", "publication_date": "2018-12-12", "keywords": "Agranulocytosis, Dasatinib, Large granular lymphocyte, Off-target effect"}, {"pubmed_id": "30520026", "title": "Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.", "authors": "JM. Umakanthan, J. Iqbal, CL. Batlevi, A. Bouska, LM. Smith, V. Shostrom, H. Nutsch, BM. William, R. Gregory Bociek, M. Lunning, P. Bierman, A. Younes, JO. Armitage, JM. Vose", "publication_date": "2018-12-07", "keywords": "\nNHL\n, dasatinib, mutation analysis, phase 2 study, relapsed/refractory lymphoma"}, {"pubmed_id": "30482914", "title": "Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.", "authors": "J. Tian, FA. Raffa, M. Dai, A. Moamer, B. Khadang, IY. Hachim, K. Bakdounes, S. Ali, B. Jean-Claude, JJ. Lebrun", "publication_date": "2018-11-30", "keywords": ""}, {"pubmed_id": "30466746", "title": "Why and how to treat Ph-like ALL?", "authors": "KG. Roberts", "publication_date": "2018-11-24", "keywords": "ABL, ALL, Acute lymphoblastic leukemia, BCR-ABL1-like ALL, Dasatinib, JAK-STAT, Larotrectinib, Ph-like ALL, Philadelphia chromosome-like ALL, Ruxolitinib, St Jude TXVII"}, {"pubmed_id": "30465234", "title": "Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.", "authors": "EH. McCafferty, S. Dhillon, ED. Deeks", "publication_date": "2018-11-23", "keywords": ""}, {"pubmed_id": "30446802", "title": "Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.", "authors": "V. Garc\u00eda-Guti\u00e9rrez, D. Milojkovic, JC. Hernandez-Boluda, S. Claudiani, ML. Martin Mateos, LF. Casado-Montero, G. Gonz\u00e1lez, A. Jimenez-Velasco, C. Boque, A. Martinez-Trillos, IM. V\u00e1zquez, \u00c1R. Payer, A. Sen\u00edn, E. Amustio D\u00edez, AB. Garc\u00eda, GB. Carrascosa, G. Ort\u00ed, BC. Ruiz, M\u00c1. Fern\u00e1ndez, M. Del Carmen Garc\u00eda Garay, P. Giraldo, JM. Guinea, N. De Las Heras Rodr\u00edguez, N. Hern\u00e1n, AI. P\u00e9rez, M. Piris-Villaespesa, JLL. Lorenzo, JMM. Mart\u00ed-Tutusaus, RO. Vallansot, F. Ortega Rivas, JM. Puerta, MJ. Ramirez, E. Romero, A. Romo, A. Rosell, SS. Saavedra, A. Sebrango, J. Tallon, S. Valencia, A. Portero, JL. Steegmann, ", "publication_date": "2018-11-18", "keywords": "Bosutinib, Chronic myeloid leukemia, Intolerant, Resistance, Treatment"}, {"pubmed_id": "30416159", "title": "[Inflammatory reactive polyposis caused by dasatinib:a case report].", "authors": "M. Kobayashi, K. Ikezawa, M. Yamaura, Y. Hagiwara, K. Iwai, D. Ochi, K. Otsuka, A. Soeda", "publication_date": "2018-11-13", "keywords": ""}, {"pubmed_id": "30370673", "title": "Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.", "authors": "T. Sasaki, OE. Franco, K. Ohishi, Y. Filipovich, K. Ishii, SE. Crawford, N. Takahashi, N. Katayama, Y. Sugimura, SW. Hayward", "publication_date": "2018-10-30", "keywords": "imatinib, nilotinib, prostate specific antigen, tyrosine kinase inhibitor"}, {"pubmed_id": "30318751", "title": "A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.", "authors": "A. Zulbaran-Rojas, HK. Lin, Q. Shi, LA. Williams, B. George, G. Garcia-Manero, E. Jabbour, S. O'Brien, F. Ravandi, W. Wierda, Z. Estrov, G. Borthakur, T. Kadia, C. Cleeland, JE. Cortes, H. Kantarjian", "publication_date": "2018-10-16", "keywords": "BCR-ABL, chronic myeloid leukemia, symptom burden, tyrosine kinase inhibitors"}, {"pubmed_id": "30296736", "title": "Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.", "authors": "MM. Fachi, FS. Tonin, LP. Leonart, KS. Aguiar, L. Lenzi, BC. Figueiredo, F. Fernandez-Llimos, R. Pontarolo", "publication_date": "2018-10-09", "keywords": "Chronic myeloid leukaemia, Efficacy, Network meta-analysis, Safety, Tyrosine kinase inhibitors"}, {"pubmed_id": "30290003", "title": "Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.", "authors": "R. Hehlmann, JE. Cortes, T. Zyczynski, C. Gambacorti-Passerini, SL. Goldberg, MJ. Mauro, M. Michallet, B. Simonsson, LA. Williams, S. Gajavelli, I. DeGutis, GP. Sen, RL. Paquette", "publication_date": "2018-10-06", "keywords": ""}, {"pubmed_id": "30288121", "title": "First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis.", "authors": "KK. Chen, TF. Du, KS. Wu, W. Yang", "publication_date": "2018-10-06", "keywords": "CML, bosutinib, dasatinib, imatinib, nilotinib, tyrosine kinase inhibitor"}, {"pubmed_id": "30288058", "title": "Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.", "authors": "M. Chaar, J. Kamta, S. Ait-Oudhia", "publication_date": "2018-10-06", "keywords": "cardiovascular toxicity, dasatinib, lapatinib, sorafenib, tyrosine kinase inhibitors"}, {"pubmed_id": "30283618", "title": "Clinical significance of dasatinib-induced pleural effusion in patients with de ", "authors": "A. Nakaya, S. Fujita, A. Satake, T. Nakanishi, Y. Azuma, Y. Tsubokura, M. Hotta, H. Yoshimura, K. Ishii, T. Ito, S. Nomura", "publication_date": "2018-10-05", "keywords": "Chronic myeloid leukemia, Dasatinib, adverse event, large granular lymphocyte, late-onset, pleural effusion"}, {"pubmed_id": "30220658", "title": "Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia.", "authors": "RB. Fiets, AHJ. Staal, GE. Cramer, NMA. Blijlevens", "publication_date": "2018-09-18", "keywords": ""}, {"pubmed_id": "30199910", "title": "[Chronic Myelogenous Leukemia].", "authors": "A. Hochhaus, E. Eigendorff, T. Ernst", "publication_date": "2018-09-11", "keywords": ""}, {"pubmed_id": "30197324", "title": "Bosutinib: Valuable therapeutic option for the Bulgarian market.", "authors": "KH. Uzunova, EP. Filipova, TY. Vekov", "publication_date": "2018-09-11", "keywords": "Bosutinib, chronic myelogenous leukemia, efficacy, review of costs, safety, tyrosine kinase inhibitors"}, {"pubmed_id": "30196795", "title": "Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature.", "authors": "P. Rujirachun, A. Junyavoraluk, W. Owattanapanich, V. Suvannarerg, S. Sirinvaravong", "publication_date": "2018-09-11", "keywords": "Chronic myeloid leukemia, Hypercalcemia, Leukemic arthritis, Osteolytic bone"}, {"pubmed_id": "30190469", "title": "Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.", "authors": "O. Ottmann, G. Saglio, JF. Apperley, C. Arthur, E. Bullorsky, A. Charbonnier, JF. Dipersio, H. Kantarjian, HJ. Khoury, DW. Kim, D. Healey, L. Strauss, JE. Cortes", "publication_date": "2018-09-08", "keywords": ""}, {"pubmed_id": "30180449", "title": "[Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].", "authors": "XL. Dou, SS. Wang, JL. Fang, L. Yu, X. Ren, XJ. Huang, Q. Jiang", "publication_date": "2018-09-06", "keywords": "Leukemia, myelogenous, chronic, Liver adverse events, Tyrosine kinase inhibitor"}, {"pubmed_id": "30159669", "title": "Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.", "authors": "X. Huang, Q. Jiang, J. Hu, J. Li, J. Jin, F. Meng, Z. Shen, T. Liu, D. Wu, J. Wang, J. Wang", "publication_date": "2018-08-31", "keywords": "chronic myeloid leukemia (CML), dasatinib, long-term follow-up, tyrosine kinase inhibitor"}, {"pubmed_id": "30155792", "title": "Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.", "authors": "K. Seiter, D. Latremouille-Viau, A. Guerin, B. Ndife, K. Habucky, DH. Tang, I. Pivneva, P. Gagnon-Sanschagrin, GJ. Joseph", "publication_date": "2018-08-30", "keywords": "Chronic myeloid leukemia, Costs, Dasatinib, Healthcare resource utilization, Infections, Nilotinib, Oncology"}, {"pubmed_id": "30151740", "title": "Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.", "authors": "N. Watanabe, T. Takaku, K. Takeda, S. Shirane, T. Toyota, M. Koike, M. Noguchi, T. Hirano, H. Fujiwara, N. Komatsu", "publication_date": "2018-08-29", "keywords": "CD57 expression, Chronic myelogenous leukemia, Cytotoxic CD4+ T cell, Dasatinib, Large granular lymphocyte"}, {"pubmed_id": "30150345", "title": "Unusual case of dasatinib-associated acute bilateral hyphemas leading to blindness in a patient with chronic myeloid leukaemia.", "authors": "S. Sharma, N. Garg, CM. Ghiuzeli", "publication_date": "2018-08-29", "keywords": "chronic myeloid leukemia, dasatinib, hyphemas"}, {"pubmed_id": "30144071", "title": "Src mediates TGF-\u03b2-induced intraocular pressure elevation in glaucoma.", "authors": "T. Tsukamoto, K. Kajiwara, S. Nada, M. Okada", "publication_date": "2018-08-26", "keywords": "CasL, Src, TGF-\u03b2, glaucoma, trabecular meshwork"}, {"pubmed_id": "30112222", "title": "Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature.", "authors": "B. Alharbi, S. Alamri, A. Mahdi, S. Marghalani", "publication_date": "2018-08-17", "keywords": ""}, {"pubmed_id": "30093398", "title": "Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.", "authors": "TP. Hughes, P. Laneuville, P. Rousselot, DS. Snyder, D. Rea, NP. Shah, D. Paar, E. Abruzzese, A. Hochhaus, JH. Lipton, JE. Cortes", "publication_date": "2018-08-11", "keywords": ""}, {"pubmed_id": "30093283", "title": "Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.", "authors": "P. Chopade, LP. Akard", "publication_date": "2018-08-11", "keywords": "BCR-ABL1, Clinical trial, Molecular monitoring, Philadelphia chromosome, Treatment-free remission"}, {"pubmed_id": "30084127", "title": "Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.", "authors": "H. Kurosawa, A. Tanizawa, H. Muramatsu, C. Tono, A. Watanabe, H. Shima, M. Ito, Y. Yuza, K. Hamamoto, N. Hotta, M. Okada, AM. Saito, A. Manabe, S. Mizutani, S. Adachi, K. Horibe, E. Ishii, H. Shimada", "publication_date": "2018-08-08", "keywords": "CML, dasatinib, imatinib, nilotinib"}, {"pubmed_id": "30078165", "title": "Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.", "authors": "A. Chiba, T. Toya, H. Mizuno, J. Tokushige, F. Nakamura, K. Nakazaki, M. Kurokawa", "publication_date": "2018-08-06", "keywords": "Allogeneic hematopoietic stem cell transplantation, Blast phase, Central nervous system, Chronic myelogenous leukemia, Tyrosine kinase inhibitor"}, {"pubmed_id": "30069627", "title": "Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.", "authors": "J. Wehrle, N. von Bubnoff", "publication_date": "2018-08-03", "keywords": "CML, Ponatinib, Tyrosine Kinase Inhibitor (TKI)"}, {"pubmed_id": "30069626", "title": "Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.", "authors": "S. Isfort, M. Crysandt, D. Gezer, S. Koschmieder, TH. Br\u00fcmmendorf, D. Wolf", "publication_date": "2018-08-03", "keywords": "Bosutinib, CML, Keywords, Tyrosine kinase inhibitor"}, {"pubmed_id": "30069624", "title": "Dasatinib.", "authors": "M. Lindauer, A. Hochhaus", "publication_date": "2018-08-03", "keywords": "Chronic myeloid leukemia, Dasatinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "30069623", "title": "Imatinib Mesylate.", "authors": "CF. Waller", "publication_date": "2018-08-03", "keywords": "CML, Imatinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "30067428", "title": "Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia.", "authors": "G. Mezei, IB. Debreceni, A. Kerenyi, G. Remenyi, R. Szasz, A. Illes, J. Kappelmayer, P. Batar", "publication_date": "2018-08-02", "keywords": "Bleeding, coated-platelets, dasatinib therapy, platelet activation, primary hemostasis"}, {"pubmed_id": "30058149", "title": "Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines.", "authors": "CCLM. Boons, L. Harbers, L. Timmers, J. de Jong, EL. Swart, N. Harry Hendrikse, JJWM. Janssen, JG. Hugtenburg", "publication_date": "2018-07-31", "keywords": "chronic myeloid leukaemia, medication adherence, medication information, patients\u2019 experiences, qualitative research, tyrosine kinase inhibitors"}, {"pubmed_id": "30054949", "title": "Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.", "authors": "Z. Racil, E. Koritakova, T. Sacha, H. Klamova, P. Belohlavkova, E. Faber, D. Rea, L. Malaskova, J. Prochazkova, D. Zackova, J. Voglova, J. W\u0105c\u0142aw, P. Cetkovsky, P. Zak, J. Mayer", "publication_date": "2018-07-29", "keywords": ""}, {"pubmed_id": "30043130", "title": "Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.", "authors": "A. Bettiol, E. Marconi, N. Lombardi, G. Crescioli, F. Gherlinzoni, T. Walley, A. Vannacci, A. Chinellato, P. Giusti", "publication_date": "2018-07-26", "keywords": ""}, {"pubmed_id": "30026450", "title": "[A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].", "authors": "M. Sato, S. Watanabe, N. Aoki, K. Asakawa, H. Moriyama, Y. Oshima, T. Koya, K. Okazuka, T. Kikuchi", "publication_date": "2018-07-22", "keywords": ""}, {"pubmed_id": "30019935", "title": "The murine dialysis fistula model exhibits a senescence phenotype: pathobiological mechanisms and therapeutic potential.", "authors": "KA. Nath, DR. O'Brien, AJ. Croatt, JP. Grande, AW. Ackerman, MC. Nath, S. Yamada, A. Terzic, T. Tchkonia, JL. Kirkland, ZS. Katusic", "publication_date": "2018-07-19", "keywords": "age, dialysis, fistula, senolytics, vascular stress"}, {"pubmed_id": "29975149", "title": "Dasatinib induces gene expression of CYP1A1, CYP1B1, and cardiac hypertrophy markers (BNP, \u03b2-MHC) in rat cardiomyocyte H9c2 cells.", "authors": "AMS. Alsaad", "publication_date": "2018-07-06", "keywords": "AhR, BNP, CYP1A1, CYP1B1, Dasatinib, H9c2, \u03b2-MHC"}, {"pubmed_id": "29956623", "title": "Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.", "authors": "Y. Qian, L. Yu, XH. Zhang, ZQ. Yuan, P. Zhao, LN. Sun, YQ. Wang", "publication_date": "2018-06-30", "keywords": "Platelet-derived growth factor receptor, pharmacodynamics, pharmacogenomics, pharmacokinetics, small-molecule inhibitors, tyrosine kinase inhibitors."}, {"pubmed_id": "29955943", "title": "Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?", "authors": "S. Osorio, V. Escudero-Vilaplana, I. G\u00f3mez-Centuri\u00f3n, R. P\u00e9rez-L\u00f3pez, R. Ayala, F. Vall-Llovera, V. Garc\u00eda-Gutierrez, MT. G\u00f3mez Casares, JD. Gonz\u00e1lez San Miguel, J\u00c1. Hern\u00e1ndez-Rivas, F. S\u00e1nchez-Guijo, AB. Mart\u00ednez-Garc\u00eda, L. Villal\u00f3n, V. Conesa-Garc\u00eda, A. Rodriguez, F. Casado, X. Garcia-Gonzalez, MN. S\u00e1ez Perdomo, \u00da. Ba\u00f1os, JL. Steegmann, ", "publication_date": "2018-06-30", "keywords": "Chronic myeloid leukemia, Drug interactions, Tyrosine kinase inhibitors"}, {"pubmed_id": "29953021", "title": "Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.", "authors": "YF. Tsai, WC. Huang, SF. Cho, HH. Hsiao, YC. Liu, SF. Lin, TC. Liu, CS. Chang", "publication_date": "2018-06-29", "keywords": ""}, {"pubmed_id": "29946911", "title": "Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.", "authors": "I. Fujioka, T. Takaku, N. Iriyama, M. Tokuhira, Y. Kimura, E. Sato, M. Ishikawa, T. Nakazato, KJ. Sugimoto, H. Fujita, N. Asou, M. Kizaki, Y. Hatta, N. Komatsu, T. Kawaguchi", "publication_date": "2018-06-28", "keywords": "Cardiovascular disease, Chronic myeloid leukemia, Japanese patients, Tyrosine kinase inhibitor, Vascular adverse events"}, {"pubmed_id": "29945329", "title": "Interferon-\u03b1 Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation.", "authors": "Y. Zeng, J. Zhang, X. Li, L. Zhang, J. Liu", "publication_date": "2018-06-27", "keywords": ""}, {"pubmed_id": "29943846", "title": "Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.", "authors": "J. Mah\u00e9, EP. de Campaigno, AL. Chen\u00e9, JL. Montastruc, F. Despas, P. Jolliet", "publication_date": "2018-06-27", "keywords": "drug safety, pharmacodynamics, pharmacovigilance"}, {"pubmed_id": "29943365", "title": "Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia.", "authors": "T. Hamada, N. Iriyama, H. Takahashi, K. Miura, Y. Uchino, M. Nakagawa, Y. Hatta, M. Takei", "publication_date": "2018-06-27", "keywords": ""}, {"pubmed_id": "29941400", "title": "Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review.", "authors": "AM. Won, P. Boddu, AO. Otun, R. Aponte-Wesson, M. Chambers", "publication_date": "2018-06-27", "keywords": ""}, {"pubmed_id": "29909197", "title": "Plasmonic Au nanostar Raman probes coupling with highly ordered TiO", "authors": "S. Wen, Y. Su, R. Wu, S. Zhou, Q. Min, GC. Fan, LP. Jiang, RB. Song, JJ. Zhu", "publication_date": "2018-06-18", "keywords": "Caspase-3, Cell apoptosis, Chronic myeloid leukemia, Drug evaluation, SERS sensor"}, {"pubmed_id": "29886783", "title": "Hsp90 inhibitors as senolytic drugs to extend healthy aging.", "authors": "H. Fuhrmann-Stroissnigg, LJ. Niedernhofer, PD. Robbins", "publication_date": "2018-06-12", "keywords": "Aging, DNA damage, Mitochondria, apoptosis, cell senescence"}, {"pubmed_id": "29867576", "title": "Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension.", "authors": "C. Fazakas, C. Nagaraj, D. Zabini, AG. V\u00e9gh, LM. Marsh, I. Wilhelm, IA. Krizbai, H. Olschewski, A. Olschewski, Z. B\u00e1lint", "publication_date": "2018-06-06", "keywords": "Rho-kinase, dasatinib, endothelial cells, endothelial elasticity, paracellular permeability, pulmonary arterial hypertension"}, {"pubmed_id": "29854497", "title": "Dasatinib-Induced Rhabdomyolysis in a 33-Year-Old Patient with Chronic Myeloid Leukemia.", "authors": "AS. Joel Chandranesan, S. Master, O. Antosz, B. PeytonThomas, N. Koshy", "publication_date": "2018-06-02", "keywords": ""}, {"pubmed_id": "29846829", "title": "Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.", "authors": "T. Nakazato, N. Iriyama, M. Tokuhira, M. Ishikawa, E. Sato, T. Takaku, KJ. Sugimoto, H. Fujita, I. Fujioka, Y. Kimura, Y. Aisa, E. Iwanaga, N. Asou, M. Kizaki, Y. Hatta, N. Komatsu, T. Kawaguchi", "publication_date": "2018-05-31", "keywords": "Chronic myeloid leukemia, Second malignancies, Standardized incidence ratio, Tyrosine kinase inhibitor"}, {"pubmed_id": "29845876", "title": "Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.", "authors": "M. Breccia, F. Efficace, A. Iurlo, L. Luciano, E. Abruzzese, A. Gozzini, P. Pregno, M. Tiribelli, G. Rosti, G. Minotti", "publication_date": "2018-05-31", "keywords": "Chronic myeloid leukemia, QoL, intolerance, safety, tyrosine kinase inhibitors"}, {"pubmed_id": "29845477", "title": "Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study.", "authors": "S. Mizuta, M. Sawa, H. Tsurumi, K. Matsumoto, K. Miyao, T. Hara, T. Takahashi, R. Sakemura, H. Kojima, A. Kohno, MS. Oba, S. Morita, J. Sakamoto, N. Emi", "publication_date": "2018-05-31", "keywords": "Chronic myeloid leukemia, Dasatinib, Individualized dasatinib therapy, Plasma concentration, Treatment adherence"}, {"pubmed_id": "29812996", "title": "Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.", "authors": "WB. Slayton, KR. Schultz, JA. Kairalla, M. Devidas, X. Mi, MA. Pulsipher, BH. Chang, C. Mullighan, I. Iacobucci, LB. Silverman, MJ. Borowitz, AJ. Carroll, NA. Heerema, JM. Gastier-Foster, BL. Wood, SL. Mizrahy, T. Merchant, VI. Brown, L. Sieger, MJ. Siegel, EA. Raetz, NJ. Winick, ML. Loh, WL. Carroll, SP. Hunger", "publication_date": "2018-05-31", "keywords": ""}, {"pubmed_id": "29806063", "title": "Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.", "authors": "M. Molica, E. Scalzulli, G. Colafigli, DA. Fegatelli, F. Massaro, R. Latagliata, R. Fo\u00e0, M. Breccia", "publication_date": "2018-05-29", "keywords": "Cardiovascular events, Chronic myeloid leukemia, Estimated glomerular filtration"}, {"pubmed_id": "29766825", "title": "Anti-glioma Effects of Caffeic Acid Phenethyl Ester and Dasatinib Combination Therapy in an in vivo Rat Glioma Model.", "authors": "HM. Balkhi, E. Haq, T. Gul, S. Sana", "publication_date": "2018-05-17", "keywords": "Antineoplastic agents, brain neoplasms, caffeic acid phenethyl ester, dasatinib, glioma, protein kinase inhibitors, wistar rats."}, {"pubmed_id": "29754527", "title": "Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib.", "authors": "JC. Bergman, TY. Ly, MM. Keating, PR. Hull", "publication_date": "2018-05-15", "keywords": "Sweet disease, dasatinib, fixed drug eruption, neutrophilic dermatosis, recurrent"}, {"pubmed_id": "29742077", "title": "Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.", "authors": "M. Yilmaz, H. Kantarjian, F. Ravandi-Kashani, NJ. Short, E. Jabbour", "publication_date": "2018-05-10", "keywords": ""}, {"pubmed_id": "29741440", "title": "Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.", "authors": "A. Gover-Proaktor, G. Granot, M. Pasmanik-Chor, O. Pasvolsky, S. Shapira, O. Raz, P. Raanani, A. Leader", "publication_date": "2018-05-10", "keywords": "CML, angiogenesis, endothelial cells, vascular biology"}, {"pubmed_id": "29727044", "title": "Chronic myeloid leukemia following treatment for bilateral retinoblastoma.", "authors": "T. Kamitori, K. Umeda, K. Tasaka, H. Ogata, T. Mikami, I. Kato, H. Hiramatsu, T. Kondo, S. Adachi", "publication_date": "2018-05-05", "keywords": ""}, {"pubmed_id": "29723397", "title": "Early results of lower dose dasatinib (50\u2009mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.", "authors": "K. Naqvi, E. Jabbour, J. Skinner, M. Yilmaz, A. Ferrajoli, P. Bose, P. Thompson, Y. Alvarado, N. Jain, K. Takahashi, J. Burger, Z. Estrov, G. Borthakur, N. Pemmaraju, S. Paul, J. Cortes, HM. Kantarjian", "publication_date": "2018-05-04", "keywords": "chronic myeloid leukemia, complete cytogenetic response, dasatinib, major molecular response"}, {"pubmed_id": "29720733", "title": "Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.", "authors": "P. Paschka, RF. Schlenk, D. Weber, A. Benner, L. Bullinger, M. Heuser, VI. Gaidzik, F. Thol, M. Agrawal, V. Teleanu, M. L\u00fcbbert, W. Fiedler, M. Radsak, J. Krauter, HA. Horst, R. Greil, K. Mayer, A. K\u00fcndgen, U. Martens, G. Heil, HR. Salih, B. Hertenstein, C. Schw\u00e4nen, G. Wulf, E. Lange, M. Pfreundschuh, M. Ringhoffer, M. Girschikofsky, T. Heinicke, D. Kraemer, G. G\u00f6hring, A. Ganser, K. D\u00f6hner, H. D\u00f6hner", "publication_date": "2018-05-04", "keywords": ""}, {"pubmed_id": "29695943", "title": "Bosutinib in chronic myeloid leukemia: patient selection and perspectives.", "authors": "S. Isfort, TH. Br\u00fcmmendorf", "publication_date": "2018-04-27", "keywords": "individual comorbidity profile, side effect profile, tyrosine kinase inhibitors"}, {"pubmed_id": "29687320", "title": "Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.", "authors": "JA. Kennedy, G. Hobbs", "publication_date": "2018-04-25", "keywords": "BCR-ABL, Chronic myeloid leukemia, Treatment-free remission, Tyrosine kinase inhibitors"}, {"pubmed_id": "29680193", "title": "Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.", "authors": "PG. Morris, S. Rota, K. Cadoo, S. Zamora, S. Patil, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, AD. Seidman, N. Sklarin, L. Norton, CA. Hudis, MN. Fornier", "publication_date": "2018-04-24", "keywords": "Advanced breast cancer, Dasatinib, Metastatic breast cancer, Paclitaxel, SRC"}, {"pubmed_id": "29675611", "title": "Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.", "authors": "M. Breccia, E. Abruzzese, F. Castagnetti, M. Bonifacio, D. Gangemi, F. Sor\u00e0, A. Iurlo, L. Luciano, A. Gozzini, M. Gentile, M. Bocchia, D. Luzi, A. Maggi, N. Sgherza, A. Isidori, M. Crugnola, P. Pregno, AR. Scortechini, I. Capodanno, M. Pizzuti, R. Fo\u00e0", "publication_date": "2018-04-21", "keywords": "Chronic myeloid leukemia, Ponatinib, Prognosis, Second line"}, {"pubmed_id": "29999860", "title": "Drugs and Lactation Database (LactMed)", "authors": "", "publication_date": "2006", "keywords": ""}, {"pubmed_id": "29660177", "title": "Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.", "authors": "S. Ota, T. Matsukawa, S. Yamamoto, S. Ito, M. Shindo, K. Sato, T. Kondo, K. Kohda, H. Sakai, A. Mori, T. Takahashi, H. Ikeda, H. Kuroda, Y. Haseyama, M. Yamamoto, T. Sarashina, M. Yoshida, R. Kobayashi, M. Nishio, T. Ishihara, Y. Hirayama, Y. Kakinoki, H. Kobayashi, T. Fukuhara, M. Imamura, M. Kurosawa", "publication_date": "2018-04-17", "keywords": "adverse events, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, tyrosine kinase inhibitor"}, {"pubmed_id": "29616864", "title": "A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.", "authors": "RL. Redner, JH. Beumer, P. Kropf, M. Agha, M. Boyiadzis, K. Dorritie, R. Farah, JZ. Hou, A. Im, SH. Lim, A. Raptis, A. Sehgal, SM. Christner, D. Normolle, DE. Johnson", "publication_date": "2018-04-05", "keywords": "AML, ATRA, dasatinib, pharmacodynamics, pharmacokinetics, phase I"}, {"pubmed_id": "29610029", "title": "Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.", "authors": "M. Okada, J. Imagawa, H. Tanaka, H. Nakamae, M. Hino, K. Murai, Y. Ishida, T. Kumagai, S. Sato, K. Ohashi, H. Sakamaki, H. Wakita, N. Uoshima, Y. Nakagawa, Y. Minami, M. Ogasawara, T. Takeoka, H. Akasaka, T. Utsumi, N. Uike, T. Sato, S. Ando, K. Usuki, S. Mizuta, S. Hashino, T. Nomura, M. Shikami, H. Fukutani, Y. Ohe, H. Kosugi, H. Shibayama, Y. Maeda, T. Fukushima, H. Yamazaki, K. Tsubaki, T. Kukita, Y. Adachi, T. Nataduka, H. Sakoda, H. Yokoyama, T. Okamoto, Y. Shirasugi, Y. Onishi, M. Nohgawa, S. Yoshihara, S. Morita, J. Sakamoto, S. Kimura, ", "publication_date": "2018-04-04", "keywords": "CML, DADI, Natural killer cell, Stop trial, Treatment-free remission"}, {"pubmed_id": "29609532", "title": "Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.", "authors": "E. Atallah, CA. Schiffer, KP. Weinfurt, MJ. Zhang, JP. Radich, VG. Oehler, J. Pinilla-Ibarz, MWN. Deininger, L. Lin, RA. Larson, MJ. Mauro, JO. Moore, EK. Ritchie, NP. Shah, RT. Silver, M. Wadleigh, J. Cortes, J. Thompson, J. Guhl, MM. Horowitz, KE. Flynn", "publication_date": "2018-04-04", "keywords": "Chronic myeloid leukemia, Clinical trial, Discontinuation, Oncology, Patient-reported outcome, Study design, Targeted therapy, Tyrosine kinase inhibitor"}, {"pubmed_id": "29567798", "title": "Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.", "authors": "JE. Cortes, DW. Kim, J. Pinilla-Ibarz, PD. le Coutre, R. Paquette, C. Chuah, FE. Nicolini, JF. Apperley, HJ. Khoury, M. Talpaz, DJ. DeAngelo, E. Abruzzese, D. Rea, M. Baccarani, MC. M\u00fcller, C. Gambacorti-Passerini, S. Lustgarten, VM. Rivera, FG. Haluska, F. Guilhot, MW. Deininger, A. Hochhaus, TP. Hughes, NP. Shah, HM. Kantarjian", "publication_date": "2018-03-24", "keywords": ""}, {"pubmed_id": "29556695", "title": "Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.", "authors": "DW. Kim, S. Saussele, LA. Williams, H. Mohamed, Y. Rong, T. Zyczynski, J. Pinilla-Ibarz, E. Abruzzese", "publication_date": "2018-03-21", "keywords": "Adverse effects, Chronic myeloid leukemia, Quality of life, Tyrosine kinase"}, {"pubmed_id": "29515069", "title": "[Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment].", "authors": "S. Watanuki, T. Kikuchi, T. Toyama, R. Abe, H. Nakayama, D. Karigane, T. Shimizu, J. Kikuchi, K. Matsumoto, H. Yasuoka, M. Kataoka, S. Okamoto, T. Mori", "publication_date": "2018-03-09", "keywords": "Chronic myeloid leukemia, Dasatinib, Mixed connective tissue disease, Pulmonary hypertension"}, {"pubmed_id": "29508628", "title": "Drug-associated pulmonary arterial hypertension.", "authors": "M. McGee, N. Whitehead, J. Martin, N. Collins", "publication_date": "2018-03-07", "keywords": "Drug-associated pulmonary artery hypertension, drug side effect, pulmonary artery hypertension"}, {"pubmed_id": "29502931", "title": "Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.", "authors": "S. Rudra, C. Hui, YJ. Rao, P. Samson, AJ. Lin, X. Chang, C. Tsien, S. Fergus, D. Mullen, D. Yang, D. Thotala, D. Hallahan, JL. Campian, J. Huang", "publication_date": "2018-03-06", "keywords": ""}, {"pubmed_id": "29494928", "title": "Efficacy and safety of nilotinib 300\u202fmg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.", "authors": "D. Hiwase, P. Tan, J. D'Rozario, J. Taper, A. Powell, I. Irving, M. Wright, S. Branford, DT. Yeung, L. Anderson, O. Gervasio, C. Levetan, W. Roberts, A. Solterbeck, R. Traficante, T. Hughes", "publication_date": "2018-03-02", "keywords": "Chronic myeloid leukemia, Nilotinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "29475747", "title": "Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura.", "authors": "ET. Demirsoy, O. Mehtap, EB. Atesoglu, P. Tarkun, N. Eren, A. Ged\u00fck, A. Hacihanefioglu", "publication_date": "2018-02-25", "keywords": "Dasatinib, Plasma exchange, Side effect, Thrombotic thromboytopenic purpura"}, {"pubmed_id": "29466183", "title": "[Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].", "authors": "LM. Makeeva, EI. Emelina, GE. Gendlin, IG. Nikitin, YA. Vasyuk, VV. Nesvetov", "publication_date": "2018-02-22", "keywords": "oncohematological diseases, cardiotoxicity, dasatinib, pulmonary arterial hypertension"}, {"pubmed_id": "29464092", "title": "mTOR inhibition enhances efficacy of dasatinib in ", "authors": "M. Gotesman, TT. Vo, LO. Herzog, T. Tea, S. Mallya, SK. Tasian, M. Konopleva, DA. Fruman", "publication_date": "2018-02-22", "keywords": "acute leukemia, animal model, childhood leukemia, leukemia therapy, tyrosine kinases"}, {"pubmed_id": "29454849", "title": "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).", "authors": "M. Reinwald, JT. Silva, NJ. Mueller, J. Fort\u00fan, C. Garzoni, JW. de Fijter, M. Fern\u00e1ndez-Ruiz, P. Grossi, JM. Aguado", "publication_date": "2018-02-20", "keywords": "BCR-ABL kinase inhibitors, Ibrutinib, Idelalisib, Infection, Janus kinase inhibitors, Small-molecule inhibitors, mTOR inhibitors"}, {"pubmed_id": "29454474", "title": "Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.", "authors": "BC. Medeiros, J. Possick, M. Fradley", "publication_date": "2018-02-20", "keywords": "Cardiovascular toxicity, Chronic myeloid leukemia, Metabolic toxicity, Pulmonary toxicity, Tyrosine kinase inhibitor"}, {"pubmed_id": "29446053", "title": "Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.", "authors": "T. Vaidya, J. Kamta, M. Chaar, A. Ande, S. Ait-Oudhia", "publication_date": "2018-02-16", "keywords": "Cardiotoxicity, DASATINIB, Quantitative systems pharmacology (QSP) models, SORAFENIB, Tyrosine kinase inhibitors (TKIs)"}, {"pubmed_id": "31249931", "title": "BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?", "authors": "H. Haguet, J. Douxfils, C. Chatelain, C. Graux, F. Mullier, JM. Dogn\u00e9", "publication_date": "2018-02-14", "keywords": "BCR-ABL, arterial thrombotic events, chronic myeloid leukemia, tyrosine kinase inhibitors"}, {"pubmed_id": "29416058", "title": "Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8", "authors": "A. Lissina, JE. McLaren, M. Ilander, EI. Andersson, CS. Lewis, M. Clement, A. Herman, K. Ladell, S. Llewellyn-Lacey, KL. Miners, E. Gostick, JJ. Melenhorst, AJ. Barrett, DA. Price, S. Mustjoki, L. Wooldridge", "publication_date": "2018-02-09", "keywords": ""}, {"pubmed_id": "29415932", "title": "[Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].", "authors": "I. Matsumura", "publication_date": "2018-02-09", "keywords": "Cardiovascular events, Chronic myeloid leukemia, Tyrosine kinase inhibitor"}, {"pubmed_id": "29411766", "title": "[Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].", "authors": "AG. Turkina, EY. Chelysheva, VA. Shuvaev, GA. Gusarova, AV. Bykova, OA. Shukhov, AN. Petrova, MV. Vakhrusheva, SR. Goryacheva, LY. Kolosova, PS. Krasikova, MS. Fominykh, IS. Martynkevich, AO. Abdullaev, AB. Sudarikov, VG. Savchenko", "publication_date": "2018-02-08", "keywords": "chronic myeloid leukemia, dasatinib, deep molecular response, imatinib, nilotinib, remission without therapy"}, {"pubmed_id": "29406237", "title": "A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.", "authors": "A. Alter, N. Chaisson, S. Mukherjee, T. Gildea", "publication_date": "2018-02-07", "keywords": ""}, {"pubmed_id": "29388066", "title": "Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.", "authors": "BM. Knoll, K. Seiter", "publication_date": "2018-02-02", "keywords": "Adenovirus hemorrhagic cystitis, BCR-ABL TKI, Cytomegalovirus pneumonitis, Dasatinib, Infections"}, {"pubmed_id": "29386436", "title": "[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].", "authors": "F. Komada", "publication_date": "2018-02-02", "keywords": "adverse reaction, interstitial lung disease, molecularly-targeted drug, time-to-onset"}, {"pubmed_id": "29384978", "title": "Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).", "authors": "S. Nishiwaki, I. Sugiura, Y. Miyata, S. Saito, M. Sawa, T. Nishida, K. Miyamura, Y. Kuwatsuka, A. Kohno, M. Yuge, M. Kasai, H. Iida, S. Kurahashi, M. Osaki, T. Goto, S. Terakura, M. Murata, H. Nishikawa, H. Kiyoi", "publication_date": "2018-02-01", "keywords": ""}, {"pubmed_id": "29370463", "title": "Dasatinib dose management for the treatment of chronic myeloid leukemia.", "authors": "M. Talpaz, G. Saglio, E. Atallah, P. Rousselot", "publication_date": "2018-01-26", "keywords": "BCR-ABL positive, chronic, dasatinib, dose optimization, leukemia, myelogenous, quality of life, tyrosine kinase inhibitor"}, {"pubmed_id": "29348177", "title": "Dasatinib increases endothelial permeability leading to pleural effusion.", "authors": "C. Phan, EM. Jutant, L. Tu, R. Thuillet, A. Seferian, D. Montani, A. Huertas, JV. Bezu, F. Breijer, A. Vonk Noordegraaf, M. Humbert, J. Aman, C. Guignabert", "publication_date": "2018-01-20", "keywords": ""}, {"pubmed_id": "29345206", "title": "Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.", "authors": "L. Cao, LP. Koh, YC. Linn", "publication_date": "2018-01-19", "keywords": ""}, {"pubmed_id": "29343154", "title": "Dasatinib-induced pulmonary arterial hypertension - A rare late complication.", "authors": "U. Ibrahim, A. Saqib, V. Dhar, M. Odaimi", "publication_date": "2018-01-19", "keywords": "CML, Chronic myeloid leukemia, dasatinib, pulmonary arterial hypertension, tyrosine kinase inhibitor"}, {"pubmed_id": "29334406", "title": "Dasatinib-induced pulmonary arterial hypertension.", "authors": "N. \u00d6zg\u00fcr Yurtta\u015f, AE. E\u015fkazan", "publication_date": "2018-01-16", "keywords": "adverse event, chronic myeloid leukaemia, dasatinib, pulmonary arterial hypertension, tyrosine kinase inhibitor"}, {"pubmed_id": "29316665", "title": "Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.", "authors": "RC. Maia, FC. Vasconcelos, PS. Souza, VM. Rumjanek", "publication_date": "2018-01-11", "keywords": "P-glycoprotein, chronic myeloid leukemia, drug resistance, inhibitor apoptosis proteins, microRNAs, microvesicles, new compounds, tyrosine kinase inhibitor"}, {"pubmed_id": "29310021", "title": "Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.", "authors": "K. Inokuchi, K. Nakayama, T. Tauchi, T. Takaku, N. Yokose, H. Yamaguchi, T. Kumagai, N. Komatsu, K. Ohyashiki", "publication_date": "2018-01-09", "keywords": "BCR-ABL1 transcripts, CML, Molecular biological effects, TKI, The best response, Three-way translocation"}, {"pubmed_id": "29296724", "title": "The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.", "authors": "LC. Fox, KD. Cummins, B. Costello, D. Yeung, R. Cleary, C. Forsyth, M. Tatarczuch, K. Burbury, O. Motorna, J. Shortt, S. Fleming, A. McQuillan, A. Schwarer, R. Harrup, A. Holmes, S. Ratnasingam, KL. Chan, WH. Hsu, A. Ashraf, F. Putt, A. Grigg", "publication_date": "2018-01-04", "keywords": ""}, {"pubmed_id": "29287600", "title": "Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.", "authors": "A. Skride, M. Sablinskis, K. Sablinskis, K. Lesina, A. Lejnieks, S. Lejniece", "publication_date": "2017-12-31", "keywords": "Chronic myelogenous leukemia, Dasatinib, Pleural effusion, Pulmonary arterial hypertension"}, {"pubmed_id": "29284357", "title": "Experience with dasatinib and nilotinib use in pregnancy.", "authors": "T. Barkoulas, PD. Hall", "publication_date": "2017-12-30", "keywords": "Dasatinib, chronic myeloid leukemia, nilotinib, pregnancy"}, {"pubmed_id": "29276418", "title": "Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study.", "authors": "T. Rattanathammethee, A. Tantiworawit, E. Rattarittamrong, C. Chai-Adisaksopha, S. Hantrakool, A. Phrommintikul, W. Wongcharoen, S. Gunaparn, L. Norasetthada", "publication_date": "2017-12-26", "keywords": "Chronic myeloid leukemia, peripheral artery occlusive disease, tyrosine kinase inhibitors"}, {"pubmed_id": "29256413", "title": "Why a case report is more than just an unexpected observation.", "authors": "S. de Bie, T. van Gelder", "publication_date": "2017-12-20", "keywords": ""}, {"pubmed_id": "29256412", "title": "Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction.", "authors": "AHG. Muller-Hansma, J. van der Lugt, CM. Zwaan", "publication_date": "2017-12-20", "keywords": ""}, {"pubmed_id": "29225458", "title": "Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.", "authors": "S. Seo, W. Suh", "publication_date": "2017-12-12", "keywords": ""}, {"pubmed_id": "29222244", "title": "Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.", "authors": "MC. Barber, MJ. Mauro, J. Moslehi", "publication_date": "2017-12-10", "keywords": ""}, {"pubmed_id": "29221983", "title": "Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.", "authors": "H. Abel Mahedi Mohamed, CEN. Nielsen, M. Schiodt", "publication_date": "2017-12-10", "keywords": ""}, {"pubmed_id": "29218828", "title": "Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.", "authors": "C. Giallongo, NL. Parrinello, P. La Cava, G. Camiolo, A. Romano, M. Scalia, F. Stagno, GA. Palumbo, R. Avola, G. Li Volti, D. Tibullo, F. Di Raimondo", "publication_date": "2017-12-09", "keywords": "exosomes, immunosurveillance, major molecular response, myeloid-derived suppressor cells, tyrosine kinase inhibitors"}, {"pubmed_id": "29212971", "title": "[Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].", "authors": "Y. Edahiro, T. Takaku, H. Konishi, Y. Tsukune, I. Fujioka, K. Takasu, A. Gotoh, H. Daida, N. Komatsu", "publication_date": "2017-12-08", "keywords": "Chronic myeloid leukemia, Dasatinib, Pulmonary arterial hypertension, Tyrosine kinase inhibitor"}, {"pubmed_id": "29207935", "title": "Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib.", "authors": "DJ. Hermel, V. Chiu, MH. Hermel, A. Tulpule, M. Akhtari", "publication_date": "2017-12-07", "keywords": "Birth defects, chronic myeloid leukemia, dasatinib, pregnancy, tyrosine kinase inhibitors"}, {"pubmed_id": "29206554", "title": "Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.", "authors": "NP. Shah", "publication_date": "2017-12-06", "keywords": ""}, {"pubmed_id": "29199677", "title": "Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients.", "authors": "EY. Romero-Ventosa, L. Otero-Mill\u00e1n, S. Gonz\u00e1lez-Costas, P. Vilasoa-Boo, A. Silva-L\u00f3pez, C. Arroyo-Conde, G. Pi\u00f1eiro-Corrales", "publication_date": "2017-12-05", "keywords": ""}, {"pubmed_id": "29185155", "title": "Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.", "authors": "SI. Fujiwara, Y. Shirato, T. Ikeda, SI. Kawaguchi, Y. Toda, S. Ito, SI. Ochi, T. Nagayama, K. Mashima, K. Umino, D. Minakata, H. Nakano, K. Morita, R. Yamasaki, Y. Kawasaki, M. Sugimoto, M. Ashizawa, C. Yamamoto, K. Hatano, K. Sato, I. Oh, K. Ohmine, K. Muroi, Y. Kanda", "publication_date": "2017-12-01", "keywords": "CML, FL, Second-generation TKI"}, {"pubmed_id": "29177615", "title": "ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.", "authors": "S. Uemura, N. Nishimura, D. Hasegawa, A. Shono, K. Sakaguchi, H. Matsumoto, Y. Nakamachi, J. Saegusa, T. Yokoi, T. Tahara, A. Tamura, N. Yamamoto, A. Saito, A. Kozaki, K. Kishimoto, T. Ishida, N. Nino, S. Takafuji, T. Mori, K. Iijima, Y. Kosaka", "publication_date": "2017-11-28", "keywords": "ETV6\u2013ABL1, Monosomy 7, Ph-like ALL"}, {"pubmed_id": "29168352", "title": "Patient satisfaction with information on oral anticancer agent use.", "authors": "CCLM. Boons, L. Timmers, NM. van Schoor, EL. Swart, NH. Hendrikse, JJWM. Janssen, JG. Hugtenburg", "publication_date": "2017-11-24", "keywords": "Cancer, illness perception, medication adherence, medication information, oral anticancer agents, patient beliefs, patient education, patient satisfaction, quality of life"}, {"pubmed_id": "29165288", "title": "Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.", "authors": "Z. Patay, TE. Merchant, R. Nguyen, CR. Pierson, A. Onar-Thomas, A. Broniscer", "publication_date": "2017-11-23", "keywords": ""}, {"pubmed_id": "29138996", "title": "Ichthyosiform Pityriasis Rubra Pilaris-Like Eruption Secondary to Ponatinib Therapy: Case Report and Literature Review.", "authors": "AE. Eber, A. Rosen, KE. Oberlin, A. Giubellino, P. Romanelli", "publication_date": "2017-11-16", "keywords": ""}, {"pubmed_id": "29104720", "title": "Dasatinib-induced Seborrheic Dermatitis-like Eruption.", "authors": "RR. Riahi, PR. Cohen", "publication_date": "2017-11-07", "keywords": "Antineoplastic, BRAF, c-kit, chemotherapy, cutaneous, dasatinib, melanoma, mucocutaneous, mucosal, seborrheic dermatitis, side effect, tyrosine kinase inhibitors"}, {"pubmed_id": "29101238", "title": "Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.", "authors": "V. Serafin, G. Capuzzo, G. Milani, SA. Minuzzo, M. Pinazza, R. Bortolozzi, S. Bresolin, E. Porc\u00f9, C. Frasson, S. Indraccolo, G. Basso, B. Accordi", "publication_date": "2017-11-05", "keywords": ""}, {"pubmed_id": "29095654", "title": "Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.", "authors": "M. Franklin, L. Burns, S. Perez, D. Yerragolam, D. Makenbaeva", "publication_date": "2017-11-03", "keywords": "CML, hyperlipidemia, metabolic outcomes, type 2 diabetes mellitus, tyrosine kinase inhibitors"}, {"pubmed_id": "29050695", "title": "How is the Ph-like signature being incorporated into ALL therapy?", "authors": "L. Maese, SK. Tasian, EA. Raetz", "publication_date": "2017-10-21", "keywords": "Acute lymphoblastic leukemia, Dasatinib, Imatinib, Janus kinase inhibitor, Philadelphia chromosome-like, Ruxolitinib, tyrosine kinase inhibitor"}, {"pubmed_id": "29047029", "title": "Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.", "authors": "S. Kato, DL. Jardim, FM. Johnson, V. Subbiah, S. Piha-Paul, AM. Tsimberidou, GS. Falchook, D. Karp, R. Zinner, J. Wheler, F. Janku, S. Fu, J. Lim, S. Bean, L. Nguyen, S. Urban, E. Browne, F. Meric-Bernstam, DS. Hong", "publication_date": "2017-10-20", "keywords": "Crizotinib, Dasatinib, MET, Phase I, Safety, c-SRC"}, {"pubmed_id": "29046979", "title": "Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?", "authors": "J. Weatherald, L. Savale, M. Humbert", "publication_date": "2017-10-20", "keywords": "Group 5 pulmonary hypertension, Hypertension treatment, PAH, Pulmonary arterial hypertension"}, {"pubmed_id": "29032513", "title": "Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.", "authors": "Y. Okada, K. Sato, S. Kobayashi, S. Nagao, K. Takano, M. Teramoto, N. Tachi, T. Kawamura, T. Horiuchi, S. Kato, R. Saga, T. Maekawa, T. Yamamura, J. Watanabe, A. Kobayashi, F. Kimura", "publication_date": "2017-10-17", "keywords": "Chronic myeloid leukemia, Dasatinib, Major molecular response, Nilotinib, Sudden blast phase"}, {"pubmed_id": "29027647", "title": "Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.", "authors": "T. Ishida, N. Akagawa, T. Miyata, N. Tominaga, T. Iizuka, M. Higashihara, T. Suzuki, K. Miyazaki", "publication_date": "2017-10-14", "keywords": "Chronic myeloid leukemia, Dasatinib, Demyelinating peripheral neuropathy, Guillain\u2013Barre syndrome"}, {"pubmed_id": "29027261", "title": "Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.", "authors": "A. Alhuraiji, H. Kantarjian, P. Boddu, F. Ravandi, G. Borthakur, C. DiNardo, N. Daver, T. Kadia, N. Pemmaraju, S. Pierce, G. Garcia-Manero, W. Wierda, S. Verstovsek, E. Jabbour, J. Cortes", "publication_date": "2017-10-14", "keywords": ""}, {"pubmed_id": "29021516", "title": "Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.", "authors": "M. Kojima, N. Nakamura, J. Amaki, H. Numata, M. Miyaoka, T. Motoori, K. Matsumoto, K. Ando", "publication_date": "2017-10-13", "keywords": "BCL6, BCR-ABL, chronic myelogenous leukemia, primary effusion lymphoma-like lymphoma, tyrosine kinase inhibitor"}, {"pubmed_id": "29017820", "title": "Possible Utility of the Basophil Activation Test for the Analysis of Mechanisms Involved in Allergic Transfusion Reactions.", "authors": "F. Hirayama, K. Yasui, N. Matsuyama, I. Okamura-Shiki", "publication_date": "2017-10-12", "keywords": "Allergen, Allergic reaction, Basophil activation test, Dasatinib, Transfusion"}, {"pubmed_id": "28990119", "title": "Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.", "authors": "DB. Cardin, LW. Goff, E. Chan, JG. Whisenant, G. Dan Ayers, N. Takebe, LR. Arlinghaus, TE. Yankeelov, J. Berlin, N. Merchant", "publication_date": "2017-10-11", "keywords": "Dasatinib, Dual Src and EGFR inhibition, Erlotinib, Pancreatic cancer"}, {"pubmed_id": "28971265", "title": "Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.", "authors": "A. Iurlo, S. Galimberti, E. Abruzzese, M. Annunziata, M. Bonifacio, R. Latagliata, P. Pregno, D. Ferrero, F. Sor\u00e0, EM. Orlandi, C. Fava, D. Cattaneo, C. Bucelli, G. Binotto, E. Pungolino, M. Tiribelli, A. Gozzini, G. Gugliotta, F. Castagnetti, F. Stagno, G. Rege-Cambrin, B. Martino, L. Luciano, M. Breccia, S. Sica, M. Bocchia, F. Pane, G. Saglio, G. Rosti, G. Specchia, A. Cortelezzi, M. Baccarani", "publication_date": "2017-10-04", "keywords": "Chronic myeloid leukemia, Dasatinib, Dose reduction, Molecular response, Pleural effusion"}, {"pubmed_id": "28939770", "title": "Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice.", "authors": "S. Kim, X. Yang, Q. Li, M. Wu, L. Costyn, Z. Beharry, MG. Bartlett, H. Cai", "publication_date": "2017-09-25", "keywords": "Src, diet, fatty acid, prostate cancer, protein myristoylation"}, {"pubmed_id": "28936634", "title": "JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).", "authors": "N. Usui", "publication_date": "2017-09-25", "keywords": ""}, {"pubmed_id": "28927784", "title": "Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.", "authors": "R. Assi, H. Kantarjian, NJ. Short, N. Daver, K. Takahashi, G. Garcia-Manero, C. DiNardo, J. Burger, J. Cortes, N. Jain, W. Wierda, S. Chamoun, M. Konopleva, E. Jabbour", "publication_date": "2017-09-21", "keywords": "ALL, Blinatumomab, CML, Philadelphia chromosome, Relapsed/refractory"}, {"pubmed_id": "28918995", "title": "Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.", "authors": "JD. Ransohoff, BY. Kwong", "publication_date": "2017-09-19", "keywords": "Chemotherapy, Dermatology, Drug side effects, Oncology, Supportive oncodermatology"}, {"pubmed_id": "28914582", "title": "A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.", "authors": "K. Seegobin, A. Babbar, J. Ferreira, B. Lyons, J. Cury, V. Seeram", "publication_date": "2017-09-16", "keywords": "bosutinib, dasatinib, pleural effusions, pulmonary arterial hypertension"}, {"pubmed_id": "28895203", "title": "Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.", "authors": "K. Murai, K. Yamaguchi, S. Ito, T. Miyagishima, M. Shindo, K. Wakasa, M. Inomata, T. Nagashima, T. Kondo, N. Fujimoto, S. Yamamoto, M. Yonezumi, T. Oyake, S. Kowata, Y. Tsukushi, T. Mine, K. Meguro, K. Ikeda, R. Watanabe, S. Saito, S. Sato, K. Tajima, T. Chou, K. Kubo, K. Oba, J. Sakamoto, Y. Ishida, ", "publication_date": "2017-09-13", "keywords": "chronic myeloid leukaemia, deep molecular response, tyrosine kinase inhibitors"}, {"pubmed_id": "28835440", "title": "Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.", "authors": "GC. Issa, HM. Kantarjian, GN. Gonzalez, G. Borthakur, G. Tang, W. Wierda, K. Sasaki, NJ. Short, F. Ravandi, T. Kadia, K. Patel, R. Luthra, A. Ferrajoli, G. Garcia-Manero, MB. Rios, S. Dellasala, E. Jabbour, JE. Cortes", "publication_date": "2017-08-25", "keywords": ""}, {"pubmed_id": "28830985", "title": "Characterization of ", "authors": "KB. Emdal, A. Dittmann, RJ. Reddy, RS. Lescarbeau, SL. Moores, S. Laquerre, FM. White", "publication_date": "2017-08-24", "keywords": ""}, {"pubmed_id": "28821556", "title": "Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.", "authors": "A. Kreutzman, B. Colom-Fern\u00e1ndez, AM. Jim\u00e9nez, M. Ilander, C. Cuesta-Mateos, Y. P\u00e9rez-Garc\u00eda, CD. Ar\u00e9valo, O. Br\u00fcck, H. Hakanen, J. Saarela, A. Ortega-Carri\u00f3n, A. de Rosendo, A. Juanes-Garc\u00eda, JL. Steegmann, S. Mustjoki, M. Vicente-Manzanares, C. Mu\u00f1oz-Calleja", "publication_date": "2017-08-20", "keywords": ""}, {"pubmed_id": "28815757", "title": "First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.", "authors": "SL. Goldberg, JE. Cortes, C. Gambacorti-Passerini, R. Hehlmann, HJ. Khoury, M. Michallet, RL. Paquette, B. Simonsson, T. Zyczynski, A. Foreman, E. Abruzzese, D. Andorsky, A. Beeker, P. Cony-Makhoul, R. Hansen, E. Lomaia, E. Olavarria, MJ. Mauro", "publication_date": "2017-08-18", "keywords": ""}, {"pubmed_id": "28810255", "title": "Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.", "authors": "A. Petrungaro, M. Gentile, C. Mazzone, R. Greco, G. Uccello, AG. Recchia, L. De Stefano, S. Bossio, A. Palummo, R. Morelli, C. Musolino, F. Morabito, E. Vigna", "publication_date": "2017-08-16", "keywords": "Acute lymphoblastic leukemia, Philadelphia-positive chromosome, Ponatinib"}, {"pubmed_id": "28796569", "title": "Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.", "authors": "M. Marchetti", "publication_date": "2017-08-11", "keywords": "Cost-effectiveness, chronic lymphoid leukemia, chronic myeloid leukemia, dasatinib, ibrutinib, idelalisib, imatinib, myelofibrosis, nilotinib, ruxolitinib"}, {"pubmed_id": "28779753", "title": "The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.", "authors": "C. De Benedittis, C. Papayannidis, C. Venturi, MC. Abbenante, S. Paolini, S. Parisi, C. Sartor, M. Cavo, G. Martinelli, S. Soverini", "publication_date": "2017-08-07", "keywords": "BCR-ABL1 mutation, Blinatumomab, Case Report, Dasatinib, Ph+\u00a0Acute Lymphoblastic Leukemia, Ponatinib, Relapse, Resistance, T315I mutation, Transplant"}, {"pubmed_id": "28770949", "title": "Treatment of patients with primary myelofibrosis using dasatinib.", "authors": "QL. Song, B. Zhang, Y. Xu, RX. Xia, XH. Lu, ZX. Pei, QW. Xu, WY. Li, ZD. Li", "publication_date": "2017-08-05", "keywords": ""}, {"pubmed_id": "28751413", "title": "Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.", "authors": "J. Weatherald, MC. Chaumais, L. Savale, X. Ja\u00efs, A. Seferian, M. Canuet, H. Bouvaist, P. Magro, A. Bergeron, C. Guignabert, O. Sitbon, G. Simonneau, M. Humbert, D. Montani", "publication_date": "2017-07-29", "keywords": ""}, {"pubmed_id": "28749919", "title": "Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.", "authors": "J. Wells, N. Jain, M. Konopleva", "publication_date": "2017-07-28", "keywords": ""}, {"pubmed_id": "28743165", "title": "Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.", "authors": "P. Jain, HM. Kantarjian, A. Ghorab, K. Sasaki, EJ. Jabbour, G. Nogueras Gonzalez, R. Kanagal-Shamanna, GC. Issa, G. Garcia-Manero, D. Kc, S. Dellasala, S. Pierce, M. Konopleva, WG. Wierda, S. Verstovsek, NG. Daver, TM. Kadia, G. Borthakur, S. O'Brien, Z. Estrov, F. Ravandi, JE. Cortes", "publication_date": "2017-07-26", "keywords": "blast phase (BP), bosutinib, chronic myeloid leukemia (CML), dasatinib, imatinib, nilotinib, ponatinib, tyrosine kinase inhibitors (TKI)"}, {"pubmed_id": "28737227", "title": "Dasatinib-induced loss of eyebrows.", "authors": "R. Naithani", "publication_date": "2017-07-25", "keywords": ""}, {"pubmed_id": "28721056", "title": "Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature.", "authors": "N. Sgherza, E. Abruzzese, G. Perla, MM. Minervini, V. Chiello, N. Sciannam\u00e8, N. Cascavilla", "publication_date": "2017-07-20", "keywords": "additional chromosomal aberration, chronic myeloid leukemia, complex karyotype, pregnancy, tyrosine kinase inhibitor, variant translocation"}, {"pubmed_id": "28639957", "title": "Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.", "authors": "J. Weatherald, MC. Chaumais, D. Montani", "publication_date": "2017-06-24", "keywords": ""}, {"pubmed_id": "28637715", "title": "Tyrosine Kinase Inhibitors Protect the Salivary Gland from Radiation Damage by Inhibiting Activation of Protein Kinase C-\u03b4.", "authors": "SM. Wie, E. Wellberg, SD. Karam, ME. Reyland", "publication_date": "2017-06-24", "keywords": ""}, {"pubmed_id": "28599273", "title": "Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.", "authors": "M. Chen, AG. Turhan, H. Ding, Q. Lin, K. Meng, X. Jiang", "publication_date": "2017-06-10", "keywords": "BCR-ABL+ human leukemia, ER\u03b136, Icaritin (SNG162 and SNG1153), leukemic stem cells, tyrosine kinase inhibitors"}, {"pubmed_id": "28586242", "title": "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?", "authors": "AE. Eskazan, D. Ozmen", "publication_date": "2017-06-07", "keywords": "Adverse event, bosutinib, chronic myeloid leukemia, dasatinib, first-line, imatinib, nilotinib, ponatinib, response, tyrosine kinase inhibitor"}, {"pubmed_id": "28566433", "title": "mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph", "authors": "TT. Vo, JS. Lee, D. Nguyen, B. Lui, W. Pandori, A. Khaw, S. Mallya, M. Lu, M. M\u00fcschen, M. Konopleva, DA. Fruman", "publication_date": "2017-06-02", "keywords": ""}, {"pubmed_id": "28566209", "title": "De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.", "authors": "RE. Clark, F. Polydoros, JF. Apperley, D. Milojkovic, C. Pocock, G. Smith, JL. Byrne, H. de Lavallade, SG. O'Brien, T. Coffey, L. Foroni, M. Copland", "publication_date": "2017-06-02", "keywords": ""}, {"pubmed_id": "28559019", "title": "IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.", "authors": "LP. Stabile, AM. Egloff, MK. Gibson, WE. Gooding, J. Ohr, P. Zhou, NJ. Rothenberger, L. Wang, JL. Geiger, JT. Flaherty, JR. Grandis, JE. Bauman", "publication_date": "2017-06-01", "keywords": "Cetuximab, Dasatinib, EGFR, HNSCC, Interleukin-6, Src-family kinases"}, {"pubmed_id": "28551924", "title": "[ADHERENCE TO ORAL ANTI-CANCER DRUGS IN HEMATO-ONCOLOGY].", "authors": "S. Ashkenazi, J. Dreyer, P. Raanani, A. Leader", "publication_date": "2017-05-30", "keywords": ""}, {"pubmed_id": "28549238", "title": "Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.", "authors": "P. Valent, E. Hadzijusufovic, G. Hoermann, W. F\u00fcreder, GH. Schernthaner, WR. Sperr, R. Kirchmair, D. Wolf", "publication_date": "2017-05-27", "keywords": "BCR-ABL1-targeting drugs, Personalized medicine, Vascular adverse events (VAE), Vascular safety"}, {"pubmed_id": "28534184", "title": "Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.", "authors": "G. Saglio, P. le Coutre, J. Cortes, J. Mayer, P. Rowlings, FX. Mahon, G. Kroog, K. Gooden, M. Subar, NP. Shah", "publication_date": "2017-05-24", "keywords": "Cardiovascular, Chronic myeloid leukemia, Dasatinib, Ischemic, Tyrosine kinase inhibitors"}, {"pubmed_id": "28531278", "title": "Cardiovascular toxic effects of targeted cancer therapy.", "authors": "K. Tajiri, K. Aonuma, I. Sekine", "publication_date": "2017-05-23", "keywords": "cancer, cardiovascular toxicity, targeted therapy"}, {"pubmed_id": "28508322", "title": "Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.", "authors": "JE. Machado-Alba, ME. Machado-Duque", "publication_date": "2017-05-17", "keywords": "BCR-ABL Positive, Chronic, Leukemia, Myelogenous, Pharmacoepidemiology, Treatment failure"}, {"pubmed_id": "28501737", "title": "The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p.", "authors": "M. Sukegawa, X. Wang, C. Nishioka, B. Pan, K. Xu, H. Ohkawara, Y. Hamasaki, M. Mita, K. Nakamura, M. Okamoto, H. Shimura, M. Ohta, T. Ikezoe", "publication_date": "2017-05-16", "keywords": "ABL tyrosine kinase inhibitor, Endothelial cell damage, Inflammatory cytokines, microRNA"}, {"pubmed_id": "28499700", "title": "Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.", "authors": "K. McGrath, B. Stein, L. Kalhagen, L. Leighton", "publication_date": "2017-05-14", "keywords": ""}, {"pubmed_id": "28446278", "title": "[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].", "authors": "X. Liu, SL. Gan, J. Ma, YF. Liu, XS. Xie, ZX. Jiang, YD. Cheng, H. Sun", "publication_date": "2017-04-28", "keywords": ""}, {"pubmed_id": "28444835", "title": "Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL.", "authors": "H. Kawaguchi, Y. Tamura, S. Suzuki, T. Asano-Murakoshi, S. Nonoyama", "publication_date": "2017-04-27", "keywords": "cytomegalovirus, dasatinib, proteinuria, tyrosine kinase inhibitor, vascular endothelial growth factor"}, {"pubmed_id": "28444644", "title": "Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.", "authors": "A. Tojo, T. Kyo, K. Yamamoto, H. Nakamae, N. Takahashi, Y. Kobayashi, T. Tauchi, S. Okamoto, K. Miyamura, K. Hatake, H. Iwasaki, I. Matsumura, N. Usui, T. Naoe, M. Tugnait, NI. Narasimhan, S. Lustgarten, H. Farin, F. Haluska, K. Ohyashiki", "publication_date": "2017-04-27", "keywords": "CML, Japanese population, Ph+ALL, Phase 1/2, Ponatinib"}, {"pubmed_id": "28439970", "title": "Dasatinib-associated follicular lymphoid hyperplasia: First pediatric case report and literature review.", "authors": "E. Bouquet, A. Jourdain, MC. Machet, F. Beau-Salinas, AP. Jonville-B\u00e9ra", "publication_date": "2017-04-26", "keywords": ""}, {"pubmed_id": "28424749", "title": "Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.", "authors": "KC. Webb, M. Harasimowicz, M. Janeczek, J. Speiser, J. Swan, R. Tung", "publication_date": "2017-04-21", "keywords": ""}, {"pubmed_id": "28423730", "title": "The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.", "authors": "C. Schubert, N. Chatain, T. Braunschweig, M. Schemionek, K. Feldberg, M. Hoffmann, O. Dufva, S. Mustjoki, TH. Br\u00fcmmendorf, S. Koschmieder", "publication_date": "2017-04-21", "keywords": "BCR-ABL, CML, dasatinib, mouse model, transgenic"}, {"pubmed_id": "28419210", "title": "Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.", "authors": "DP. Prestes, E. Arbona, A. Nevett-Fernandez, AE. Woolley, VT. Ho, S. Koo, LR. Baden, J. Koreth, SP. Hammond, NC. Issa, FM. Marty", "publication_date": "2017-04-19", "keywords": "acute lymphoblastic leukemia, chronic myelogenous leukemia, cytomegalovirus, dasatinib, hematopoietic cell transplantation"}, {"pubmed_id": "28408343", "title": "The impact of cellular senescence in skin ageing: A notion of mosaic and therapeutic strategies.", "authors": "M. Toutfaire, E. Bauwens, F. Debacq-Chainiaux", "publication_date": "2017-04-15", "keywords": "8-Methoxypsoralen (PubChem CID: 4114), Dasatinib (PubChem CID: 3062316), Genistein (PubChem CID: 5280961), MLN8237 (PubChem CID: 24771867), Navitoclax or ABT-263 (PubChem CID: 24978538), Nutlin-3 (PubChem CID: 216345), Piperlongumine (PubChem CID: 637858), Quercetin (PubChem CID: 5280343), Senescence, Senescence-associated secretory phenotype (SASP), Senolytic, Skin ageing, Stress-induced premature senescence (SIPS)"}, {"pubmed_id": "28396095", "title": "Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg.", "authors": "H. Itamura, Y. Kubota, T. Shindo, T. Ando, K. Kojima, S. Kimura", "publication_date": "2017-04-12", "keywords": "Adverse events, Age, BCR-ABL, Large granular lymphocyte, Tyrosine kinase inhibitor"}, {"pubmed_id": "28378056", "title": "Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.", "authors": "KJ. Suh, JY. Lee, DY. Shin, Y. Koh, SM. Bang, SS. Yoon, S. Park, I. Kim, JO. Lee", "publication_date": "2017-04-06", "keywords": "Dasatinib, Discontinuation, Nilotinib, Pleural effusion, Toxicity"}, {"pubmed_id": "28341918", "title": "Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.", "authors": "H. Nakamae, S. Fujisawa, M. Ogura, T. Uchida, Y. Onishi, M. Taniwaki, A. Utsunomiya, K. Matsue, Y. Takamatsu, K. Usuki, M. Tanimoto, Y. Ishida, K. Ohashi, L. Li, M. Miyoshi", "publication_date": "2017-03-28", "keywords": "CML, Dasatinib, Imatinib, Japan, Tyrosine kinase inhibitor"}, {"pubmed_id": "28340283", "title": "Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.", "authors": "M. Minami, T. Arita, H. Iwasaki, T. Muta, T. Aoki, K. Aoki, S. Yamasaki, T. Matsushima, K. Kato, K. Takenaka, K. Tanimoto, T. Kamimura, R. Ogawa, K. Akashi, T. Miyamoto", "publication_date": "2017-03-25", "keywords": "chronic myeloid leukaemia, dasatinib, imatinib, nilotinib, pulmonary hypertension"}, {"pubmed_id": "28334439", "title": "A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).", "authors": "K. Kalinsky, S. Lee, KM. Rubin, DP. Lawrence, AJ. Iafrarte, DR. Borger, KA. Margolin, MM. Leitao, AA. Tarhini, HB. Koon, AL. Pecora, AJ. Jaslowski, GI. Cohen, TM. Kuzel, CD. Lao, JM. Kirkwood", "publication_date": "2017-03-24", "keywords": "KIT mutation, acral, dasatinib, melanoma, mucosal, vulvovaginal"}, {"pubmed_id": "28332166", "title": "Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.", "authors": "Y. Osada, H. Arakaki, S. Takanashi, C. Ito, Y. Aisa, T. Nakazato", "publication_date": "2017-03-24", "keywords": ""}, {"pubmed_id": "28327053", "title": "Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.", "authors": "D. Lekovic, M. Gotic, N. Milic, B. Zivojinovic, J. Jovanovic, N. Colovic, V. Milosevic, A. Bogdanovic", "publication_date": "2017-03-23", "keywords": "Myeloproliferative neoplasms, chronic myeloid leukemia, imatinib, prediction"}, {"pubmed_id": "28321349", "title": "Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia.", "authors": "A. Armas, C. Chen, M. Mims, G. Rivero", "publication_date": "2017-03-23", "keywords": ""}, {"pubmed_id": "28316033", "title": "Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.", "authors": "R. Damrongwatanasuk, MG. Fradley", "publication_date": "2017-03-21", "keywords": "Cardio-oncology, Cardiotoxicity, Chronic myeloid leukemia, Nilotinib, Ponatinib, Tyrosine kinase inhibitors"}, {"pubmed_id": "28287043", "title": "Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.", "authors": "J. Lin, D. Makenbaeva, M. Lingohr-Smith, R. Bilmes", "publication_date": "2017-03-14", "keywords": "Adverse events, Chronic myelogenous leukemia, Cost, Healthcare, Tyrosine kinase inhibitors"}, {"pubmed_id": "28287008", "title": "The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.", "authors": "L. Das, M. Gitlin, LR. Siegartel, D. Makenbaeva", "publication_date": "2017-03-14", "keywords": "Chronic myelogenous leukemia, dasatinib, formulary restriction, imatinib, nilotinib, open access, step therapy, tyrosine kinase inhibitor"}, {"pubmed_id": "28280091", "title": "Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.", "authors": "CM. Parseghian, NU. Parikh, JY. Wu, ZQ. Jiang, L. Henderson, F. Tian, B. Pastor, M. Ychou, K. Raghav, A. Dasari, DR. Fogelman, AD. Katsiampoura, DG. Menter, RA. Wolff, C. Eng, MJ. Overman, AR. Thierry, GE. Gallick, S. Kopetz", "publication_date": "2017-03-11", "keywords": ""}, {"pubmed_id": "28199133", "title": "Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient.", "authors": "K. Saeki, S. Watanabe, Y. Waseda, K. Kasahara", "publication_date": "2017-02-16", "keywords": ""}, {"pubmed_id": "28127140", "title": "Dasatinib-induced chylothorax in chronic myeloid leukemia.", "authors": "ZQ. Baloch, SA. Abbas, H. Bhatti, Y. Braver, SK. Ali", "publication_date": "2017-01-28", "keywords": ""}, {"pubmed_id": "28109974", "title": "Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.", "authors": "N. Iriyama, M. Tokuhira, T. Takaku, E. Sato, M. Ishikawa, T. Nakazato, KJ. Sugimoto, H. Fujita, I. Fujioka, Y. Hatta, M. Kizaki, N. Komatsu, N. Asou, T. Kawaguchi", "publication_date": "2017-01-23", "keywords": "Prognosis, Therapy-related chronic myeloid leukemia, Tyrosine kinase inhibitor"}, {"pubmed_id": "28102731", "title": "Microfluidic whole blood testing of platelet response to pharmacological agents.", "authors": "R. Li, T. Grosser, SL. Diamond", "publication_date": "2017-01-20", "keywords": "adenosine diphosphate, aspirin, cyclooxygenase, thromboxane"}, {"pubmed_id": "28098949", "title": "Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.", "authors": "E. Patras de Campaigno, E. Bondon-Guitton, G. Laurent, F. Montastruc, JL. Montastruc, M. Lapeyre-Mestre, F. Despas", "publication_date": "2017-01-19", "keywords": "Abl, cardiac failure, oncology, pharmacodynamics, pharmacovigilance, protein kinase inhibitor"}, {"pubmed_id": "28093990", "title": "Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.", "authors": "R. Wang, C. Zhong, C. Zhang, M. Hua, D. Ma", "publication_date": "2017-01-18", "keywords": "Tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML), influence factors, pharmacokinetics, plasma concentration., treatment"}, {"pubmed_id": "28090053", "title": "A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib.", "authors": "Y. Sakoda, Y. Arimori, M. Ueno, T. Matsumoto", "publication_date": "2017-01-17", "keywords": ""}, {"pubmed_id": "28090014", "title": "Retrospective analysis of clinical outcomes of the patients with chronic myeloid leukemia who stopped administration of tyrosine kinase inhibitors: a single institution experience.", "authors": "Y. Senoo, K. Yoshioka, S. Kaito, S. Kurosawa, K. Harada, K. Yamamoto, Y. Hino, M. Sakaguchi, S. Ikegawa, D. Watanabe, K. Watakabe, T. Hagino, A. Igarashi, Y. Najima, N. Doki, T. Kobayashi, K. Kakihana, H. Sakamaki, K. Ohashi", "publication_date": "2017-01-17", "keywords": ""}, {"pubmed_id": "28082112", "title": "Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.", "authors": "JE. Cortes, CA. Jimenez, MJ. Mauro, A. Geyer, J. Pinilla-Ibarz, BD. Smith", "publication_date": "2017-01-14", "keywords": "Adverse events, Algorithms, BCR-ABL1, Fluid retention, Tyrosine kinase inhibitor"}, {"pubmed_id": "28073814", "title": "Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor.", "authors": "FA. Kinsella, MR. Amel Kashipaz, J. Scarisbrick, R. Malladi", "publication_date": "2017-01-12", "keywords": ""}, {"pubmed_id": "28070919", "title": "Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study.", "authors": "I. Okamura, N. Matsuyama, K. Yasui, F. Hirayama, T. Ikeda", "publication_date": "2017-01-11", "keywords": "allergic transfusion reactions, anaphylaxis, basophil activation test"}, {"pubmed_id": "28058062", "title": "Short overview on the current treatment of chronic myeloid leukemia in chronic phase.", "authors": "S. Schmidt", "publication_date": "2017-01-07", "keywords": "Adverse events, CML, ELN recommendations, Treatment free remission, Tyrosine kinase inhibitor"}, {"pubmed_id": "28032244", "title": "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.", "authors": "GM. Keating", "publication_date": "2016-12-30", "keywords": ""}, {"pubmed_id": "28007774", "title": "Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.", "authors": "SP. D'Angelo, AN. Shoushtari, ML. Keohan, MA. Dickson, MM. Gounder, P. Chi, JK. Loo, L. Gaffney, L. Schneider, Z. Patel, JP. Erinjeri, MJ. Bluth, A. Sjoberg, H. Streicher, N. Takebe, LX. Qin, C. Antonescu, RP. DeMatteo, RD. Carvajal, WD. Tap", "publication_date": "2016-12-23", "keywords": ""}, {"pubmed_id": "28006851", "title": "Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.", "authors": "NJ. Short, HM. Kantarjian, K. Sasaki, F. Ravandi, H. Ko, C. Cameron Yin, G. Garcia-Manero, JE. Cortes, R. Garris, SM. O'Brien, K. Patel, M. Khouri, D. Thomas, N. Jain, TM. Kadia, NG. Daver, CB. Benton, GC. Issa, M. Konopleva, E. Jabbour", "publication_date": "2016-12-23", "keywords": ""}, {"pubmed_id": "27998964", "title": "Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.", "authors": "TRJ. Evans, E. Van Cutsem, MJ. Moore, IS. Bazin, A. Rosemurgy, G. Bodoky, G. Deplanque, M. Harrison, B. Melichar, D. Pezet, A. Elekes, E. Rock, C. Lin, L. Strauss, PJ. O'Dwyer", "publication_date": "2016-12-22", "keywords": "anticancer therapy, dasatinib, gemcitabine, pancreatic cancer"}, {"pubmed_id": "27911119", "title": "Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.", "authors": "MJ. Kelley, G. Jha, D. Shoemaker, JE. Herndon, L. Gu, WT. Barry, J. Crawford, N. Ready", "publication_date": "2016-12-03", "keywords": "Non-small cell lung cancer, Src, gene expression"}, {"pubmed_id": "27901368", "title": "Second line small molecule therapy options for treating chronic myeloid leukemia.", "authors": "M. Molica, F. Massaro, M. Breccia", "publication_date": "2016-12-03", "keywords": "Chronic myeloid leukemia, efficacy, safety, second line, tyrosine kinase inhibitors"}, {"pubmed_id": "27865897", "title": "Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).", "authors": "CIE. Smith", "publication_date": "2016-11-21", "keywords": "Acalabrutinib, Alectinib, Brigatinib, Ceritinib, Crizotinib, Dabrafenib, Dasatinib, Erlotinib, Gefitinib, Ibrutinib, Imatinib, Lorlatinib, Nilotinib, Osimertinib, Rociletinib, Trametinib, Vemurafenib"}, {"pubmed_id": "27864292", "title": "Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.", "authors": "S. Nishiwaki, M. Maeda, M. Yamada, S. Okuno, Y. Harada, K. Suzuki, S. Kurahashi, F. Urano, S. Okamura, I. Sugiura", "publication_date": "2016-11-20", "keywords": ""}, {"pubmed_id": "27852118", "title": "Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.", "authors": "H. Haguet, J. Douxfils, F. Mullier, C. Chatelain, C. Graux, JM. Dogn\u00e9", "publication_date": "2016-11-18", "keywords": "Arterial occlusive disease, BCR-ABL positive, chronic, leukemia, meta-analysis, myelogenous, protein kinase inhibitors, venous thrombosis"}, {"pubmed_id": "27842767", "title": "Drug Hepatotoxicity: Newer Agents.", "authors": "C. Bunchorntavakul, KR. Reddy", "publication_date": "2016-11-16", "keywords": "Antibiotics, Anticoagulants, Antiplatelet, Antiretrovirals, Drug-induced liver injury, Hepatotoxicity, Monoclonal antibodies, Tyrosine kinase inhibitors"}, {"pubmed_id": "27841717", "title": "Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.", "authors": "N. Li, X. Yang, L. Fan, T. Totev, A. Guerin, L. Chen, S. Bhattacharyya, G. Joseph", "publication_date": "2016-11-15", "keywords": "Cost-effectiveness, Philadelphia chromosome-positive, chronic myeloid leukemia, dasatinib, nilotinib, second-line"}, {"pubmed_id": "27825730", "title": "Nodular histiocytic hyperplasia: Is this a cause of dasatinib-pleural effusion?", "authors": "S. Hamada, E. Hayashi, M. Tsukino", "publication_date": "2016-11-09", "keywords": ""}, {"pubmed_id": "27803756", "title": "Dasatinib-induced pleural effusion: Chylothorax, an option to consider.", "authors": "L. Ferreiro, E. San-Jos\u00e9, J. Su\u00e1rez-Antelo, L. Vald\u00e9s", "publication_date": "2016-11-03", "keywords": "Chylothorax, dasatinib, pleural effusion"}, {"pubmed_id": "27752053", "title": "Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?", "authors": "G. Rosti, F. Castagnetti, G. Gugliotta, M. Baccarani", "publication_date": "2016-11-03", "keywords": ""}, {"pubmed_id": "27799395", "title": "Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.", "authors": "M. Riou, A. Seferian, L. Savale, MC. Chaumais, C. Guignabert, M. Canuet, P. Magro, D. Rea, O. Sitbon, X. Ja\u00efs, M. Humbert, D. Montani", "publication_date": "2016-11-02", "keywords": ""}, {"pubmed_id": "27589085", "title": "The Cancer Drug Dasatinib Increases PGC-1\u03b1 in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.", "authors": "L. Sylow, JZ. Long, IA. Lokurkar, X. Zeng, EA. Richter, BM. Spiegelman", "publication_date": "2016-11-02", "keywords": ""}, {"pubmed_id": "27784355", "title": "[Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].", "authors": "L. Yang, N. Lu, Y. Jing, L. Yu", "publication_date": "2016-10-28", "keywords": ""}, {"pubmed_id": "27665844", "title": "Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.", "authors": "M. Hagihara, N. Iriyama, C. Yoshida, H. Wakita, S. Chiba, S. Okamoto, K. Kawakami, N. Takezako, T. Kumagai, K. Inokuchi, K. Ohyashiki, J. Taguchi, S. Yano, T. Igarashi, Y. Kouzai, S. Morita, J. Sakamoto, H. Sakamaki", "publication_date": "2016-10-26", "keywords": ""}, {"pubmed_id": "27460678", "title": "Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.", "authors": "A. Hino, H. Yoshida, Y. Tada, M. Koike, R. Minami, H. Masaie, J. Ishikawa", "publication_date": "2016-10-26", "keywords": "Chronic myelogenous leukemia, Imatinib, Renal impairment"}, {"pubmed_id": "27756880", "title": "LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.", "authors": "YJ. Kim, S. Hong, M. Sung, MJ. Park, K. Jung, KW. Noh, DY. Oh, MS. Lee, E. Oh, YK. Shin, YL. Choi", "publication_date": "2016-10-21", "keywords": "LYN, SRC, YES, dasatinib, lung adenocarcinoma subgroup"}, {"pubmed_id": "27713843", "title": "Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management.", "authors": "S. Bauer, S. Buchanan, I. Ryan", "publication_date": "2016-10-08", "keywords": ""}, {"pubmed_id": "27659013", "title": "Frontline Dasatinib Treatment in a \"Real-Life\" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.", "authors": "R. Latagliata, F. Stagno, M. Annunziata, E. Abruzzese, A. Iurlo, A. Guarini, C. Fava, A. Gozzini, M. Bonifacio, F. Sor\u00e0, S. Leonetti Crescenzi, M. Bocchia, M. Crugnola, F. Castagnetti, I. Capodanno, S. Galimberti, C. Feo, R. Porrini, P. Pregno, M. Rizzo, A. Antolino, E. Mauro, N. Sgherza, L. Luciano, M. Tiribelli, A. Russo Rossi, M. Trawinska, P. Vigneri, M. Breccia, G. Rosti, G. Alimena", "publication_date": "2016-09-24", "keywords": ""}, {"pubmed_id": "27656875", "title": "Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature.", "authors": "M. Shanshal, A. Shakespeare, S. Thirumala, B. Fenton, DP. Quick", "publication_date": "2016-09-23", "keywords": ""}, {"pubmed_id": "27629971", "title": "Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.", "authors": "H. Ureshino, A. Nishioka, K. Kojima, H. Kizuka, H. Sano, T. Shindo, Y. Kubota, T. Ando, S. Kimura", "publication_date": "2016-09-16", "keywords": ""}, {"pubmed_id": "27618144", "title": "Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.", "authors": "D. Renzi, F. Marchesi, G. De Angelis, L. Elia, E. Salvatorelli, S. Gumenyuk, F. Palombi, F. Pisani, A. Romano, A. Spadea, E. Papa, M. Canfora, W. Arcese, A. Mengarelli, ", "publication_date": "2016-09-13", "keywords": ""}, {"pubmed_id": "27599415", "title": "Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.", "authors": "S. Morishita, M. Hagihara, M. Itabashi, Y. Ishii, W. Yamamoto, A. Numata, K. Motohashi, K. Matsumoto, S. Fujisawa, H. Nakajima", "publication_date": "2016-09-08", "keywords": ""}, {"pubmed_id": "27583255", "title": "Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.", "authors": "S. Kimura", "publication_date": "2016-09-02", "keywords": "ABL tyrosine kinase inhibitor (TKI), chronic myeloid leukemia (CML), discontinuation, stop"}, {"pubmed_id": "27562641", "title": "Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.", "authors": "L. Caldemeyer, LP. Akard", "publication_date": "2016-08-27", "keywords": "Chronic myeloid leukemia, deep molecular response, treatment-free remission, tyrosine kinase inhibitors"}, {"pubmed_id": "27560448", "title": "First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.", "authors": "R. Gurion, P. Raanani, L. Vidal, A. Leader, A. Gafter-Gvili", "publication_date": "2016-08-26", "keywords": ""}, {"pubmed_id": "27531525", "title": "Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.", "authors": "JE. Cortes, HJ. Khoury, HM. Kantarjian, JH. Lipton, DW. Kim, P. Schafhausen, E. Matczak, E. Leip, K. Noonan, TH. Br\u00fcmmendorf, C. Gambacorti-Passerini", "publication_date": "2016-08-18", "keywords": ""}, {"pubmed_id": "27521332", "title": "Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.", "authors": "D. Hoehn, JE. Cortes, LJ. Medeiros, EJ. Jabbour, JE. Hidalgo, R. Kanagal-Shamanna, CE. Bueso-Ramos", "publication_date": "2016-08-16", "keywords": "Bone marrow, Bone metabolism, Dasatinib, Digital image analysis, Trabecular bone"}, {"pubmed_id": "27520378", "title": "Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.", "authors": "TG. Gabig, WC. Waltzer, T. Whyard, V. Romanov", "publication_date": "2016-08-16", "keywords": "Bladder cancer, Claudin 4, Clostridium perfringens enterotoxin"}, {"pubmed_id": "27494812", "title": "Simultaneous determination of 6-mercaptopruine, 6-thioguanine and dasatinib as three important anticancer drugs using nanostructure voltammetric sensor employing Pt/MWCNTs and 1-butyl-3-methylimidazolium hexafluoro phosphate.", "authors": "H. Karimi-Maleh, AF. Shojaei, K. Tabatabaeian, F. Karimi, S. Shakeri, R. Moradi", "publication_date": "2016-08-06", "keywords": "6-Mercaptopurine, 6-Thioguanine, Dasatinib, Ionic liquid, Pt/MWCNTs, Sensor"}, {"pubmed_id": "27494773", "title": "The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.", "authors": "N. Alhawiti, KL. Burbury, FA. Kwa, CJ. O'Malley, P. Shuttleworth, M. Alzard, A. Hamadi, AP. Grigg, DE. Jackson", "publication_date": "2016-08-06", "keywords": "Bcr-Abl tyrosine kinase, Endothelial activation, Nilotinib, P-selectin, Platelet activation, Thrombosis"}, {"pubmed_id": "27485109", "title": "In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.", "authors": "S. Soverini, C. De Benedittis, F. Castagnetti, G. Gugliotta, M. Mancini, L. Bavaro, K. Machova Polakova, J. Linhartova, A. Iurlo, D. Russo, F. Pane, G. Saglio, G. Rosti, M. Cavo, M. Baccarani, G. Martinelli", "publication_date": "2016-08-04", "keywords": "BCR-ABL1, Chronic myeloid leukemia, Deep sequencing, Tyrosine kinase inhibitors, Warning"}, {"pubmed_id": "27482885", "title": "Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.", "authors": "C. Guignabert, C. Phan, A. Seferian, A. Huertas, L. Tu, R. Thuillet, C. Sattler, M. Le Hiress, Y. Tamura, EM. Jutant, MC. Chaumais, S. Bouchet, B. Man\u00e9glier, M. Molimard, P. Rousselot, O. Sitbon, G. Simonneau, D. Montani, M. Humbert", "publication_date": "2016-08-03", "keywords": ""}, {"pubmed_id": "27408366", "title": "A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient.", "authors": "H. Ahn, JE. Kwon, SW. Sohn, JH. Kwon, JS. Kim, SS. Yoon, HR. Kang, KS. Hong", "publication_date": "2016-07-14", "keywords": "Adverse drug reaction, Dasatinib, Drug hypersensitivity, Hemorrhagic colitis"}, {"pubmed_id": "27406834", "title": "Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.", "authors": "S. Bhalla, D. Tremblay, J. Mascarenhas", "publication_date": "2016-07-14", "keywords": "Cure, Dasatinib, Imatinib, Molecular remission, Nilotinib"}, {"pubmed_id": "27391073", "title": "Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity.", "authors": "C. Dong, B. Li, Z. Li, S. Shetty, J. Fu", "publication_date": "2016-07-09", "keywords": "drug carrier, endothelial barrier, leukemia, nanoparticles, tyrosine kinase"}, {"pubmed_id": "27367039", "title": "Deep molecular responses for treatment-free remission in chronic myeloid leukemia.", "authors": "S. Dulucq, FX. Mahon", "publication_date": "2016-07-02", "keywords": "Chronic myeloid leukemia, deep molecular response, treatment-free remission, tyrosine kinase inhibitors"}, {"pubmed_id": "27352939", "title": "Management of pregnant chronic myeloid leukemia patients.", "authors": "E. Abruzzese, MM. Trawinska, P. de Fabritiis, M. Baccarani", "publication_date": "2016-06-30", "keywords": "Chronic myeloid leukemia, TKIs, bosutinib, conception, dasatinib, imatinib, nilotinib, ponatinib, pregnancy"}, {"pubmed_id": "27346662", "title": "Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.", "authors": "I. Aldoss, K. Gaal, MM. Al Malki, H. Ali, R. Nakamura, SJ. Forman, V. Pullarkat", "publication_date": "2016-06-28", "keywords": "Allogeneic, Colitis, Dasatinib, Hematopoietic cell transplantation, Hemorrhagic"}, {"pubmed_id": "27309127", "title": "Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.", "authors": "S. Giebel, A. Czyz, O. Ottmann, F. Baron, E. Brissot, F. Ciceri, JJ. Cornelissen, J. Esteve, NC. Gorin, B. Savani, C. Schmid, M. Mohty, A. Nagler", "publication_date": "2016-06-17", "keywords": "Philadelphia chromosome-positive acute lymphoblastic leukemia, allogeneic hematopoietic stem cell transplantation, dasatinib, imatinib, maintenance therapy, nilotinib, recommendations, tyrosine kinase inhibitors"}, {"pubmed_id": "27297665", "title": "Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?", "authors": "Z. DeFilipp, AA. Langston, Z. Chen, C. Zhang, ML. Arellano, F. El Rassi, CR. Flowers, VK. Kota, Z. Al-Kadhimi, R. Veldman, AP. Jillella, S. Lonial, EK. Waller, HJ. Khoury", "publication_date": "2016-06-15", "keywords": "Acute lymphoblastic leukemia, Chronic myeloid leukemia, Ph(+), Relapse, TKIs"}, {"pubmed_id": "27295519", "title": "Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.", "authors": "T. Dahl\u00e9n, G. Edgren, M. Lambe, M. H\u00f6glund, M. Bj\u00f6rkholm, F. Sandin, A. Sj\u00e4lander, J. Richter, U. Olsson-Str\u00f6mberg, L. Ohm, M. B\u00e4ck, L. Stenke, ", "publication_date": "2016-06-14", "keywords": ""}, {"pubmed_id": "27267844", "title": "Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug.", "authors": "F. Davalos, B. Chaucer, W. Zafar, S. Salman, J. Nfonoyim", "publication_date": "2016-06-09", "keywords": ""}, {"pubmed_id": "27263788", "title": "Reversible dasatinib-related pulmonary arterial hypertension in a CML patient.", "authors": "J. Nagasaki, Y. Aoyama, Y. Nomoto, K. Ido, H. Ichihara, A. Mugitani", "publication_date": "2016-06-07", "keywords": ""}, {"pubmed_id": "27246579", "title": "Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia.", "authors": "M. Imamura", "publication_date": "2016-06-02", "keywords": ""}, {"pubmed_id": "27221912", "title": "Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.", "authors": "A. Tantiworawit, S. Kongjarern, E. Rattarittamrong, S. Lekawanvijit, K. Bumroongkit, N. Boonma, T. Rattanathammethee, S. Hantrakool, C. Chai-Adisaksopha, L. Norasetthada", "publication_date": "2016-05-26", "keywords": ""}, {"pubmed_id": "27217448", "title": "Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial.", "authors": "JE. Cortes, G. Saglio, HM. Kantarjian, M. Baccarani, J. Mayer, C. Boqu\u00e9, NP. Shah, C. Chuah, L. Casanova, B. Bradley-Garelik, G. Manos, A. Hochhaus", "publication_date": "2016-05-25", "keywords": ""}, {"pubmed_id": "27214026", "title": "Interferon-\u03b1 Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.", "authors": "V. Polivkova, P. Rohon, H. Klamova, O. Cerna, M. Divoka, N. Curik, J. Zach, M. Novak, I. Marinov, S. Soverini, E. Faber, K. Machova Polakova", "publication_date": "2016-05-24", "keywords": ""}, {"pubmed_id": "27210877", "title": "[Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].", "authors": "J. Wang, Y. Zhang, J. Zhou, YL. Zu, Z. Li, YP. Song", "publication_date": "2016-05-24", "keywords": ""}, {"pubmed_id": "27194112", "title": "Proteome-wide drug screening using mass spectrometric imaging of bead-arrays.", "authors": "Y. Zhou, Z. Liu, KJ. Rothschild, MJ. Lim", "publication_date": "2016-05-20", "keywords": ""}, {"pubmed_id": "27192969", "title": "Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.", "authors": "NP. Shah, P. Rousselot, C. Schiffer, D. Rea, JE. Cortes, J. Milone, H. Mohamed, D. Healey, H. Kantarjian, A. Hochhaus, G. Saglio", "publication_date": "2016-05-20", "keywords": ""}, {"pubmed_id": "27182202", "title": "Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.", "authors": "N. Iriyama, B. Yuan, Y. Hatta, N. Takagi, M. Takei", "publication_date": "2016-05-18", "keywords": "Acute myeloid leukemia, All-trans retinoic acid, Dihydroxyvitamin D3, Lyn, c-Myc, dasatinib"}, {"pubmed_id": "27166393", "title": "TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.", "authors": "Z. Mitri, R. Nanda, K. Blackwell, CM. Costelloe, I. Hood, C. Wei, AM. Brewster, NK. Ibrahim, KB. Koenig, GN. Hortobagyi, C. Van Poznak, MF. Rimawi, S. Moulder-Thompson, ", "publication_date": "2016-05-12", "keywords": ""}, {"pubmed_id": "27166066", "title": "Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case.", "authors": "R. Juneja, G. Dhamija, T. Dadu, A. Handoo", "publication_date": "2016-05-12", "keywords": ""}, {"pubmed_id": "27161743", "title": "PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?", "authors": "S. Deb, C. Sj\u00f6str\u00f6m, A. Tharmakulanathan, N. Bokn\u00e4s, K. Lotfi, S. Ramstr\u00f6m", "publication_date": "2016-05-11", "keywords": ""}, {"pubmed_id": "27150875", "title": "Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone.", "authors": "H. Takata, T. Ikebe, H. Sasaki, Y. Miyazaki, E. Ohtsuka, Y. Saburi, M. Ogata, K. Shirao", "publication_date": "2016-05-07", "keywords": ""}, {"pubmed_id": "27133948", "title": "Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.", "authors": "HJ. Khoury, SL. Goldberg, MJ. Mauro, RM. Stone, MW. Deininger, MB. Bradley-Garelik, H. Mohamed, F. Guilhot", "publication_date": "2016-05-03", "keywords": "BCR-ABL, Drug toxicity, Recurrent adverse event, Treatment discontinuation, Tyrosine kinase inhibitor"}, {"pubmed_id": "27126835", "title": "Specialty pharmacy for hematologic malignancies.", "authors": "S. Fajardo, F. Zook, E. Dotson", "publication_date": "2016-04-30", "keywords": ""}, {"pubmed_id": "27121472", "title": "Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.", "authors": "P. Rousselot, MM. Coud\u00e9, N. Gokbuget, C. Gambacorti Passerini, S. Hayette, JM. Cayuela, F. Huguet, T. Leguay, P. Chevallier, C. Salanoubat, C. Bonmati, M. Alexis, M. Hunault, S. Glaisner, P. Agape, C. Berthou, E. Jourdan, J. Fernandes, L. Sutton, A. Banos, O. Reman, B. Lioure, X. Thomas, N. Ifrah, M. Lafage-Pochitaloff, A. Bornand, L. Morisset, V. Robin, H. Pfeifer, A. Delannoy, J. Ribera, R. Bassan, M. Delord, D. Hoelzer, H. Dombret, OG. Ottmann, ", "publication_date": "2016-04-29", "keywords": ""}, {"pubmed_id": "27107729", "title": "[Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].", "authors": "V. Garc\u00eda-Guti\u00e9rrez, A. Jim\u00e9nez-Velasco, MT. G\u00f3mez-Casares, F. S\u00e1nchez-Guijo, JL. L\u00f3pez-Send\u00f3n, JL. Steegmann Olmedillas", "publication_date": "2016-04-25", "keywords": "Cardiovascular risk factors, Chronic myeloid leukemia, Comprehensive treatment, Conferencia de consenso, Consensus meeting, Factores de riesgo cardiovascular, Leucemia mieloide cr\u00f3nica, Tratamiento integral"}, {"pubmed_id": "27101984", "title": "Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.", "authors": "S. Yun, ND. Vincelette, JM. Segar, Y. Dong, Y. Shen, DW. Kim, I. Abraham", "publication_date": "2016-04-23", "keywords": "Bosutinib, Dasatinib, Nilotinib, Ponatinib, Radotinib"}, {"pubmed_id": "27100618", "title": "Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.", "authors": "J. Samis, P. Lee, D. Zimmerman, RJ. Arceci, M. Suttorp, N. Hijiya", "publication_date": "2016-04-22", "keywords": "CML, TKI, children, endocrine, growth"}, {"pubmed_id": "27085529", "title": "Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.", "authors": "Q. Jiang, ZC. Liu, SX. Zhang, RP. Gale", "publication_date": "2016-04-18", "keywords": "Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Tyrosine kinase inhibitors"}, {"pubmed_id": "27067491", "title": "Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.", "authors": "M. \u017d\u00e1\u010dkov\u00e1, T. Mach\u00e1\u010dkov\u00e1-Lopotov\u00e1, Z. Ondr\u00e1\u010dkov\u00e1, K. Ku\u017eelov\u00e1, H. Klamov\u00e1, J. Moravcov\u00e1", "publication_date": "2016-04-14", "keywords": "Chronic myeloid leukemia, Early predictors, Resistance"}, {"pubmed_id": "27033238", "title": "New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.", "authors": "AV. Moorman", "publication_date": "2016-04-02", "keywords": ""}, {"pubmed_id": "27009771", "title": "Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.", "authors": "G. Tournaire, F. Despas, F. Huguet, JL. Montastruc, E. Bondon-Guitton", "publication_date": "2016-03-25", "keywords": "adverse drug reactions, protein kinase inhibitors, risk factors, vasculopathies"}, {"pubmed_id": "27003817", "title": "Linking MedDRA(\u00ae)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.", "authors": "S. Sarntivijai, S. Zhang, DG. Jagannathan, S. Zaman, KK. Burkhart, GS. Omenn, Y. He, BD. Athey, DR. Abernethy", "publication_date": "2016-03-24", "keywords": ""}, {"pubmed_id": "26998677", "title": "Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.", "authors": "CA. Schiffer, JE. Cortes, A. Hochhaus, G. Saglio, P. le Coutre, K. Porkka, S. Mustjoki, H. Mohamed, NP. Shah", "publication_date": "2016-03-22", "keywords": "T-lymphocytes, chronic myeloid, dasatinib, killer cells, leukemia, lymphocytosis, natural"}, {"pubmed_id": "26969425", "title": "[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].", "authors": "C. Jovelet, S. Broutin, S. Gil, O. Mir, A. Paci", "publication_date": "2016-03-13", "keywords": "Cancer, Grossesse, Inhibiteurs de tyrosine kinase, Pregnancy, Tyrosine kinase inhibitors"}, {"pubmed_id": "26961484", "title": "Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.", "authors": "E. Yim, YG. Choi, YJ. Nam, J. Lee, JA. Kim", "publication_date": "2016-03-11", "keywords": "Dasatinib, Hemorrhagic colitis, Leukemia, myelogenous, chronic, BCR-ABL positive"}, {"pubmed_id": "26951627", "title": "Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "JH. Yoon, HY. Yhim, JY. Kwak, JS. Ahn, DH. Yang, JJ. Lee, SJ. Kim, JS. Kim, SJ. Park, CW. Choi, HS. Eom, SK. Park, SY. Choi, SH. Kim, DW. Kim, S. Lee", "publication_date": "2016-03-10", "keywords": "Philadelphia chromosome, acute lymphoblastic leukemia, allogeneic stem cell transplantation, dasatinib, minimal residual disease"}, {"pubmed_id": "26923326", "title": "Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.", "authors": "J. El Cheikh, ZK. Otrock, AA. Qannus, MA. Kharfan-Dabaja, A. Bazarbachi", "publication_date": "2016-03-01", "keywords": "5-Azacytidine, Allogeneic stem cell transplantation, Dasatinib, Personalized conditioning, Sorafenib"}, {"pubmed_id": "26922746", "title": "Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.", "authors": "L. Caldemeyer, M. Dugan, J. Edwards, L. Akard", "publication_date": "2016-02-29", "keywords": "BCR-ABL1, CML, Dasatinib, Imatinib, Nilotinib, TKI"}, {"pubmed_id": "26916020", "title": "Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets.", "authors": "M. Levade, S. Severin, MP. Gratacap, L. Ysebaert, B. Payrastre", "publication_date": "2016-02-27", "keywords": ""}, {"pubmed_id": "26907461", "title": "Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.", "authors": "F. Vignani, V. Bertaglia, C. Buttigliero, M. Tucci, GV. Scagliotti, M. Di Maio", "publication_date": "2016-02-26", "keywords": "Bone metastasis, Bone-targeted therapy, Castration resistant prostate cancer, Chemotherapy, New generation hormonal agents, Skeletal related event"}, {"pubmed_id": "26879609", "title": "[Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].", "authors": "J. Jin, XM. Xu, C. Wang", "publication_date": "2016-02-18", "keywords": ""}, {"pubmed_id": "26870658", "title": "An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis.", "authors": "B. Uz, I. Dolasik", "publication_date": "2016-02-13", "keywords": "Creatine kinase, Dasatinib, Rhabdomyolysis"}, {"pubmed_id": "26847662", "title": "Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.", "authors": "J. Douxfils, H. Haguet, F. Mullier, C. Chatelain, C. Graux, JM. Dogn\u00e9", "publication_date": "2016-02-06", "keywords": ""}, {"pubmed_id": "26841016", "title": "The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.", "authors": "PA. Pophali, MM. Patnaik", "publication_date": "2016-02-04", "keywords": ""}, {"pubmed_id": "26840448", "title": "Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.", "authors": "F. Jacob, AY. Yonis, F. Cuello, P. Luther, T. Schulze, A. Eder, T. Streichert, I. Mannhardt, MN. Hirt, S. Schaaf, J. Stenzig, T. Force, T. Eschenhagen, A. Hansen", "publication_date": "2016-02-04", "keywords": ""}, {"pubmed_id": "26825166", "title": "Neutrophilic Dermatosis Limited to Lipo-Lymphedematous Skin in a Morbidly Obese Woman on Dasatinib Therapy.", "authors": "S. Ainechi, JA. Carlson", "publication_date": "2016-01-31", "keywords": ""}, {"pubmed_id": "26803529", "title": "Postpartum estrogen withdrawal impairs hippocampal neurogenesis and causes depression- and anxiety-like behaviors in mice.", "authors": "Z. Zhang, J. Hong, S. Zhang, T. Zhang, S. Sha, R. Yang, Y. Qian, L. Chen", "publication_date": "2016-01-25", "keywords": "Brain-derived neurotrophic factor (BDNF), Estradiol benzoate (EB), Hormone-simulated pregnancy (HSP), NMDA receptor (NMDAr), Neurogenesis, Postpartum depression (PPD)"}, {"pubmed_id": "26799612", "title": "Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.", "authors": "E. Jabbour, H. Kantarjian", "publication_date": "2016-01-23", "keywords": ""}, {"pubmed_id": "26796981", "title": "Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.", "authors": "K. Sasaki, A. Lahoti, E. Jabbour, P. Jain, S. Pierce, G. Borthakur, N. Daver, T. Kadia, N. Pemmaraju, A. Ferrajoli, S. O'Brien, H. Kantarjian, J. Cortes", "publication_date": "2016-01-23", "keywords": "CML, Dasatinib, Liver dysfunction, Nilotinib, Renal dysfunction"}, {"pubmed_id": "26796903", "title": "Treatment of chronic myelogenous leukemia.", "authors": "C. Kujak, JM. Kolesar", "publication_date": "2016-01-23", "keywords": ""}, {"pubmed_id": "26785036", "title": "Heart failure associated with small molecule tyrosine kinase inhibitors.", "authors": "TF. Imran, R. Shah, AS. Ha, R. Thomas, J. Joseph", "publication_date": "2016-01-20", "keywords": ""}, {"pubmed_id": "26769227", "title": "Chronic myeloid leukemia: First-line drug of choice.", "authors": "E. Jabbour", "publication_date": "2016-01-16", "keywords": ""}, {"pubmed_id": "26758269", "title": "Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.", "authors": "SC. Howard, S. Trifilio, TK. Gregory, N. Baxter, A. McBride", "publication_date": "2016-01-14", "keywords": "Hematologic malignancies, Prophylaxis, Targeted treatment, Tumor lysis syndrome"}, {"pubmed_id": "26743563", "title": "Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.", "authors": "BD. Smith, J. Liu, D. Latremouille-Viau, A. Guerin, D. Fernandez, L. Chen", "publication_date": "2016-01-09", "keywords": "Chronic myeloid leukemia, Healthcare resource use, Medical costs, Medicare, Overall survival, Treatment patterns, Tyrosine kinase inhibitors"}, {"pubmed_id": "26725357", "title": "[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib].", "authors": "M. Kurimoto, A. Nagata, N. Sekiguchi, S. Noto, N. Takezako", "publication_date": "2016-01-05", "keywords": ""}, {"pubmed_id": "28373825", "title": "Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors.", "authors": "A. Piekarska, L. Gil, K. Jakitowicz, W. Prejzner, M. Komarnicki, A. Hellmann", "publication_date": "2016-01-01", "keywords": "allogeneic hematopoietic cell transplantation, quality of life, tyrosine kinase inhibitors"}, {"pubmed_id": "26710211", "title": "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.", "authors": "SM. Schuetze, JK. Wathen, DR. Lucas, E. Choy, BL. Samuels, AP. Staddon, KN. Ganjoo, M. von Mehren, WA. Chow, DM. Loeb, HA. Tawbi, DA. Rushing, SR. Patel, DG. Thomas, R. Chugh, DK. Reinke, LH. Baker", "publication_date": "2015-12-29", "keywords": "Bayesian, Choi, adaptive, dasatinib, phase 2, sarcoma"}, {"pubmed_id": "26686247", "title": "Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials.", "authors": "PD. le Coutre, TP. Hughes, FX. Mahon, DW. Kim, JL. Steegmann, NP. Shah, K. Gooden, N. Wallis, JE. Cortes", "publication_date": "2015-12-22", "keywords": ""}, {"pubmed_id": "26648184", "title": "Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.", "authors": "R. Latagliata, I. Carmosino, F. Vozella, P. Volpicelli, F. De Angelis, MG. Loglisci, A. Salaroli, ML. De Luca, C. Montagna, A. Serrao, M. Molica, D. Diverio, M. Nanni, M. Mancini, M. Breccia, G. Alimena", "publication_date": "2015-12-10", "keywords": "chronic myeloid leukaemia, dasatinib, imatinib, nilotinib, real-life"}, {"pubmed_id": "26646444", "title": "Optimal management for pediatric chronic myeloid leukemia.", "authors": "A. Tanizawa", "publication_date": "2015-12-10", "keywords": "child, chronic myeloid leukemia, imatinib mesylate, stem cell transplantation, tyrosine kinase inhibitor"}, {"pubmed_id": "26643920", "title": "Dasatinib first-line: Multicentric Italian experience outside clinical trials.", "authors": "M. Breccia, F. Stagno, L. Luciano, E. Abruzzese, M. Annunziata, M. D'Adda, A. Maggi, N. Sgherza, A. Russo-Rossi, P. Pregno, F. Castagnetti, A. Iurlo, R. Latagliata, M. Cedrone, N. Di Renzo, F. Sor\u00e0, G. Rege-Cambrin, G. La Nasa, AR. Scortechini, G. Greco, L. Franceschini, S. Sica, M. Bocchia, M. Crugnola, E. Orlandi, A. Guarini, G. Specchia, G. Rosti, G. Saglio, G. Alimena", "publication_date": "2015-12-09", "keywords": "Chronic myeloid leukemia, Dasatinib, Prognosis"}, {"pubmed_id": "26615132", "title": "Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.", "authors": "M. Yilmaz, E. Jabbour", "publication_date": "2015-11-29", "keywords": ""}, {"pubmed_id": "26613118", "title": "Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.", "authors": "J. Whalen, I. Stillman, A. Ambavane, E. Felber, D. Makenbaeva, B. Bolinder", "publication_date": "2015-11-28", "keywords": "Chronic myelogenous leukemia, Cost-effectiveness analysis, Dasatinib, Economic analysis, TKI"}, {"pubmed_id": "26607773", "title": "Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice.", "authors": "O. Yilmaz, F. Oztay, O. Kayalar", "publication_date": "2015-11-27", "keywords": "ERK1/2, PDGFR-\u03b1, Pulmonary fibrosis, c-Abl, dasatinib, fibroblasts"}, {"pubmed_id": "26598548", "title": "Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.", "authors": "SJ. Wong, T. Karrison, DN. Hayes, MS. Kies, KJ. Cullen, T. Tanvetyanon, A. Argiris, N. Takebe, D. Lim, NF. Saba, FP. Worden, J. Gilbert, HJ. Lenz, AR. Razak, JD. Roberts, EE. Vokes, EE. Cohen", "publication_date": "2015-11-26", "keywords": "adenoid cystic carcinoma, cKIT, dasatinib, malignant salivary gland cancer, phase II"}, {"pubmed_id": "26588811", "title": "Chronic myeloid leukemia: Second-line drugs of choice.", "authors": "C. Gambacorti-Passerini, A. Aroldi, N. Cordani, R. Piazza", "publication_date": "2015-11-21", "keywords": ""}, {"pubmed_id": "26566972", "title": "Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.", "authors": "M. Faraci, S. Matthes-Martin, E. Lanino, G. Morreale, M. Ferretti, S. Giardino, C. Micalizzi, A. Balduzzi", "publication_date": "2015-11-15", "keywords": "chronic myeloid leukemia, premature ovarian insufficiency, reduced intensity conditioning regimen"}, {"pubmed_id": "26507546", "title": "Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.", "authors": "Y. Ishida, K. Murai, K. Yamaguchi, T. Miyagishima, M. Shindo, K. Ogawa, T. Nagashima, S. Sato, R. Watanabe, S. Yamamoto, T. Hirose, S. Saitou, M. Yonezumi, T. Kondo, Y. Kato, N. Mochizuki, K. Ohno, S. Kishino, K. Kubo, T. Oyake, S. Ito, ", "publication_date": "2015-10-29", "keywords": "Dasatinib, Half maximal inhibitory concentration, Molecular response, Phamacokinetics, Pharmacodynamics"}, {"pubmed_id": "26458186", "title": "Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model.", "authors": "S. Balasubramanian, DL. Pleasant, H. Kasiganesan, L. Quinones, Y. Zhang, KP. Sundararaj, S. Roche, R. O'Connor, AD. Bradshaw, D. Kuppuswamy", "publication_date": "2015-10-13", "keywords": ""}, {"pubmed_id": "26457282", "title": "MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.", "authors": "M. Lardo, M. Castro, B. Moiraghi, F. Rojas, N. Borda, JA. Rey, A. Lazarowski", "publication_date": "2015-10-13", "keywords": "ABCB1, BCR-ABL, CML, SNPs, TKIs"}, {"pubmed_id": "26455714", "title": "Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.", "authors": "B. Firwana, MB. Sonbol, M. Diab, S. Raza, R. Hasan, I. Yousef, A. Zarzour, A. Garipalli, D. Doll, MH. Murad, A. Al-Kali", "publication_date": "2015-10-13", "keywords": "BCR-ABL, chronic myelogenous leukemia, dasatinib, hematologic neoplasms, imatinib, nilotinib, tyrosine kinase inhibitor"}, {"pubmed_id": "26436329", "title": "Dasatinib-induced nephrotic syndrome.", "authors": "T. Hirano, M. Hashimoto, Y. Korogi, T. Tsuji, K. Miyanaka, H. Yamasaki, H. Tsuda", "publication_date": "2015-10-06", "keywords": ""}, {"pubmed_id": "26434556", "title": "Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia.", "authors": "A. Fujimi, S. Ibata, Y. Kanisawa, T. Shibata, H. Sakamoto, S. Yamada, T. Okuda, S. Takahashi, S. Minami, A. Hashimoto", "publication_date": "2015-10-06", "keywords": ""}, {"pubmed_id": "26399382", "title": "Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.", "authors": "YS. Jung, M. Kim, JH. Lee, DW. Kim, HJ. Park", "publication_date": "2015-09-25", "keywords": ""}, {"pubmed_id": "26379451", "title": "Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy.", "authors": "MA. Yassin, AJ. Nashwan, AT. Soliman, A. Yousif, A. Moustafa, A. AlBattah, SF. Mohamed, DS. Mudawi, S. Elkourashy, DR. Asaari, HL. Gutierrez, M. Almusharaf, RM. Hussein, AH. Moustafa, HE. Derhoubi, S. Boukhris, S. Kohla, N. AlDewik", "publication_date": "2015-09-18", "keywords": "CML, colitis, dasatinib"}, {"pubmed_id": "26376678", "title": "Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?", "authors": "A. Iurlo, E. Orsi, D. Cattaneo, V. Resi, C. Bucelli, N. Orofino, M. Scium\u00e8, C. Elena, V. Grancini, D. Consonni, EM. Orlandi, A. Cortelezzi", "publication_date": "2015-09-18", "keywords": "dasatinib, diabetes mellitus, imatinib, metabolic syndrome, nilotinib"}, {"pubmed_id": "26376592", "title": "Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.", "authors": "Y. Sekiguchi, A. Shimada, M. Matsuzawa, H. Imai, M. Wakabayashi, K. Sugimoto, N. Nakamura, T. Sawada, J. Arita, N. Komatsu, M. Noguchi", "publication_date": "2015-09-18", "keywords": ""}, {"pubmed_id": "26375182", "title": "Dasatinib therapy can result in significant pulmonary toxicity.", "authors": "M. Tatarczuch, K. Burbury, L. Creati, EH. Januszewicz, JF. Seymour", "publication_date": "2015-09-17", "keywords": ""}, {"pubmed_id": "26373533", "title": "Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.", "authors": "C. Chai-Adisaksopha, W. Lam, C. Hillis", "publication_date": "2015-09-17", "keywords": "Cerebrovascular disease, chronic myeloid leukemia, coronary artery disease, peripheral arterial disease"}, {"pubmed_id": "26371140", "title": "Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.", "authors": "JJ. Moslehi, M. Deininger", "publication_date": "2015-09-16", "keywords": ""}, {"pubmed_id": "26364871", "title": "Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.", "authors": "AS. Yong, E. Brissot, S. Rubinstein, BN. Savani, M. Mohty", "publication_date": "2015-09-15", "keywords": "allogeneic hematopoietic stem cell transplant, chronic myeloid leukemia, cure, treatment-free remission, tyrosine kinase inhibitor"}, {"pubmed_id": "26360368", "title": "Dasatinib-related Follicular Hyperplasia: An Underrecognized Entity With Characteristic Morphology.", "authors": "MG. Ozawa, MD. Ewalt, D. Gratzinger", "publication_date": "2015-09-12", "keywords": ""}, {"pubmed_id": "26355082", "title": "Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.", "authors": "YC. Kwon, SK. Bose, R. Steele, K. Meyer, AM. Di Bisceglie, RB. Ray, R. Ray", "publication_date": "2015-09-12", "keywords": ""}, {"pubmed_id": "26352467", "title": "Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.", "authors": "AB. Patel, AR. Solomon, MJ. Mauro, BD. Ehst", "publication_date": "2015-09-10", "keywords": ""}, {"pubmed_id": "26348106", "title": "The impact of dasatinib on pregnancy outcomes.", "authors": "JE. Cortes, E. Abruzzese, E. Chelysheva, M. Guha, N. Wallis, JF. Apperley", "publication_date": "2015-09-09", "keywords": ""}, {"pubmed_id": "26342236", "title": "Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.", "authors": "C. Le Tourneau, JP. Delord, A. Gon\u00e7alves, C. Gavoille, C. Dubot, N. Isambert, M. Campone, O. Tr\u00e9dan, MA. Massiani, C. Mauborgne, S. Armanet, N. Servant, I. Bi\u00e8che, V. Bernard, D. Gentien, P. Jezequel, V. Attignon, S. Boyault, A. Vincent-Salomon, V. Servois, MP. Sablin, M. Kamal, X. Paoletti, ", "publication_date": "2015-09-08", "keywords": ""}, {"pubmed_id": "26321221", "title": "Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.", "authors": "ML. Churchman, J. Low, C. Qu, EM. Paietta, LH. Kasper, Y. Chang, D. Payne-Turner, MJ. Althoff, G. Song, SC. Chen, J. Ma, M. Rusch, D. McGoldrick, M. Edmonson, P. Gupta, YD. Wang, W. Caufield, B. Freeman, L. Li, JC. Panetta, S. Baker, YL. Yang, KG. Roberts, K. McCastlain, I. Iacobucci, JL. Peters, VE. Centonze, F. Notta, SM. Dobson, S. Zandi, JE. Dick, L. Janke, J. Peng, K. Kodali, V. Pagala, J. Min, A. Mayasundari, RT. Williams, CL. Willman, J. Rowe, S. Luger, RA. Dickins, RK. Guy, T. Chen, CG. Mullighan", "publication_date": "2015-09-01", "keywords": ""}, {"pubmed_id": "26308885", "title": "Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "F. Ravandi, SM. O'Brien, JE. Cortes, DM. Thomas, R. Garris, S. Faderl, JA. Burger, ME. Rytting, A. Ferrajoli, WG. Wierda, S. Verstovsek, R. Champlin, P. Kebriaei, DA. McCue, X. Huang, E. Jabbour, G. Garcia-Manero, Z. Estrov, HM. Kantarjian", "publication_date": "2015-08-27", "keywords": "Philadelphia chromosome, acute lymphoblastic leukemia, chemotherapy, combination, dasatinib"}, {"pubmed_id": "26300669", "title": "Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy.", "authors": "KH. Wu, HP. Wu, T. Weng, CT. Peng, YH. Chao", "publication_date": "2015-08-25", "keywords": "Dasatinib, Philadelphia chromosome, acute lymphoblastic leukemia, children, complete molecular remission"}, {"pubmed_id": "26297264", "title": "Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.", "authors": "S. Soverini, C. de Benedittis, M. Mancini, G. Martinelli", "publication_date": "2015-08-25", "keywords": "BCR-ABL1 mutations, Dasatinib, Imatinib, Nilotinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "26284693", "title": "Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.", "authors": "NP. Shah, N. Wallis, HW. Farber, MJ. Mauro, RA. Wolf, D. Mattei, M. Guha, D. Rea, A. Peacock", "publication_date": "2015-08-19", "keywords": ""}, {"pubmed_id": "26278893", "title": "Is dasatinib-related pulmonary hypertension a clinical concern?", "authors": "S. Szmit", "publication_date": "2015-08-19", "keywords": "cardio-oncology, dasatinib, pleural effusion, pulmonary hypertension, sildenafil"}, {"pubmed_id": "26220759", "title": "Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.", "authors": "A. Piekarska, L. Gil, W. Prejzner, P. Wi\u015bniewski, A. Leszczy\u0144ska, M. Gniot, M. Komarnicki, A. Hellmann", "publication_date": "2015-07-30", "keywords": "Allogeneic hematopoietic cell transplantation, Chronic myeloid leukemia, Dasatinib, Nilotinib, Second-generation tyrosine kinase inhibitors"}, {"pubmed_id": "26217876", "title": "Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.", "authors": "M. Yilmaz, A. Lahoti, S. O'Brien, GM. Nogueras-Gonz\u00e1lez, J. Burger, A. Ferrajoli, G. Borthakur, F. Ravandi, S. Pierce, E. Jabbour, H. Kantarjian, JE. Cortes", "publication_date": "2015-07-29", "keywords": "chronic myeloid leukemia (CML), dasatinib, glomerular filtration rate changes, imatinib, kidney injury, nilotinib, outcome, tyrosine kinase inhibitor"}, {"pubmed_id": "26198824", "title": "Should vascular effects of newer treatments be addressed more completely?", "authors": "EH. Yang, KE. Watson, J. Herrmann", "publication_date": "2015-07-23", "keywords": "cardio-oncology, cardiotoxicity, dasatinib, imatinib resistance, leukemia, nilotinib, peripheral arterial disease, ponatinib, tyrosine kinase inhibitors, vascular toxicity"}, {"pubmed_id": "26108329", "title": "[Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].", "authors": "Y. Guo, TF. Liu, WY. Yang, SC. Wang, M. Ruan, XJ. Chen, L. Zhang, F. Liu, Y. Zou, XF. Zhu", "publication_date": "2015-06-26", "keywords": ""}, {"pubmed_id": "26089312", "title": "Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone.", "authors": "J. Hill, J. Shields, V. Passero", "publication_date": "2015-06-20", "keywords": "Dasatinib, hyponatremia, syndrome of inappropriate secretion of anti-diuretic hormone, tyrosine kinase inhibitor"}, {"pubmed_id": "26029798", "title": "Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.", "authors": "L. Kostos, K. Burbury, G. Srivastava, HM. Prince", "publication_date": "2015-06-02", "keywords": "Bleeding, chronic myeloid leukaemia, dasatinib, platelet-dysfunction"}, {"pubmed_id": "25971713", "title": "Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.", "authors": "E. Jabbour, H. Kantarjian, J. Cortes", "publication_date": "2015-05-15", "keywords": "BCR-ABL1, Outcome, Prognosis, Resistance, Response"}, {"pubmed_id": "25960668", "title": "Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.", "authors": "R. Chen, F. Wang, X. Zhang, C. Gao, B. Chen", "publication_date": "2015-05-12", "keywords": "hematological malignancies, monoclonal antibody, platelet"}, {"pubmed_id": "25948193", "title": "[A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].", "authors": "ZC. Zhang, JH. Qaio, HS. Ai", "publication_date": "2015-05-08", "keywords": ""}, {"pubmed_id": "25947908", "title": "Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.", "authors": "M. Miura", "publication_date": "2015-05-08", "keywords": ""}, {"pubmed_id": "25938861", "title": "Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.", "authors": "BA. Carneiro, JB. Kaplan, FJ. Giles", "publication_date": "2015-05-06", "keywords": "adverse events, bosutinib, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, ponatinib, safety, tolerability, tyrosine kinase inhibitors"}, {"pubmed_id": "25935168", "title": "Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.", "authors": "C. Ustun, N. Randall, E. Podgaetz, K. Amin, HE. Dincer", "publication_date": "2015-05-04", "keywords": "Drug induced Lung Disease, Pleural Disease"}, {"pubmed_id": "25922090", "title": "Renal Toxicities of Targeted Therapies.", "authors": "A. Abbas, MM. Mirza, AK. Ganti, K. Tendulkar", "publication_date": "2015-04-30", "keywords": ""}, {"pubmed_id": "25921387", "title": "Selecting the best frontline treatment in chronic myeloid leukemia.", "authors": "M. Yilmaz, Y. Abaza, E. Jabbour", "publication_date": "2015-04-30", "keywords": ""}, {"pubmed_id": "25910316", "title": "Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.", "authors": "AE. Eskazan, \u0130. Hatemi, S. \u00d6ng\u00f6ren Ayd\u0131n, MC. Ar, T. Soysal", "publication_date": "2015-04-25", "keywords": ""}, {"pubmed_id": "25865674", "title": "A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.", "authors": "AS. Lang, M. Mounier, M. Roques, ML. Chretien, M. Boulin", "publication_date": "2015-04-14", "keywords": "chronic myeloid leukaemia, efficacy, prescription practices, tolerance, tyrosine kinase inhibitors"}, {"pubmed_id": "25860113", "title": "[Chronic myelogenous leukemia].", "authors": "A. Hochhaus, P. La Ros\u00e9e, E. Eigendorff, T. Ernst", "publication_date": "2015-04-11", "keywords": ""}, {"pubmed_id": "25855138", "title": "Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.", "authors": "S. Ohta, Y. Najima, J. Imamura", "publication_date": "2015-04-10", "keywords": ""}, {"pubmed_id": "25842192", "title": "Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.", "authors": "T. Ando, K. Kojima, H. Isoda, Y. Eguchi, T. Honda, M. Ishigami, S. Kimura", "publication_date": "2015-04-07", "keywords": ""}, {"pubmed_id": "25840771", "title": "The IgE-dependent pathway in allergic transfusion reactions: involvement of donor blood allergens other than plasma proteins.", "authors": "N. Matsuyama, K. Yasui, E. Amakishi, T. Hayashi, A. Kuroishi, H. Ishii, H. Matsukura, Y. Tani, RA. Furuta, F. Hirayama", "publication_date": "2015-04-05", "keywords": ""}, {"pubmed_id": "25831762", "title": "[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].", "authors": "T. Nishida, K. Tsukazaki", "publication_date": "2015-04-04", "keywords": ""}, {"pubmed_id": "25826695", "title": "Update on emerging treatments for chronic myeloid leukemia.", "authors": "C. Fava, A. Morotti, I. Dogliotti, G. Saglio, G. Rege-Cambrin", "publication_date": "2015-04-01", "keywords": "bosutinib, chronic myeloid leukemia, dasatinib, nilotinib, ponatinib, target therapy, tyrosine kinase inhibitors"}, {"pubmed_id": "25814080", "title": "A review of the European LeukemiaNet recommendations for the management of CML.", "authors": "M. Baccarani, F. Castagnetti, G. Gugliotta, G. Rosti", "publication_date": "2015-03-31", "keywords": ""}, {"pubmed_id": "25814079", "title": "Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.", "authors": "A. Hochhaus, T. Ernst, E. Eigendorff, P. La Ros\u00e9e", "publication_date": "2015-03-31", "keywords": ""}, {"pubmed_id": "25814078", "title": "The choice of first-line chronic myelogenous leukemia treatment.", "authors": "C. Fava, G. Rege-Cambrin, G. Saglio", "publication_date": "2015-03-31", "keywords": ""}, {"pubmed_id": "25805678", "title": "Dasatinib-related chylothorax.", "authors": "YM. Huang, CH. Wang, JS. Huang, KY. Yeh, CH. Lai, TH. Wu, PH. Chang, PH. Chang, YS. Chang, YJ. Lan", "publication_date": "2015-03-26", "keywords": ""}, {"pubmed_id": "25759797", "title": "Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.", "authors": "S. Virakul, L. van Steensel, VA. Dalm, D. Paridaens, PM. van Hagen, WA. Dik", "publication_date": "2015-03-12", "keywords": "Cytokines, Dasatinib, Graves\u2019 ophthalmopathy, Hyaluronan, Imatinib mesylate, Nilotinib, Orbital fibroblast, Platelet-derived growth factor\u00a0, Proliferation, Thyroid stimulating hormone receptor"}, {"pubmed_id": "25749037", "title": "Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.", "authors": "X. Yang, J. Wang, J. Dai, J. Shao, J. Ma, C. Chen, S. Ma, Q. He, P. Luo, B. Yang", "publication_date": "2015-03-10", "keywords": "autophagy, dasatinib, hepatotoxicity, p38 signaling"}, {"pubmed_id": "25745541", "title": "Drug Therapy in the Progressed CML Patient with multi-TKI Failure.", "authors": "IC. Haznedaroglu", "publication_date": "2015-03-10", "keywords": ""}, {"pubmed_id": "25744241", "title": "Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.", "authors": "HC. Wang, CS. Lee, TC. Liu", "publication_date": "2015-03-07", "keywords": ""}, {"pubmed_id": "25744045", "title": "[Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].", "authors": "H. Hattori, M. Kuwayama, H. Takamori, N. Nishiura, T. Karasuno", "publication_date": "2015-03-07", "keywords": ""}, {"pubmed_id": "25736937", "title": "Bosutinib for the treatment of chronic myeloid leukemia.", "authors": "V. Doan, A. Wang, H. Prescott", "publication_date": "2015-03-05", "keywords": ""}, {"pubmed_id": "25715404", "title": "Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.", "authors": "N. Boissel, A. Renneville, T. Leguay, PC. Lefebvre, C. Recher, T. Lecerf, E. Delabesse, C. Berthon, O. Blanchet, T. Prebet, C. Pautas, P. Chevallier, S. Lepr\u00eatre, S. Girault, C. Bonmati, R. Gui\u00e8ze, C. Himberlin, E. Randriamalala, C. Preudhomme, E. Jourdan, H. Dombret, N. Ifrah", "publication_date": "2015-02-26", "keywords": ""}, {"pubmed_id": "25709401", "title": "The role of dasatinib in the management of chronic myeloid leukemia.", "authors": "R. Chen, B. Chen", "publication_date": "2015-02-25", "keywords": "clinical trials, imatinib, tyrosine kinase inhibitor"}, {"pubmed_id": "25703064", "title": "A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.", "authors": "K. Murai, T. Akagi, K. Shimosegawa, T. Sugawara, K. Ishizawa, S. Ito, K. Murai, M. Motegi, H. Yokoyama, H. Noji, K. Tajima, J. Kimura, T. Chou, K. Ogawa, H. Harigae, K. Kubo, K. Oba, J. Sakamoto, Y. Ishida", "publication_date": "2015-02-24", "keywords": "European LeukemiaNet 2013 recommendations, chronic myeloid leukemia, dasatinib, major molecular response, molecular response \u22674.5 log reduction"}, {"pubmed_id": "25683226", "title": "Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.", "authors": "VR. Belum, C. Washington, CA. Pratilas, V. Sibaud, F. Boralevi, ME. Lacouture", "publication_date": "2015-02-17", "keywords": "adverse events, dermatologic, mucositis, pediatric, pruritus, rash, targeted therapies"}, {"pubmed_id": "25655855", "title": "Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.", "authors": "G. Ta\u00e7oy, A. \u00c7engel, ZN. \u00d6zkurt, S. T\u00fcrko\u011flu", "publication_date": "2015-02-07", "keywords": ""}, {"pubmed_id": "25655601", "title": "Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.", "authors": "CJ. Saret, AN. Winn, G. Shah, SK. Parsons, PJ. Lin, JT. Cohen, PJ. Neumann", "publication_date": "2015-02-07", "keywords": ""}, {"pubmed_id": "25648097", "title": "Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.", "authors": "JH. Hong, SE. Lee, SY. Choi, SH. Kim, EJ. Jang, JH. Bang, JE. Park, HR. Jeon, YJ. Oh, JE. Yi, HO. Jung, HJ. Youn, DW. Kim", "publication_date": "2015-02-05", "keywords": "Chronic myeloid leukemia, Dasatinib, Pulmonary arterial hypertension"}, {"pubmed_id": "25641047", "title": "The targeting of human and mouse B lymphocytes by dasatinib.", "authors": "MP. Oksvold, JM. Duyvestyn, SA. Dagger, SJ. Taylor, L. Forfang, JH. Myklebust, EB. Smeland, WY. Langdon", "publication_date": "2015-02-03", "keywords": ""}, {"pubmed_id": "25635758", "title": "Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.", "authors": "C. Ustun, G. Marcucci", "publication_date": "2015-01-31", "keywords": ""}, {"pubmed_id": "25618211", "title": "[Dasatinib-related pneumonia? An example of pharmacovigilance survey].", "authors": "A. Audemard, B. de la Gastine, S. Chantepie, H. Verger, AC. Gac, E. Bergot, O. Reman", "publication_date": "2015-01-27", "keywords": "Chronic myeloid leukemia, Dasatinib, Drug-induced pneumonitis, Interstitial pneumonia, Leuc\u00e9mie my\u00e9lo\u00efde chronique, Pneumopathie interstitielle, Pneumopathie m\u00e9dicamenteuse"}, {"pubmed_id": "25592338", "title": "Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.", "authors": "JB. Macdonald, B. Macdonald, LE. Golitz, P. LoRusso, A. Sekulic", "publication_date": "2015-01-17", "keywords": "BCR-ABL, HER2, KIT, adverse sequelae, alopecia, antiangiogenic agents, anticancer, bevacizumab, cancer treatment, canertinib, cetuximab, chemotherapy, cutaneous adverse effects, dasatinib, dermatologic toxicities, disturbed wound healing, drug eruption, drug rash, drug reaction, dry skin, dual kinase inhibitors, epidermal growth factor receptor inhibitors, erbB receptor, erlotinib, gefitinib, genital rash, hyperkeratotic hand\u2013foot skin reaction, imatinib, lapatinib, macular eruption, monoclonal antibodies, morbilliform, mucocutaneous hemorrhage, mucositis, multikinase inhibitors, nilotinib, panitumumab, papulopustular eruption, paronychia, pazopanib, photosensitivity, pigment changes, platelet-derived growth factor receptor, ranibizumab, side effects, small molecule, sorafenib, stomatitis, sunitinib, supportive oncodermatology, targeted therapy, toxic erythema, tyrosine kinase inhibitors, vandetanib, vascular endothelial growth factor, xerosis"}, {"pubmed_id": "25584281", "title": "Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib.", "authors": "K. Boudadi, R. Chugh", "publication_date": "2015-01-15", "keywords": "Sarcoma, Skin pigmentation, Tyrosine kinase inhibitor (TKI)"}, {"pubmed_id": "25580915", "title": "Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.", "authors": "J. Cortes, M. Mauro, JL. Steegmann, G. Saglio, R. Malhotra, JA. Ukropec, NT. Wallis", "publication_date": "2015-01-13", "keywords": ""}, {"pubmed_id": "25563556", "title": "Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.", "authors": "J. Gora-Tybor, E. Medras, M. Calbecka, A. Kolkowska-Le\u015bniak, E. Ponikowska-Szyba, T. Robak, K. Jamroziak", "publication_date": "2015-01-08", "keywords": "CML, PAOD, dasatinib, nilotinib, non-hematological complication, vascular complication"}, {"pubmed_id": "31388478", "title": "Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.", "authors": "C. Varallo-Rodriguez, CW. Freyer, EP. Ontiveros, EA. Griffiths, ES. Wang, M. Wetzler", "publication_date": "2015-01-01", "keywords": ""}, {"pubmed_id": "25540064", "title": "A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.", "authors": "C. Nakaseko, N. Takahashi, K. Ishizawa, Y. Kobayashi, K. Ohashi, Y. Nakagawa, K. Yamamoto, K. Miyamura, M. Taniwaki, M. Okada, T. Kawaguchi, A. Shibata, Y. Fujii, C. Ono, K. Ohnishi", "publication_date": "2014-12-30", "keywords": ""}, {"pubmed_id": "25530131", "title": "Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.", "authors": "N. Iriyama, S. Fujisawa, C. Yoshida, H. Wakita, S. Chiba, S. Okamoto, K. Kawakami, N. Takezako, T. Kumagai, K. Inokuchi, K. Ohyashiki, J. Taguchi, S. Yano, T. Igarashi, Y. Kouzai, S. Morita, J. Sakamoto, H. Sakamaki", "publication_date": "2014-12-23", "keywords": ""}, {"pubmed_id": "25525119", "title": "Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.", "authors": "P. Valent, E. Hadzijusufovic, GH. Schernthaner, D. Wolf, D. Rea, P. le Coutre", "publication_date": "2014-12-20", "keywords": ""}, {"pubmed_id": "25517484", "title": "Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia.", "authors": "E. Eliacik, A. Isik, C. Aydin, A. Uner, S. Aksu, N. Sayinalp, H. Demiroglu, H. Goker, Y. Buyukasik, O. Ozcebe, IC. Haznedaroglu", "publication_date": "2014-12-18", "keywords": "Bone marrow f\u0131brosis, TKI drugs"}, {"pubmed_id": "25466286", "title": "Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.", "authors": "JH. Lipton, P. Bryden, MK. Sidhu, H. Huang, LJ. McGarry, S. Lustgarten, S. Mealing, B. Woods, J. Whelan, N. Hawkins", "publication_date": "2014-12-04", "keywords": "CML, Ponatinib, Response, Second-generation tyrosine kinase inhibitor, Systematic review"}, {"pubmed_id": "25449685", "title": "How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.", "authors": "M. Breccia, M. Molica, G. Alimena", "publication_date": "2014-12-03", "keywords": "Endocrine, Metabolic, Tyrosine kinase inhibitors"}, {"pubmed_id": "25449280", "title": "Stem cell factor (SCF) protects osteoblasts from oxidative stress through activating c-Kit-Akt signaling.", "authors": "L. Yang, Z. Wu, G. Yin, H. Liu, X. Guan, X. Zhao, J. Wang, J. Zhu", "publication_date": "2014-12-03", "keywords": "Akt, Osteoblasts, Oxidative stress, Stem cell factor, c-Kit"}, {"pubmed_id": "25445469", "title": "Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.", "authors": "Y. Ito, T. Miyamoto, T. Kamimura, K. Aoki, H. Henzan, T. Aoki, M. Shiratsuchi, K. Kato, K. Nagafuji, R. Ogawa, T. Eto, H. Iwasaki, K. Akashi", "publication_date": "2014-12-03", "keywords": "Adverse events, Allogeneic stem cell transplantation, Dasatinib, Large granular lymphocyte, Philadelphia-positive ALL"}, {"pubmed_id": "25427232", "title": "Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.", "authors": "J. Whiteley, S. Iyer, SD. Candrilli, JA. Kaye", "publication_date": "2014-11-27", "keywords": "BCR-ABL positive, Chronic, Dasatinib, Imatinib, Leukemia, Myelogenous, Nilotinib"}, {"pubmed_id": "25393806", "title": "Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.", "authors": "U. Rochau, G. Sroczynski, D. Wolf, S. Schmidt, B. Jahn, M. Kluibenschaedl, A. Conrads-Frank, D. Stenehjem, D. Brixner, J. Radich, G. Gastl, U. Siebert", "publication_date": "2014-11-14", "keywords": "Chronic myeloid leukemia, cost-effectiveness analysis, decision analysis, decision-analytic model, health economic modeling, tyrosine kinase inhibitors"}, {"pubmed_id": "25379619", "title": "Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.", "authors": "Q. Jiang, YZ. Qin, YY. Lai, H. Jiang, J. Wang, XJ. Huang", "publication_date": "2014-11-08", "keywords": "BCR\u2013ABL, chronic myeloid leukemia, dasatinib, imatinib, mutation, nilotinib"}, {"pubmed_id": "25374410", "title": "Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.", "authors": "T. Sueda, T. Kudo, D. Sakai, M. Uemura, J. Nishimura, T. Hata, I. Takemasa, T. Mizushima, H. Yamamoto, S. Ezoe, K. Matsumoto, Y. Doki, M. Mori, T. Satoh", "publication_date": "2014-11-07", "keywords": ""}, {"pubmed_id": "25370814", "title": "How I treat newly diagnosed chronic myeloid leukemia in 2015.", "authors": "C. Gambacorti-Passerini, R. Piazza", "publication_date": "2014-11-06", "keywords": ""}, {"pubmed_id": "25356574", "title": "Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.", "authors": "ML. Heaney", "publication_date": "2014-10-31", "keywords": ""}, {"pubmed_id": "25331939", "title": "Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.", "authors": "E. Weisberg, A. Nonami, JD. Griffin", "publication_date": "2014-10-22", "keywords": ""}, {"pubmed_id": "25324906", "title": "Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.", "authors": "O. Warszawik-Hendzel, M. S\u0142owi\u0144ska, M. Olszewska, L. Rudnicka", "publication_date": "2014-10-18", "keywords": "dermoscopy, head and neck cancer, head and neck melanoma, mucosal melanoma, oral cancer"}, {"pubmed_id": "25301744", "title": "Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.", "authors": "S. Deutsch, P. Koerner, RT. Miller, Z. Craft, K. Fancher", "publication_date": "2014-10-11", "keywords": "Oral oncology, adherence, adverse events, cycle management, oral chemotherapy"}, {"pubmed_id": "25276139", "title": "Pleural effusion: a rare side effect of nilotinib-a case report.", "authors": "H. Usk\u00fcdar Teke, OM. Akay, D. G\u00f6ren \u015eahin, M. Karag\u00fclle, E. G\u00fcnd\u00fcz, N. And\u0131\u00e7", "publication_date": "2014-10-03", "keywords": ""}, {"pubmed_id": "25267743", "title": "Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.", "authors": "DJ. Harding, G. MacQuillan, R. Howman, B. de Boer, L. Adams, A. Mitchell, G. Jeffrey", "publication_date": "2014-10-01", "keywords": ""}, {"pubmed_id": "25257190", "title": "Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.", "authors": "S. Korkmaz, MS. Dal, I. Berber, DG. Sahin, MH. Dogu, O. Ayyildiz, I. Nizam, M. Albayrak, R. Esen, S. Namdaroglu, M. Sencan, OM. Akay, S. Hacioglu, R. Yildirim, A. Eser, A. Tombak, C. Pala, O. Ilhan", "publication_date": "2014-09-27", "keywords": "chronic myeloid leukemia, dasatinib, elderly patients, imatinib, nilotinib"}, {"pubmed_id": "25226617", "title": "Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.", "authors": "H. Lin, M. Chen, K. Rothe, MV. Lorenzi, A. Woolfson, X. Jiang", "publication_date": "2014-09-17", "keywords": ""}, {"pubmed_id": "25212679", "title": "ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.", "authors": "M. Yoshimura, K. Kojima, R. Tomimasu, N. Fukushima, S. Hayashi, E. Sueoka, S. Kimura", "publication_date": "2014-09-13", "keywords": ""}, {"pubmed_id": "25207766", "title": "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.", "authors": "KG. Roberts, Y. Li, D. Payne-Turner, RC. Harvey, YL. Yang, D. Pei, K. McCastlain, L. Ding, C. Lu, G. Song, J. Ma, J. Becksfort, M. Rusch, SC. Chen, J. Easton, J. Cheng, K. Boggs, N. Santiago-Morales, I. Iacobucci, RS. Fulton, J. Wen, M. Valentine, C. Cheng, SW. Paugh, M. Devidas, IM. Chen, S. Reshmi, A. Smith, E. Hedlund, P. Gupta, P. Nagahawatte, G. Wu, X. Chen, D. Yergeau, B. Vadodaria, H. Mulder, NJ. Winick, EC. Larsen, WL. Carroll, NA. Heerema, AJ. Carroll, G. Grayson, SK. Tasian, AS. Moore, F. Keller, M. Frei-Jones, JA. Whitlock, EA. Raetz, DL. White, TP. Hughes, JM. Guidry Auvil, MA. Smith, G. Marcucci, CD. Bloomfield, K. Mr\u00f3zek, J. Kohlschmidt, W. Stock, SM. Kornblau, M. Konopleva, E. Paietta, CH. Pui, S. Jeha, MV. Relling, WE. Evans, DS. Gerhard, JM. Gastier-Foster, E. Mardis, RK. Wilson, ML. Loh, JR. Downing, SP. Hunger, CL. Willman, J. Zhang, CG. Mullighan", "publication_date": "2014-09-11", "keywords": ""}, {"pubmed_id": "25186488", "title": "[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].", "authors": "M. Shibazaki, M. Sumi, W. Takeda, T. Kirihara, T. Kurihara, K. Sato, T. Ueki, Y. Hiroshima, M. Ueno, N. Ichikawa, Y. Mori, H. Kobayashi", "publication_date": "2014-09-05", "keywords": ""}, {"pubmed_id": "25172932", "title": "Gene signature-guided dasatinib therapy in metastatic breast cancer.", "authors": "L. Pusztai, S. Moulder, M. Altan, D. Kwiatkowski, V. Valero, NT. Ueno, FJ. Esteva, R. Avritscher, Y. Qi, L. Strauss, GN. Hortobagyi, C. Hatzis, WF. Symmans", "publication_date": "2014-08-31", "keywords": ""}, {"pubmed_id": "25170013", "title": "A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.", "authors": "KA. Gold, JJ. Lee, N. Harun, X. Tang, J. Price, JD. Kawedia, HT. Tran, JJ. Erasmus, GR. Blumenschein, WN. William, II. Wistuba, FM. Johnson", "publication_date": "2014-08-30", "keywords": ""}, {"pubmed_id": "25115782", "title": "Severe agitation in depression precipitated by dasatinib.", "authors": "MB. Sami, F. Yousaf, A. Fialho", "publication_date": "2014-08-15", "keywords": ""}, {"pubmed_id": "25099472", "title": "Presence and utility of intrinsically disordered regions in kinases.", "authors": "JJ. Kathiriya, RR. Pathak, E. Clayman, B. Xue, VN. Uversky, V. Dav\u00e9", "publication_date": "2014-08-08", "keywords": ""}, {"pubmed_id": "25099443", "title": "Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.", "authors": "DD. Stenehjem, F. Albright, KL. Kuo, K. Raimundo, H. Bauer, PJ. Shami, MW. Deininger, L. Chen, DI. Brixner", "publication_date": "2014-08-08", "keywords": ""}, {"pubmed_id": "25082346", "title": "Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).", "authors": "H. Hjorth-Hansen, L. Stenke, S. S\u00f6derlund, A. Dreimane, H. Ehrencrona, T. Gedde-Dahl, BT. Gjertsen, M. H\u00f6glund, P. Koskenvesa, K. Lotfi, W. Majeed, B. Markev\u00e4rn, L. Ohm, U. Olsson-Str\u00f6mberg, K. Remes, M. Suominen, B. Simonsson, K. Porkka, S. Mustjoki, J. Richter, ", "publication_date": "2014-08-02", "keywords": "dasatinib, deep response, imatinib, randomized controlled trial, toxicity"}, {"pubmed_id": "25075175", "title": "Profile and potential of ixabepilone in the treatment of pancreatic cancer.", "authors": "BG. Smaglo, MJ. Pishvaian", "publication_date": "2014-07-31", "keywords": "ixabepilone, microtubules, pancreatic cancer"}, {"pubmed_id": "25060522", "title": "ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.", "authors": "CY. Lin, HJ. Chen, CC. Huang, LC. Lai, TP. Lu, GC. Tseng, TT. Kuo, QY. Kuok, JL. Hsu, SY. Sung, MC. Hung, YP. Sher", "publication_date": "2014-07-26", "keywords": ""}, {"pubmed_id": "25056801", "title": "Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.", "authors": "A. Egron, P. Olivier-Abbal, A. Gouraud, S. Babai, S. Combret, JL. Montastruc, E. Bondon-Guitton", "publication_date": "2014-07-25", "keywords": ""}, {"pubmed_id": "25052596", "title": "[Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].", "authors": "B. Liu, Y. Wang, Y. Mi, J. Wang", "publication_date": "2014-07-24", "keywords": ""}, {"pubmed_id": "25025538", "title": "Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.", "authors": "MK. Mustafa Ali, MM. Sabha, KH. Al-Rabi", "publication_date": "2014-07-16", "keywords": "Acute lymphoblastic leukemia, Philadelphia chromosome, dasatinib, subdural hematoma"}, {"pubmed_id": "25016806", "title": "[Chronic myeloid leukemia].", "authors": "N. Usui", "publication_date": "2014-07-16", "keywords": ""}, {"pubmed_id": "24984571", "title": "Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.", "authors": "MS. Mathisen, HM. Kantarjian, J. Cortes, EJ. Jabbour", "publication_date": "2014-07-06", "keywords": "Bosutinib, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Ponatinib, Tyrosine kinase inhibitors"}, {"pubmed_id": "24958829", "title": "Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.", "authors": "JK. Jasielec, RA. Larson", "publication_date": "2014-06-25", "keywords": ""}, {"pubmed_id": "24956141", "title": "Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.", "authors": "F. Estephan, HJ. Rogers, V. Visconte, A. Tabarroki, J. Ai, HK. Duong, M. Kalaycio, RV. Tiu", "publication_date": "2014-06-24", "keywords": ""}, {"pubmed_id": "24932855", "title": "Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.", "authors": "H. Chang, YS. Hung, WC. Chou", "publication_date": "2014-06-17", "keywords": "Acute lymphoblastic leukemia, Chronic myeloid leukemia, Dasatinib, Philadelphia chromosome, Pneumocystis jiroveci pneumonia"}, {"pubmed_id": "24891015", "title": "Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.", "authors": "LA. Gardner, J. Klawitter, MA. Gregory, V. Zaberezhnyy, D. Baturin, DA. Pollyea, N. Takebe, U. Christians, L. Gore, J. DeGregori, CC. Porter", "publication_date": "2014-06-04", "keywords": ""}, {"pubmed_id": "24857230", "title": "[A case report of dasatinib-induced tumor lysis syndrome].", "authors": "H. Zhou, J. Shen", "publication_date": "2014-05-27", "keywords": ""}, {"pubmed_id": "24832371", "title": "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.", "authors": "AE. Eskazan, D. Eyice, EA. Kurt, T. Elverdi, FF. Yalniz, A. Salihoglu, MC. Ar, S. Ongoren Aydin, Z. Baslar, B. Ferhanoglu, Y. Aydin, N. Tuzuner, U. Ozbek, T. Soysal", "publication_date": "2014-05-17", "keywords": "CML, Chronic myeloid leukemia, Dasatinib, Lymphocytosis, Pleural effusion"}, {"pubmed_id": "24821006", "title": "Thyroid dysfunctions induced by tyrosine kinase inhibitors.", "authors": "P. Fallahi, SM. Ferrari, R. Vita, A. Di Domenicantonio, A. Corrado, S. Benvenga, A. Antonelli", "publication_date": "2014-05-14", "keywords": "axitinib, dasatinib, hyperthyroidism, hypothyroidism, imatinib, motesanib, nilotinib, pazopanib, sorafenib, sunitinib, thyroid cancer, thyroid dysfunctions, tivozanib, tyrosine kinase inhibitors, vandetanib"}, {"pubmed_id": "24819759", "title": "Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope.", "authors": "V. Grasso, C. Vassallo, G. Croci, V. Brazzelli", "publication_date": "2014-05-14", "keywords": ""}, {"pubmed_id": "24811835", "title": "Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome.", "authors": "SA. Faiz, S. Sahay, CA. Jimenez", "publication_date": "2014-05-09", "keywords": ""}, {"pubmed_id": "24810451", "title": "Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.", "authors": "S. Yun, F. Anwer, ND. Vincelette", "publication_date": "2014-05-09", "keywords": ""}, {"pubmed_id": "24804581", "title": "Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.", "authors": "P. Giansanti, C. Preisinger, KV. Huber, M. Gridling, G. Superti-Furga, KL. Bennett, AJ. Heck", "publication_date": "2014-05-09", "keywords": ""}, {"pubmed_id": "24794907", "title": "Dasatinib.", "authors": "HM. Korashy, AF. Rahman, MG. Kassem", "publication_date": "2014-05-06", "keywords": "Analysis, Cytochrome P450, Dasatinib, Synthesis, Tyrosine kinase inhibitor"}, {"pubmed_id": "24788563", "title": "A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.", "authors": "A. Spreafico, KN. Chi, SS. Sridhar, DC. Smith, MA. Carducci, P. Kavsak, TS. Wong, L. Wang, SP. Ivy, SD. Mukherjee, CK. Kollmannsberger, MA. Sukhai, N. Takebe, S. Kamel-Reid, LL. Siu, SJ. Hotte", "publication_date": "2014-05-03", "keywords": ""}, {"pubmed_id": "24779033", "title": "Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.", "authors": "O. Benjamini, TL. Dumlao, H. Kantarjian, S. O'Brien, G. Garcia-Manero, S. Faderl, J. Jorgensen, R. Luthra, R. Garris, D. Thomas, P. Kebriaei, R. Champlin, E. Jabbour, J. Burger, J. Cortes, F. Ravandi", "publication_date": "2014-04-30", "keywords": ""}, {"pubmed_id": "24756786", "title": "Bosutinib: a novel second-generation tyrosine kinase inhibitor.", "authors": "S. Isfort, G. Keller-v Amsberg, P. Schafhausen, S. Koschmieder, TH. Br\u00fcmmendorf", "publication_date": "2014-04-24", "keywords": ""}, {"pubmed_id": "24756784", "title": "Dasatinib.", "authors": "M. Lindauer, A. Hochhaus", "publication_date": "2014-04-24", "keywords": ""}, {"pubmed_id": "24756783", "title": "Imatinib mesylate.", "authors": "CF. Waller", "publication_date": "2014-04-24", "keywords": ""}, {"pubmed_id": "24711014", "title": "First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.", "authors": "G. Gugliotta, F. Castagnetti, M. Apolinari, S. Pirondi, M. Cavo, M. Baccarani, G. Rosti", "publication_date": "2014-04-09", "keywords": ""}, {"pubmed_id": "24668331", "title": "The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.", "authors": "Z. Hanaizi, C. Unkrig, H. Enzmann, J. Camarero, A. Sancho-Lopez, T. Salmonson, C. Gisselbrecht, E. Laane, F. Pignatti", "publication_date": "2014-03-29", "keywords": "Bosulif, Bosutinib, Chronic myelogenous leukemia, EMA, European Medicines Agency"}, {"pubmed_id": "24647683", "title": "Pneumatosis intestinalis and imatinib mesylate.", "authors": "C. O'Rafferty, F. McElligott, L. Storey, A. O'Marcaigh, O. Smith", "publication_date": "2014-03-22", "keywords": ""}, {"pubmed_id": "24606654", "title": "[Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].", "authors": "X. Yu, C. Li, X. Wu, L. Ye, H. Liu, C. Ma, J. Ma, C. Gu, D. Wu", "publication_date": "2014-03-13", "keywords": ""}, {"pubmed_id": "24569263", "title": "Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.", "authors": "NP. Shah, F. Guilhot, JE. Cortes, CA. Schiffer, P. le Coutre, TH. Br\u00fcmmendorf, HM. Kantarjian, A. Hochhaus, P. Rousselot, H. Mohamed, D. Healey, M. Cunningham, G. Saglio", "publication_date": "2014-02-27", "keywords": ""}, {"pubmed_id": "24503243", "title": "Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.", "authors": "KR. Anderson, CR. Chambers, N. Lam, PS. Yau, F. Cusano, ML. Savoie, N. Sheikh", "publication_date": "2014-02-08", "keywords": "Cancer, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, oncology, oral chemotherapy, patient adherence"}, {"pubmed_id": "24501014", "title": "Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "S. Jeha, E. Coustan-Smith, D. Pei, JT. Sandlund, JE. Rubnitz, SC. Howard, H. Inaba, D. Bhojwani, ML. Metzger, C. Cheng, JK. Choi, J. Jacobsen, SA. Shurtleff, S. Raimondi, RC. Ribeiro, CH. Pui, D. Campana", "publication_date": "2014-02-07", "keywords": "Philadelphia chromosome-positive, acute lymphoblastic leukemia, minimal residual disease, pediatric, tyrosine kinase inhibitors"}, {"pubmed_id": "24492046", "title": "[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].", "authors": "M. Saito, K. Izumiyama, A. Mori, T. Irie, M. Tanaka, M. Morioka, A. Saga, M. Musashi, T. Kato, T. Meguro, M. Tanino", "publication_date": "2014-02-05", "keywords": ""}, {"pubmed_id": "24492036", "title": "[Chronic myeloid leukemia: up-to-date management].", "authors": "K. Nakayama, K. Inokuchi", "publication_date": "2014-02-05", "keywords": ""}, {"pubmed_id": "24478055", "title": "Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.", "authors": "JO. Alem\u00e1n, A. Farooki, M. Girotra", "publication_date": "2014-01-31", "keywords": "bone, calcium, metastasis, parathyroid hormone, tyrosine kinase inhibitor"}, {"pubmed_id": "24455114", "title": "Treatment recommendations for chronic myeloid leukemia.", "authors": "M. Baccarani, F. Castagnetti, G. Gugliotta, F. Palandri, G. Rosti", "publication_date": "2014-01-24", "keywords": ""}, {"pubmed_id": "24420842", "title": "Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.", "authors": "YY. Syed, PL. McCormack, GL. Plosker", "publication_date": "2014-01-15", "keywords": ""}, {"pubmed_id": "24396109", "title": "Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.", "authors": "L. Stansfield, TE. Hughes, TL. Walsh-Chocolaad", "publication_date": "2014-01-08", "keywords": "CML, bosutinib, tyrosine kinase inhibitor"}, {"pubmed_id": "24385803", "title": "Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.", "authors": "IC. Haznedaro\u011flu", "publication_date": "2014-01-05", "keywords": "Bosutinib, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Ponatinib, Tyrosine kinase inhibitor"}, {"pubmed_id": "24371772", "title": "A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.", "authors": "S. Martino, E. Daguindau, C. Ferrand, J. Bamoulid, S. Hayette, FE. Nicolini, G. Capellier, E. Deconinck, F. Larosa", "publication_date": "2013-12-29", "keywords": "CML, Dasatinib, Kidney transplantation, Nilotinib, TTP/HUS"}, {"pubmed_id": "24357015", "title": "Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.", "authors": "S. Fujisawa, H. Nakamae, M. Ogura, K. Ishizawa, M. Taniwaki, A. Utsunomiya, K. Matsue, Y. Takamatsu, K. Usuki, M. Tanimoto, Y. Ishida, H. Akiyama, S. Onishi", "publication_date": "2013-12-21", "keywords": ""}, {"pubmed_id": "24352048", "title": "Large granular lymphocytosis during dasatinib therapy.", "authors": "ZY. Qiu, W. Xu, JY. Li", "publication_date": "2013-12-20", "keywords": "dasatinib, large granular lymphocyte, pleural effusion, response, tyrosine kinase inhibitor"}, {"pubmed_id": "24351780", "title": "Off-Target Effects of BCR-ABL and JAK2 Inhibitors.", "authors": "MR. Green, MD. Newton, KM. Fancher", "publication_date": "2013-12-20", "keywords": ""}, {"pubmed_id": "24334470", "title": "Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis.", "authors": "MM. Chisti, A. Khachani, GR. Brahmanday, J. Klamerus", "publication_date": "2013-12-18", "keywords": ""}, {"pubmed_id": "24319178", "title": "Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.", "authors": "T. Hughes, D. White", "publication_date": "2013-12-10", "keywords": ""}, {"pubmed_id": "24310825", "title": "Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.", "authors": "RL. Ruebner, L. Copelovitch, NF. Evageliou, MR. Denburg, JB. Belasco, BS. Kaplan", "publication_date": "2013-12-07", "keywords": ""}, {"pubmed_id": "24289108", "title": "Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.", "authors": "CT. Chuah, H. Nakamae, ZX. Shen, MB. Bradley-Garelik, DW. Kim", "publication_date": "2013-12-03", "keywords": "CML, East Asian, dasatinib, first-line treatment, imatinib"}, {"pubmed_id": "24264834", "title": "Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.", "authors": "L. Harbaum, A. Marx, E. Goekkurt, P. Schafhausen, D. Atanackovic", "publication_date": "2013-11-23", "keywords": ""}, {"pubmed_id": "24262013", "title": "Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.", "authors": "A. Nuno-Gonzalez, L. Dehesa, C. Ricotti, F. Kerdel", "publication_date": "2013-11-23", "keywords": ""}, {"pubmed_id": "24256006", "title": "[Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].", "authors": "V. Gonz\u00e1lez Rosa, F. Guti\u00e9rrez Nicol\u00e1s, R. Gavira Moreno, MM. Vi\u00f1a Romero, MT. Moreno Carvajal, R. G\u00e1zquez P\u00e9rez", "publication_date": "2013-11-22", "keywords": ""}, {"pubmed_id": "24238639", "title": "Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.", "authors": "AP. Kater, M. Spiering, RD. Liu, G. Doreen Te Raa, E. Slinger, SH. Tonino, MM. Beckers, S. Daenen, JK. Doorduijn, NA. Lankheet, DM. Luijks, E. Eldering, MH. van Oers", "publication_date": "2013-11-19", "keywords": "CLL, Dasatinib, Fludarabine refractory, Kinase inhibitor, Microenvironment, NOXA"}, {"pubmed_id": "24211163", "title": "Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.", "authors": "JC. Araujo, GC. Trudel, F. Saad, AJ. Armstrong, EY. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, SV. Serrano, VB. Matveev, E. Efstathiou, S. Oudard, MJ. Morris, B. Sizer, PJ. Goebell, A. Heidenreich, JS. de Bono, S. Begbie, JH. Hong, E. Richardet, E. Gallardo, P. Paliwal, S. Durham, S. Cheng, CJ. Logothetis", "publication_date": "2013-11-12", "keywords": ""}, {"pubmed_id": "24210599", "title": "Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?", "authors": "S. Paydas", "publication_date": "2013-11-12", "keywords": "Chronic myeloid leukemia, Dasatinib, Immune regulation, Large granular lymphocytosis, Pleural effusion, Response"}, {"pubmed_id": "24188312", "title": "Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.", "authors": "G. Kaiafa, N. Kakaletsis, C. Savopoulos, V. Perifanis, A. Giannouli, N. Papadopoulos, S. Zisekas, AI. Hatzitolios", "publication_date": "2013-11-06", "keywords": "acute renal failure, adverse event, dasatinib, pleural effusion, simultaneous, tyrosine kinase inhibitor"}, {"pubmed_id": "24180494", "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.", "authors": "JE. Cortes, DW. Kim, J. Pinilla-Ibarz, P. le Coutre, R. Paquette, C. Chuah, FE. Nicolini, JF. Apperley, HJ. Khoury, M. Talpaz, J. DiPersio, DJ. DeAngelo, E. Abruzzese, D. Rea, M. Baccarani, MC. M\u00fcller, C. Gambacorti-Passerini, S. Wong, S. Lustgarten, VM. Rivera, T. Clackson, CD. Turner, FG. Haluska, F. Guilhot, MW. Deininger, A. Hochhaus, T. Hughes, JM. Goldman, NP. Shah, H. Kantarjian, ", "publication_date": "2013-11-05", "keywords": ""}, {"pubmed_id": "24173967", "title": "Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.", "authors": "JH. Strickler, S. McCall, AB. Nixon, JC. Brady, H. Pang, C. Rushing, A. Cohn, A. Starodub, C. Arrowood, S. Haley, KL. Meadows, MA. Morse, HE. Uronis, GC. Blobe, SD. Hsu, SY. Zafar, HI. Hurwitz", "publication_date": "2013-11-01", "keywords": ""}, {"pubmed_id": "24160847", "title": "Medical decision analysis for first-line therapy of chronic myeloid leukemia.", "authors": "U. Rochau, G. Sroczynski, D. Wolf, S. Schmidt, A. Conrads-Frank, B. Jahn, K. Saverno, D. Brixner, J. Radich, G. Gastl, U. Siebert", "publication_date": "2013-10-29", "keywords": "Chronic myeloid leukemia, decision analysis, decision-analytic model, quality-adjusted life years, tyrosine kinase inhibitors"}, {"pubmed_id": "24159167", "title": "Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.", "authors": "C. Roux, FE. Nicolini, D. Rea, M. Niault, L. Mollica, F. Berger, C. Chassagne-Cl\u00e9ment, I. Tigaud, M. Tulliez, S. Giraudier, A. Turhan, P. Rousselot, L. Legros", "publication_date": "2013-10-26", "keywords": ""}, {"pubmed_id": "24151050", "title": "HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.", "authors": "P. Strati, H. Kantarjian, D. Thomas, S. O'Brien, S. Konoplev, JL. Jorgensen, R. Luthra, L. Abruzzo, E. Jabbour, A. Quintas-Cardama, G. Borthakur, S. Faderl, F. Ravandi, J. Cortes", "publication_date": "2013-10-24", "keywords": "HCVAD, blast phase, chronic myeloid leukemia, lymphoid variant, tyrosine kinase inhibitors"}, {"pubmed_id": "24149673", "title": "Reversible pre-capillary pulmonary hypertension due to dasatinib.", "authors": "HL. Buchelli Ramirez, CM. \u00c1lvarez \u00c1lvarez, JJ. Rodr\u00edguez Reguero, MM. Garc\u00eda Clemente, P. Casan Clar\u00e0", "publication_date": "2013-10-24", "keywords": "chronic myeloid leukemia, drug-induced, long-term therapy, pulmonary hypertension"}, {"pubmed_id": "24143950", "title": "BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.", "authors": "AM. Khan, DL. Bixby", "publication_date": "2013-10-23", "keywords": "BCR-ABL inhibitors, CML, Dasatinib, Imatinib, Nilotinib"}, {"pubmed_id": "24137941", "title": "[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].", "authors": "AG. Turkina, EIu. Chelysheva", "publication_date": "2013-10-22", "keywords": ""}, {"pubmed_id": "24128713", "title": "Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.", "authors": "AM. Brunner, DB. Costa, RS. Heist, E. Garcia, NI. Lindeman, LM. Sholl, GR. Oxnard, BE. Johnson, PS. Hammerman", "publication_date": "2013-10-17", "keywords": ""}, {"pubmed_id": "24128110", "title": "[Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].", "authors": "C. Cama\u00f1as-Troyano, C. Calder\u00f3n-Acedos, Mdel C. Moriel-S\u00e1nchez, M. Segura-Bedmar", "publication_date": "2013-10-17", "keywords": ""}, {"pubmed_id": "24124828", "title": "Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.", "authors": "L. Delgado, S. Giraudier, N. Ortonne, O. Zehou, C. Cordonnier, A. Hulin, O. Chosidow, M. Tulliez, L. Valeyrie-Allanore", "publication_date": "2013-10-16", "keywords": ""}, {"pubmed_id": "24099272", "title": "Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.", "authors": "I. Hirji, S. Gupta, A. Goren, DR. Chirovsky, AB. Moadel, E. Olavarria, TW. Victor, CC. Davis", "publication_date": "2013-10-09", "keywords": ""}, {"pubmed_id": "24095296", "title": "A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.", "authors": "E. Jabbour, JH. Lipton", "publication_date": "2013-10-08", "keywords": "Dasatinib, Imatinib, Nilotinib, Outcomes, Response"}, {"pubmed_id": "24083594", "title": "The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.", "authors": "N. Jain, S. O'Brien", "publication_date": "2013-10-03", "keywords": ""}, {"pubmed_id": "24081749", "title": "[Current diagnostic requirements in chronic myeloid leukemia].", "authors": "T. Lion, G. Webersinke, U. Kastner, C. Seger, G. Mitterbauer-Hohendanner, G. Gastl", "publication_date": "2013-10-02", "keywords": ""}, {"pubmed_id": "24072218", "title": "Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.", "authors": "CE. Chee, S. Krishnamurthi, CJ. Nock, NJ. Meropol, J. Gibbons, P. Fu, J. Bokar, L. Teston, T. O'Brien, V. Gudena, A. Reese, M. Bergman, J. Saltzman, JJ. Wright, A. Dowlati, J. Brell", "publication_date": "2013-09-28", "keywords": ""}, {"pubmed_id": "24064822", "title": "[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].", "authors": "M. Miura, N. Takahashi", "publication_date": "2013-09-26", "keywords": ""}, {"pubmed_id": "24043361", "title": "Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).", "authors": "E. Abruzzese, M. Breccia, R. Latagliata", "publication_date": "2013-09-18", "keywords": ""}, {"pubmed_id": "24037637", "title": "Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?", "authors": "L. Godinas, C. Guignabert, A. Seferian, F. Perros, E. Bergot, Y. Sibille, M. Humbert, D. Montani", "publication_date": "2013-09-17", "keywords": ""}, {"pubmed_id": "24037625", "title": "Idiopathic pulmonary arterial hypertension.", "authors": "R. Souza, C. Jardim, M. Humbert", "publication_date": "2013-09-17", "keywords": ""}, {"pubmed_id": "24032404", "title": "Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.", "authors": "P. Gallipoli, J. Stobo, N. Heaney, FE. Nicolini, R. Clark, G. Wilson, J. Tighe, L. McLintock, T. Hughes, F. Michor, J. Paul, M. Drummond, TL. Holyoake", "publication_date": "2013-09-17", "keywords": "BCR-ABL1, chronic myeloid leukaemia, stem cells, therapy, trials"}, {"pubmed_id": "23997051", "title": "Drug-induced pulmonary arterial hypertension: a recent outbreak.", "authors": "D. Montani, A. Seferian, L. Savale, G. Simonneau, M. Humbert", "publication_date": "2013-09-03", "keywords": ""}, {"pubmed_id": "23986642", "title": "Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.", "authors": "KE. Price, N. Saleem, G. Lee, M. Steinberg", "publication_date": "2013-08-30", "keywords": "BCR-ABL, Philadelphia chromosome, T315I, TKI, tyrosine kinase inhibitor"}, {"pubmed_id": "23984805", "title": "Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.", "authors": "IC. Haznedaroglu", "publication_date": "2013-08-30", "keywords": ""}, {"pubmed_id": "23981682", "title": "Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.", "authors": "CJ. Ensslin, AC. Rosen, S. Wu, ME. Lacouture", "publication_date": "2013-08-29", "keywords": "AE, B-lymphocyte antigen cluster of differentiation 20, Bcr-Abl, CD20, CI, CTLA4, EGFR, EGFRIs, HER2, QoL, RR, Raf, T-lymphocyte antigen 4, VEGFR, adverse events, cancer, confidence interval, epidermal growth factor receptor, epidermal growth factor receptor inhibitors, human epidermal growth factor receptor 2, inhibitor, itch, mammalian target of rapamycin, pruritus, quality of life, relative risk, vascular endothelial growth factor receptor"}, {"pubmed_id": "23972547", "title": "Drugs induced pulmonary arterial hypertension.", "authors": "A. Seferian, MC. Chaumais, L. Savale, S. G\u00fcnther, P. Tubert-Bitter, M. Humbert, D. Montani", "publication_date": "2013-08-27", "keywords": ""}, {"pubmed_id": "23961831", "title": "Investigation of the rat model for preclinical evaluation of pH-dependent oral absorption in humans.", "authors": "JW. Lubach, JZ. Chen, J. Hau, J. Imperio, M. Coraggio, L. Liu, H. Wong", "publication_date": "2013-08-22", "keywords": ""}, {"pubmed_id": "23949495", "title": "Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.", "authors": "MR. Savona, G. Saglio", "publication_date": "2013-08-21", "keywords": ""}, {"pubmed_id": "23942795", "title": "The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.", "authors": "A. Hochhaus, H. Kantarjian", "publication_date": "2013-08-15", "keywords": ""}, {"pubmed_id": "23941515", "title": "Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era.", "authors": "D. Russo, M. Malagola, C. Skert, C. Fil\u00ec, C. Bergonzi, V. Cancelli, F. Cattina", "publication_date": "2013-08-15", "keywords": ""}, {"pubmed_id": "23913852", "title": "Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.", "authors": "L. Falchi, HM. Kantarjian, X. Wang, D. Verma, A. Quint\u00e1s-Cardama, S. O'Brien, EJ. Jabbour, F. Ravandi-Kashani, G. Borthakur, G. Garcia-Manero, S. Verstovsek, JA. Burger, R. Luthra, JE. Cortes", "publication_date": "2013-08-06", "keywords": ""}, {"pubmed_id": "23906052", "title": "New insights into biology of chronic myeloid leukemia: implications in therapy.", "authors": "M. Cea, A. Cagnetta, A. Nencioni, M. Gobbi, F. Patrone", "publication_date": "2013-08-03", "keywords": ""}, {"pubmed_id": "23898127", "title": "Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.", "authors": "T. Iliakis, V. Papadopoulou, PT. Diamantopoulos, P. Panayiotidis, K. Zervakis, N. Giannakopoulou, G. Tilimidos, M. Angelopoulou, MP. Siakantaris, G. Pangalis, M. Mantzourani, E. Variami, NA. Viniou", "publication_date": "2013-07-31", "keywords": "Chronic-phase CML, TKI, complete molecular response"}, {"pubmed_id": "23882932", "title": "[Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].", "authors": "R. Ryczek, J. G\u00f3ra-Tybor, K. Betkier-Lipi\u0144ska, A. Cwetsch", "publication_date": "2013-07-26", "keywords": ""}, {"pubmed_id": "23852951", "title": "Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.", "authors": "M. Rancea, A. Will, P. Borchmann, I. Monsef, A. Engert, N. Skoetz", "publication_date": "2013-07-16", "keywords": ""}, {"pubmed_id": "23815902", "title": "[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].", "authors": "Y. Zhu, LQ. Pan, SX. Qian, P. Song, H. Yu, SJ. Zhang, Z. Ge, M. Hong, T. Tian, JY. Li", "publication_date": "2013-07-03", "keywords": ""}, {"pubmed_id": "23810242", "title": "BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.", "authors": "RD. Press, S. Kamel-Reid, D. Ang", "publication_date": "2013-07-03", "keywords": ""}, {"pubmed_id": "23788844", "title": "Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.", "authors": "X. Wang, A. Roy, A. Hochhaus, HM. Kantarjian, TT. Chen, NP. Shah", "publication_date": "2013-06-22", "keywords": "chronic myeloid leukemia, major cytogenetic response, pharmacokinetics, pleural effusion"}, {"pubmed_id": "23787123", "title": "Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.", "authors": "JE. Cortes, FE. Nicolini, M. Wetzler, JH. Lipton, L. Akard, A. Craig, N. Nanda, AC. Benichou, J. Leonoudakis, HJ. Khoury, A. Hochhaus, M. Baccarani, HM. Kantarjian", "publication_date": "2013-06-22", "keywords": "Dasatinib, Homoharringtonine, Intolerance, Nilotinib, Resistance"}, {"pubmed_id": "23782380", "title": "Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "A. Watanabe, S. Chansu, A. Ogawa, K. Asami, M. Imamura", "publication_date": "2013-06-21", "keywords": ""}, {"pubmed_id": "23770156", "title": "Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.", "authors": "A. Eghtedar, H. Kantarjian, E. Jabbour, S. O'Brien, E. Burton, G. Garcia-Manero, S. Verstovsek, F. Ravandi, G. Borthakur, M. Konopleva, A. Quintas-Cardama, J. Cortes", "publication_date": "2013-06-19", "keywords": "CML, Dasatinib, Discontinuation, Nilotinib, TKIs"}, {"pubmed_id": "23757199", "title": "Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.", "authors": "M. Cerrano, E. Cris\u00e0, P. Pregno, C. Aguzzi, P. Riccomagno, M. Boccadoro, D. Ferrero", "publication_date": "2013-06-13", "keywords": ""}, {"pubmed_id": "23748749", "title": "Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.", "authors": "E. Faye, E. Bondon-Guitton, P. Olivier-Abbal, JL. Montastruc, ", "publication_date": "2013-06-12", "keywords": ""}, {"pubmed_id": "23734955", "title": "Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.", "authors": "T. Nagai, M. Karakawa, M. Komine, K. Muroi, M. Ohtsuki, K. Ozawa", "publication_date": "2013-06-06", "keywords": "chronic myelogenous leukaemia, nilotinib, psoriasis, tyrosine kinase inhibitor"}, {"pubmed_id": "23719297", "title": "Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.", "authors": "H. de Lavallade, A. Khoder, M. Hart, A. Sarvaria, T. Sekine, A. Alsuliman, S. Mielke, A. Bazeos, K. Stringaris, S. Ali, D. Milojkovic, L. Foroni, A. Chaidos, N. Cooper, I. Gabriel, J. Apperley, S. Belsey, RJ. Flanagan, J. Goldman, EJ. Shpall, P. Kelleher, D. Marin, K. Rezvani", "publication_date": "2013-05-31", "keywords": ""}, {"pubmed_id": "23716272", "title": "TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.", "authors": "A. Ulmer, J. Tabea Tauer, I. Glauche, R. Jung, M. Suttorp", "publication_date": "2013-05-30", "keywords": ""}, {"pubmed_id": "23715577", "title": "Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.", "authors": "CM. Zwaan, C. Rizzari, F. Mechinaud, DL. Lancaster, T. Lehrnbecher, VH. van der Velden, BB. Beverloo, ML. den Boer, R. Pieters, D. Reinhardt, M. Dworzak, J. Rosenberg, G. Manos, S. Agrawal, L. Strauss, A. Baruchel, PR. Kearns", "publication_date": "2013-05-30", "keywords": ""}, {"pubmed_id": "23712327", "title": "Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.", "authors": "M. Shi, B. Lou, J. Ji, H. Shi, C. Zhou, Y. Yu, B. Liu, Z. Zhu, J. Zhang", "publication_date": "2013-05-29", "keywords": ""}, {"pubmed_id": "23697842", "title": "The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.", "authors": "E. Togasaki-Yoshimoto, K. Shono, M. Onoda, A. Yokota", "publication_date": "2013-05-24", "keywords": ""}, {"pubmed_id": "23680477", "title": "Novel agents for chronic lymphocytic leukemia.", "authors": "M. Wu, A. Akinleye, X. Zhu", "publication_date": "2013-05-18", "keywords": ""}, {"pubmed_id": "23677113", "title": "Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.", "authors": "S. Samimi, E. Chu, J. Seykora, A. Loren, C. Vittorio, A. Rook, M. Rosenbach, EJ. Kim", "publication_date": "2013-05-17", "keywords": ""}, {"pubmed_id": "23676950", "title": "Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.", "authors": "RA. Silveira, AA. Fachel, YB. Moreira, CA. De Souza, FF. Costa, S. Verjovski-Almeida, KB. Pagnano", "publication_date": "2013-05-17", "keywords": "Chronic myeloid leukemia, Dasatinib, Imatinib, Long ncRNAs, Resistance"}, {"pubmed_id": "23676643", "title": "[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].", "authors": "T. Narita, S. Kayukawa, T. Yoshida, S. Kusumoto, T. Kataoka", "publication_date": "2013-05-17", "keywords": ""}, {"pubmed_id": "23652925", "title": "Analyses of the combination of 6-MP and dasatinib in cell culture.", "authors": "G. Kaur, H. Behrsing, RE. Parchment, MD. Millin, BA. Teicher", "publication_date": "2013-05-09", "keywords": ""}, {"pubmed_id": "23625298", "title": "Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.", "authors": "P. La Ros\u00e9e, P. Martiat, A. Leitner, T. Klag, MC. M\u00fcller, P. Erben, T. Schenk, S. Saussele, A. Hochhaus", "publication_date": "2013-04-30", "keywords": ""}, {"pubmed_id": "23612033", "title": "Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.", "authors": "M. Llamas-Velasco, JL. Steegmann, R. Carrascosa, J. Fraga, A. Garc\u00eda Diez, L. Requena", "publication_date": "2013-04-25", "keywords": ""}, {"pubmed_id": "23611501", "title": "Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.", "authors": "V. Brazzelli, V. Grasso, G. Borroni", "publication_date": "2013-04-25", "keywords": ""}, {"pubmed_id": "23611212", "title": "[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].", "authors": "L. Zhou, JX. Wang, XJ. Huang, JD. Hu, ZX. Shen", "publication_date": "2013-04-25", "keywords": ""}, {"pubmed_id": "23567227", "title": "[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].", "authors": "V. Sibaud, C. Robert", "publication_date": "2013-04-10", "keywords": ""}, {"pubmed_id": "23564552", "title": "[Adequate supportive treatment in therapeutic use of \"biologicals\" for GI tumours in oncosurgery--what does the surgeon need to know?].", "authors": "E. Kettner, H. H\u00fctten, J. Ricke, F. Meyer", "publication_date": "2013-04-09", "keywords": ""}, {"pubmed_id": "23553655", "title": "Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.", "authors": "E. Irvine, C. Williams", "publication_date": "2013-04-05", "keywords": "BCR-ABL1, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, tyrosine kinase inhibitors"}, {"pubmed_id": "23549840", "title": "Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.", "authors": "GM. Keating, KA. Lyseng-Williamson, PL. McCormack, SJ. Keam", "publication_date": "2013-04-04", "keywords": ""}, {"pubmed_id": "23540262", "title": "Dasatinib-induced nephrotic-range proteinuria.", "authors": "E. Wallace, W. Lyndon, P. Chumley, EA. Jaimes, H. Fatima", "publication_date": "2013-04-02", "keywords": ""}, {"pubmed_id": "23536435", "title": "Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.", "authors": "A. Broniscer, SD. Baker, C. Wetmore, AS. Pai Panandiker, J. Huang, AM. Davidoff, A. Onar-Thomas, JC. Panetta, TK. Chin, TE. Merchant, JN. Baker, SC. Kaste, A. Gajjar, CF. Stewart", "publication_date": "2013-03-29", "keywords": ""}, {"pubmed_id": "23526749", "title": "Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.", "authors": "SC. Kaste, RA. Kaufman, A. Gajjar, A. Broniscer", "publication_date": "2013-03-26", "keywords": "VEGF, antiangiogenesis agents, chemotherapy, magnetic resonance imaging, pediatric brain tumors, skeletalgenesis"}, {"pubmed_id": "23517347", "title": "Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.", "authors": "JD. Griffin, A. Guerin, L. Chen, AR. Macalalad, J. Luo, R. Ionescu-Ittu, EQ. Wu", "publication_date": "2013-03-23", "keywords": ""}, {"pubmed_id": "23473918", "title": "Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.", "authors": "M. Breccia, G. Alimena", "publication_date": "2013-03-12", "keywords": ""}, {"pubmed_id": "23468307", "title": "Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.", "authors": "J. Cortes, R. Digumarti, PM. Parikh, M. Wetzler, JH. Lipton, A. Hochhaus, AR. Craig, AC. Benichou, FE. Nicolini, HM. Kantarjian, ", "publication_date": "2013-03-08", "keywords": ""}, {"pubmed_id": "23439757", "title": "High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.", "authors": "J. Martz, S. Jain, LT. Vahdat, L. Qin, JM. Mosquera, CR. Antonescu, EC. Popa", "publication_date": "2013-02-27", "keywords": ""}, {"pubmed_id": "23430094", "title": "Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.", "authors": "JC. Kim, SH. Shin, HG. Yi, SH. Kim, SI. Woo, DH. Kim, KS. Park, J. Kwan", "publication_date": "2013-02-23", "keywords": ""}, {"pubmed_id": "23422286", "title": "The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.", "authors": "S. Mealing, L. Barcena, N. Hawkins, J. Clark, V. Eaton, I. Hirji, C. Davis", "publication_date": "2013-02-21", "keywords": ""}, {"pubmed_id": "23409382", "title": "Chronic myeloid leukemia: advances in diagnosis and management.", "authors": "S. Noronha, S. Sawyer", "publication_date": "2013-02-16", "keywords": ""}, {"pubmed_id": "23403636", "title": "Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.", "authors": "G. Somlo, F. Atzori, LC. Strauss, WJ. Geese, JM. Specht, WJ. Gradishar, A. Rybicki, O. Sy, LT. Vahdat, J. Cortes", "publication_date": "2013-02-14", "keywords": ""}, {"pubmed_id": "23381448", "title": "Management of the new patient with CML in chronic phase.", "authors": "D. Marin", "publication_date": "2013-02-06", "keywords": ""}, {"pubmed_id": "23380743", "title": "Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.", "authors": "P. Neelakantan, G. Gerrard, C. Lucas, D. Milojkovic, P. May, L. Wang, C. Paliompeis, M. Bua, A. Reid, K. Rezvani, S. O'Brien, R. Clark, J. Goldman, D. Marin", "publication_date": "2013-02-06", "keywords": ""}, {"pubmed_id": "23374617", "title": "Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents.", "authors": "SJ. Bowlin, F. Xia, W. Wang, KD. Robinson, EJ. Stanek", "publication_date": "2013-02-05", "keywords": ""}, {"pubmed_id": "23372106", "title": "Treating chronic myeloid leukemia: improving management through understanding of the patient experience.", "authors": "CA. Simoneau", "publication_date": "2013-02-02", "keywords": ""}, {"pubmed_id": "23363742", "title": "[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].", "authors": "XJ. Huang, JD. Hu, JY. Li, J. Jin, FY. Meng, ZX. Shen, T. Liu, DP. Wu, JM. Wang, JX. Wang", "publication_date": "2013-02-01", "keywords": ""}, {"pubmed_id": "23316400", "title": "Haemorrhagic colitis caused by dasatinib.", "authors": "N. Patodi, N. Sagar, Z. Rudzki, G. Langman, N. Sharma", "publication_date": "2013-01-15", "keywords": ""}, {"pubmed_id": "23279183", "title": "Activity-based kinase profiling of approved tyrosine kinase inhibitors.", "authors": "D. Kitagawa, K. Yokota, M. Gouda, Y. Narumi, H. Ohmoto, E. Nishiwaki, K. Akita, Y. Kirii", "publication_date": "2013-01-03", "keywords": ""}, {"pubmed_id": "23273539", "title": "Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.", "authors": "VH. Duong, MV. Jaglal, L. Zhang, V. Kale, JE. Lancet, RS. Komrokji, AF. List", "publication_date": "2013-01-01", "keywords": ""}, {"pubmed_id": "23240881", "title": "Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.", "authors": "AM. Drucker, S. Wu, KJ. Busam, E. Berman, I. Amitay-Laish, ME. Lacouture", "publication_date": "2012-12-18", "keywords": ""}, {"pubmed_id": "23237282", "title": "[Successive cutaneous adverse reactions to nilotinib and imatinib in a single patient].", "authors": "M. Lamchahab, M. Qachouh, F. Hali, H. Benchikhi, A. Quessar, S. Benchekroun", "publication_date": "2012-12-15", "keywords": ""}, {"pubmed_id": "23222377", "title": "Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues.", "authors": "M. W\u00f6lfl, F. Langhammer, V. Wiegering, M. Eyrich, PG. Schlegel", "publication_date": "2012-12-12", "keywords": ""}, {"pubmed_id": "23192016", "title": "Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.", "authors": "S. Mustjoki, K. Auvinen, A. Kreutzman, P. Rousselot, S. Hernesniemi, T. Melo, AM. Lahesmaa-Korpinen, S. Hautaniemi, S. Bouchet, M. Molimard, R. Smykla, FY. Lee, J. Vakkila, S. Jalkanen, M. Salmi, K. Porkka", "publication_date": "2012-11-30", "keywords": ""}, {"pubmed_id": "23185821", "title": "[Pharmacovigilance].", "authors": "F. Livio, D. Renard, T. Buclin", "publication_date": "2012-11-29", "keywords": ""}, {"pubmed_id": "23179903", "title": "Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.", "authors": "Y. Ito, T. Miyamoto, Y. Chong, T. Maki, K. Akashi, T. Kamimura", "publication_date": "2012-11-28", "keywords": ""}, {"pubmed_id": "23179489", "title": "Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.", "authors": "KM. Phillips, J. Pinilla-Ibarz, E. Sotomayor, MR. Lee, HS. Jim, BJ. Small, L. Sokol, J. Lancet, S. Tinsley, K. Sweet, R. Komrokji, PB. Jacobsen", "publication_date": "2012-11-28", "keywords": ""}, {"pubmed_id": "23179336", "title": "A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.", "authors": "DS. Hong, JH. Choe, A. Naing, JJ. Wheler, GS. Falchook, S. Piha-Paul, SL. Moulder, GC. George, JM. Choe, LC. Strauss, GE. Gallick, R. Kurzrock", "publication_date": "2012-11-28", "keywords": ""}, {"pubmed_id": "23175995", "title": "Is imatinib still an acceptable first-line treatment for CML in chronic phase?", "authors": "JM. Goldman, D. Marin", "publication_date": "2012-11-28", "keywords": ""}, {"pubmed_id": "23154573", "title": "Successful treatment of nilotinib-induced pleural effusion with prednisone.", "authors": "K. Chakraborty, JB. Bossaer, R. Patel, K. Krishnan", "publication_date": "2012-11-17", "keywords": "Tyrosine kinase inhibitors, pleural effusion, treatment"}, {"pubmed_id": "23134589", "title": "Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.", "authors": "T. Pavey, M. Hoyle, O. Ciani, L. Crathorne, T. Jones-Hughes, C. Cooper, L. Osipenko, M. Venkatachalam, C. Rudin, O. Ukoumunne, R. Garside, R. Anderson", "publication_date": "2012-11-09", "keywords": ""}, {"pubmed_id": "23108877", "title": "Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.", "authors": "T. Uchiyama, N. Sato, M. Narita, A. Yamahira, M. Iwabuchi, T. Furukawa, H. Sone, M. Takahashi", "publication_date": "2012-10-31", "keywords": "NK cells, cytotoxicity, dasatinib, proliferation"}, {"pubmed_id": "23090987", "title": "EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.", "authors": "E. Franceschi, R. Stupp, MJ. van den Bent, C. van Herpen, F. Laigle Donadey, T. Gorlia, M. Hegi, B. Lhermitte, LC. Strauss, A. Allgeier, D. Lacombe, AA. Brandes", "publication_date": "2012-10-24", "keywords": ""}, {"pubmed_id": "23090888", "title": "Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.", "authors": "E. Jabbour, H. Kantarjian", "publication_date": "2012-10-24", "keywords": ""}, {"pubmed_id": "23053188", "title": "Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.", "authors": "M. Tiribelli, R. Latagliata, L. Luciano, F. Castagnetti, A. Gozzini, GR. Cambrin, M. Annunziata, F. Stagno, P. Pregno, F. Albano, E. Abruzzese, P. Musto, E. Montefusco, C. Fava, R. Fanin, F. Pane, G. Rosti, M. Breccia, G. Alimena, P. Vigneri", "publication_date": "2012-10-12", "keywords": ""}, {"pubmed_id": "23043319", "title": "Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.", "authors": "M. Breccia, A. Serrao, A. Salaroli, G. Loglisci, I. Zacheo, G. Alimena", "publication_date": "2012-10-10", "keywords": ""}, {"pubmed_id": "23032801", "title": "New and established tyrosine kinase inhibitors for chronic myeloid leukemia.", "authors": "CD. Thienelt, K. Green, DW. Bowles", "publication_date": "2012-10-04", "keywords": ""}, {"pubmed_id": "23020072", "title": "Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice.", "authors": "SH. Jung, X. Sun, WS. Ryu, BS. Yang", "publication_date": "2012-10-02", "keywords": ""}, {"pubmed_id": "22975544", "title": "Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.", "authors": "M. Sano, M. Saotome, T. Urushida, H. Katoh, H. Satoh, K. Ohnishi, H. Hayashi", "publication_date": "2012-09-15", "keywords": ""}, {"pubmed_id": "22942827", "title": "Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis.", "authors": "ML. Raborn, EM. Pelletier, DB. Smith, CM. Reyes", "publication_date": "2012-09-04", "keywords": ""}, {"pubmed_id": "22927532", "title": "Evidence for therapeutic drug monitoring of targeted anticancer therapies.", "authors": "B. Gao, S. Yeap, A. Clements, B. Balakrishnar, M. Wong, H. Gurney", "publication_date": "2012-08-29", "keywords": ""}, {"pubmed_id": "22915985", "title": "Treatments for chronic myeloid leukemia: a qualitative systematic review.", "authors": "R. Ferdinand, SA. Mitchell, S. Batson, I. Tumur", "publication_date": "2012-08-24", "keywords": "bosutinib, chronic myeloid leukemia, dasatinib, imatinib, nilotinib"}, {"pubmed_id": "22915637", "title": "A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.", "authors": "JP. Radich, KJ. Kopecky, FR. Appelbaum, S. Kamel-Reid, W. Stock, G. Malnassy, E. Paietta, M. Wadleigh, RA. Larson, P. Emanuel, M. Tallman, J. Lipton, AR. Turner, M. Deininger, BJ. Druker", "publication_date": "2012-08-24", "keywords": ""}, {"pubmed_id": "22907947", "title": "Disintegration of chemotherapy tablets for oral administration in patients with swallowing difficulties.", "authors": "R. Siden, M. Wolf", "publication_date": "2012-08-22", "keywords": "Oral chemotherapy, disintegration, oral syringe, safe administration, tablet crushing"}, {"pubmed_id": "22897916", "title": "Dasatinib in chronic myeloid leukemia: a limited Indian experience.", "authors": "A. Sharma, A. Bahl, V. Raina, L. Kumar, R. Gupta", "publication_date": "2012-08-18", "keywords": ""}, {"pubmed_id": "27175245", "title": "Initial treatment for patients with chronic myeloid leukemia.", "authors": "M. Baccarani", "publication_date": "2012-08-01", "keywords": "BCR-ABL, Philadelphia chromosome, chronic myeloid leukemia, dasatinib, imatinib, nilotinib"}, {"pubmed_id": "22843568", "title": "Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.", "authors": "P. Rana, B. Anson, S. Engle, Y. Will", "publication_date": "2012-07-31", "keywords": ""}, {"pubmed_id": "22842168", "title": "Optimizing second-line therapy for chronic myeloid leukemia.", "authors": "T. Raja", "publication_date": "2012-07-31", "keywords": ""}, {"pubmed_id": "22837181", "title": "A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.", "authors": "AA. Secord, DK. Teoh, WT. Barry, M. Yu, G. Broadwater, LJ. Havrilesky, PS. Lee, A. Berchuck, J. Lancaster, RM. Wenham", "publication_date": "2012-07-28", "keywords": ""}, {"pubmed_id": "22815278", "title": "Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.", "authors": "R. Latagliata, M. Breccia, C. Fava, F. Stagno, M. Tiribelli, L. Luciano, A. Gozzini, G. Gugliotta, M. Annunziata, F. Cavazzini, D. Ferrero, P. Musto, I. Capodanno, A. Iurlo, G. Visani, M. Crugnola, E. Calistri, F. Castagnetti, P. Vigneri, G. Alimena", "publication_date": "2012-07-21", "keywords": ""}, {"pubmed_id": "22801965", "title": "Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.", "authors": "A. Russo Rossi, M. Breccia, E. Abruzzese, F. Castagnetti, L. Luciano, A. Gozzini, M. Annunziata, B. Martino, F. Stagno, F. Cavazzini, M. Tiribelli, G. Visani, P. Pregno, P. Musto, C. Fava, N. Sgherza, F. Albano, G. Rosti, G. Alimena, G. Specchia", "publication_date": "2012-07-18", "keywords": ""}, {"pubmed_id": "22767140", "title": "Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.", "authors": "H. Tanaka, S. Nakashima, M. Usuda", "publication_date": "2012-07-07", "keywords": ""}, {"pubmed_id": "22762548", "title": "Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.", "authors": "M. Cea, A. Cagnetta, G. Cirmena, A. Garuti, I. Rocco, C. Palermo, I. Pierri, D. Reverberi, A. Nencioni, A. Ballestrero, M. Gobbi, AM. Carella, F. Patrone", "publication_date": "2012-07-06", "keywords": ""}, {"pubmed_id": "22738777", "title": "A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.", "authors": "A. Gu\u00e9rin, L. Chen, EQ. Wu, D. Ponce de Leon, JD. Griffin", "publication_date": "2012-06-29", "keywords": ""}, {"pubmed_id": "22693982", "title": "Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.", "authors": "ML. Raborn, EM. Pelletier, DB. Smith, CM. Reyes", "publication_date": "2012-06-22", "keywords": ""}, {"pubmed_id": "22710075", "title": "Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.", "authors": "RJ. Schilder, WE. Brady, HA. Lankes, JV. Fiorica, MS. Shahin, XC. Zhou, RS. Mannel, HB. Pathak, W. Hu, RK. Alpaugh, AK. Sood, AK. Godwin", "publication_date": "2012-06-20", "keywords": ""}, {"pubmed_id": "22687981", "title": "[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].", "authors": "J. Ueyama, A. Kure, K. Okuno, H. Sano, N. Tamoto, S. Kanzaki", "publication_date": "2012-06-13", "keywords": ""}, {"pubmed_id": "22677127", "title": "Polymorphisms of protein tyrosine phosphatase CD148 influence Fc\u03b3RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.", "authors": "J. Rollin, C. Pouplard, MP. Gratacap, D. Leroux, MA. May, M. Aupart, V. Gouilleux-Gruart, B. Payrastre, Y. Gruel", "publication_date": "2012-06-09", "keywords": ""}, {"pubmed_id": "22616642", "title": "Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.", "authors": "JL. Steegmann, F. Cervantes, P. le Coutre, K. Porkka, G. Saglio", "publication_date": "2012-05-24", "keywords": ""}, {"pubmed_id": "22575184", "title": "[Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].", "authors": "Q. Jiang, B. Jiang, SS. Chen, H. Jiang, YZ. Qin, YY. Lai, HX. Shi, XJ. Huang", "publication_date": "2012-05-12", "keywords": ""}, {"pubmed_id": "22555087", "title": "Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.", "authors": "H. Herrmann, K. Blatt, V. Ghanim, M. Kneidinger, K. Marth, R. Valenta, P. Valent", "publication_date": "2012-05-05", "keywords": ""}, {"pubmed_id": "22551803", "title": "Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.", "authors": "G. Rogers, M. Hoyle, J. Thompson Coon, T. Moxham, Z. Liu, M. Pitt, K. Stein", "publication_date": "2012-05-04", "keywords": ""}, {"pubmed_id": "22548456", "title": "Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.", "authors": "F. Giles, FX. Mahon, B. Gjertsen, R. Swords, B. Labar, A. Turkina, G. Rosti", "publication_date": "2012-05-03", "keywords": ""}, {"pubmed_id": "22538973", "title": "Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations.", "authors": "I. Glauche, K. Horn, M. Horn, L. Thielecke, MA. Essers, A. Trumpp, I. Roeder", "publication_date": "2012-04-28", "keywords": ""}, {"pubmed_id": "22526649", "title": "An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.", "authors": "L. Couchman, M. Birch, R. Ireland, A. Corrigan, S. Wickramasinghe, D. Josephs, J. Spicer, RJ. Flanagan", "publication_date": "2012-04-25", "keywords": ""}, {"pubmed_id": "22507785", "title": "CML treatment in Asia-Pacific region.", "authors": "S. Jootar", "publication_date": "2012-04-25", "keywords": ""}, {"pubmed_id": "22519766", "title": "Tyrosine kinase inhibitors in acute and chronic leukemias.", "authors": "M. Ohanian, J. Cortes, H. Kantarjian, E. Jabbour", "publication_date": "2012-04-24", "keywords": ""}, {"pubmed_id": "22502918", "title": "Towards a need to a \"biological Sokal risk\" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.", "authors": "F. Stagno, P. Vigneri, F. Di Raimondo", "publication_date": "2012-04-17", "keywords": ""}, {"pubmed_id": "22462037", "title": "Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.", "authors": "A. Quint\u00e1s-Cardama, H. Kantarjian, J. Cortes", "publication_date": "2012-03-31", "keywords": ""}, {"pubmed_id": "22451584", "title": "Pulmonary arterial hypertension in patients treated by dasatinib.", "authors": "D. Montani, E. Bergot, S. G\u00fcnther, L. Savale, A. Bergeron, A. Bourdin, H. Bouvaist, M. Canuet, C. Pison, M. Macro, P. Poubeau, B. Girerd, D. Natali, C. Guignabert, F. Perros, DS. O'Callaghan, X. Ja\u00efs, P. Tubert-Bitter, G. Zalcman, O. Sitbon, G. Simonneau, M. Humbert", "publication_date": "2012-03-28", "keywords": ""}, {"pubmed_id": "22451582", "title": "Double-edged sword of the new cancer therapeutics.", "authors": "T. Force", "publication_date": "2012-03-28", "keywords": ""}, {"pubmed_id": "22450750", "title": "How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.", "authors": "M. Breccia, G. Alimena", "publication_date": "2012-03-28", "keywords": ""}, {"pubmed_id": "22429140", "title": "Treatment options for chronic myeloid leukemia.", "authors": "MF. Tanaka, H. Kantarjian, J. Cortes, M. Ohanian, E. Jabbour", "publication_date": "2012-03-21", "keywords": ""}, {"pubmed_id": "22425926", "title": "Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.", "authors": "AZ. Dudek, H. Pang, RA. Kratzke, GA. Otterson, L. Hodgson, EE. Vokes, HL. Kindler, ", "publication_date": "2012-03-20", "keywords": ""}, {"pubmed_id": "22421368", "title": "A dramatic fetal outcome following transplacental transfer of dasatinib.", "authors": "P. Berveiller, A. Andreoli, O. Mir, O. Anselem, AL. Delezoide, H. Sauvageon, N. Chapuis, V. Tsatsaris", "publication_date": "2012-03-17", "keywords": ""}, {"pubmed_id": "22407177", "title": "Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.", "authors": "DA. Reardon, JJ. Vredenburgh, A. Desjardins, KB. Peters, S. Sathornsumetee, S. Threatt, JH. Sampson, JE. Herndon, A. Coan, F. McSherry, JN. Rich, RE. McLendon, S. Zhang, HS. Friedman", "publication_date": "2012-03-13", "keywords": ""}, {"pubmed_id": "22403810", "title": "NICE guidance on dasatinib, high-dose imatinib, and  nilotinib for patients with CML who are resistant or  intolerant to imatinib.", "authors": "S. Goulden, F. Sutcliffe, A. Stevens", "publication_date": "2012-03-10", "keywords": ""}, {"pubmed_id": "22403059", "title": "Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "HY. Yhim, HS. Kim, NR. Lee, EK. Song, JY. Kwak, CY. Yim", "publication_date": "2012-03-10", "keywords": ""}, {"pubmed_id": "22392508", "title": "Phase I trial of dasatinib and ixabepilone in patients with solid tumors.", "authors": "P. Herbolsheimer, R. Kapoor, KL. Smith, D. Perry, N. Verma, I. Veytsman, J. Jelinek, SM. Swain", "publication_date": "2012-03-07", "keywords": ""}, {"pubmed_id": "22385514", "title": "Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.", "authors": "M. Breccia, G. Alimena", "publication_date": "2012-03-06", "keywords": ""}, {"pubmed_id": "22371878", "title": "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.", "authors": "HJ. Khoury, JE. Cortes, HM. Kantarjian, C. Gambacorti-Passerini, M. Baccarani, DW. Kim, A. Zaritskey, A. Countouriotis, N. Besson, E. Leip, V. Kelly, TH. Br\u00fcmmendorf", "publication_date": "2012-03-01", "keywords": ""}, {"pubmed_id": "22351162", "title": "Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study.", "authors": "D. Mitra, PC. Trask, S. Iyer, SD. Candrilli, JA. Kaye", "publication_date": "2012-02-22", "keywords": ""}, {"pubmed_id": "22338305", "title": "New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.", "authors": "E. Seront, F. Mazzeo, M. Mano, M. Sterckx, Y. Humblet, JP. Machiels, JF. Baurain", "publication_date": "2012-02-18", "keywords": ""}, {"pubmed_id": "22307953", "title": "Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.", "authors": "V. Brazzelli, V. Grasso, V. Barbaccia, G. Manna, N. Rivetti, M. Zecca, G. Giorgiani, C. Vassallo, G. Borroni", "publication_date": "2012-02-07", "keywords": ""}, {"pubmed_id": "22280914", "title": "Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.", "authors": "M. Breccia, M. Tiribelli, G. Alimena", "publication_date": "2012-01-28", "keywords": ""}, {"pubmed_id": "22272968", "title": "Recommendations for the management of adult chronic myeloid leukaemia in South Africa.", "authors": "VJ. Louw, L. Dreosti, P. Ruff, V. Jogessar, D. Moodley, N. Novitzky, M. Patel, A. Schmidt, P. Willem", "publication_date": "2012-01-26", "keywords": ""}, {"pubmed_id": "22271898", "title": "Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.", "authors": "N. Pemmaraju, H. Kantarjian, J. Shan, E. Jabbour, A. Quintas-Cardama, S. Verstovsek, F. Ravandi, W. Wierda, S. O'Brien, J. Cortes", "publication_date": "2012-01-25", "keywords": ""}, {"pubmed_id": "22263567", "title": "Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.", "authors": "GH. Rodriguez, SI. Ahmed, F. Al-akhrass, V. Rallapalli, A. Safdar", "publication_date": "2012-01-24", "keywords": ""}, {"pubmed_id": "22252576", "title": "Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.", "authors": "HP. Erba, DC. Pham, R. Zaiden, H. Vu, S. Tai", "publication_date": "2012-01-19", "keywords": ""}, {"pubmed_id": "22244674", "title": "Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner.", "authors": "M. Cornelison, EJ. Jabbour, MA. Welch", "publication_date": "2012-01-17", "keywords": ""}, {"pubmed_id": "22233429", "title": "Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "PL. McCormack, SJ. Keam", "publication_date": "2012-01-12", "keywords": ""}, {"pubmed_id": "22227529", "title": "Current treatment strategies in chronic myeloid leukemia.", "authors": "F. Guilhot, L. Roy, C. Tomowiak", "publication_date": "2012-01-10", "keywords": ""}, {"pubmed_id": "22223872", "title": "Practical monitoring of chronic myelogenous leukemia: when to change treatment.", "authors": "G. Saglio, C. Fava", "publication_date": "2012-01-10", "keywords": ""}, {"pubmed_id": "22210874", "title": "Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.", "authors": "WT. Parker, M. Ho, HS. Scott, TP. Hughes, S. Branford", "publication_date": "2012-01-03", "keywords": ""}, {"pubmed_id": "22168217", "title": "Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.", "authors": "MU. Yood, SA. Oliveria, M. Cziraky, I. Hirji, M. Hamdan, C. Davis", "publication_date": "2011-12-16", "keywords": ""}, {"pubmed_id": "22160483", "title": "Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).", "authors": "HM. Kantarjian, NP. Shah, JE. Cortes, M. Baccarani, MB. Agarwal, MS. Undurraga, J. Wang, JJ. Ipi\u00f1a, DW. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, JH. Milone, FE. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, MB. Bradley-Garelik, C. Zhu, A. Hochhaus", "publication_date": "2011-12-14", "keywords": ""}, {"pubmed_id": "22160058", "title": "Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.", "authors": "SP. Hunger", "publication_date": "2011-12-14", "keywords": ""}, {"pubmed_id": "22130962", "title": "Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.", "authors": "L. Rice, S. Lepler, C. Pampo, DW. Siemann", "publication_date": "2011-12-02", "keywords": ""}, {"pubmed_id": "22127285", "title": "Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.", "authors": "AP. Algazi, JS. Weber, SC. Andrews, P. Urbas, PN. Munster, RC. DeConti, J. Hwang, VK. Sondak, JL. Messina, T. McCalmont, AI. Daud", "publication_date": "2011-12-01", "keywords": ""}, {"pubmed_id": "25610192", "title": "Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia.", "authors": "M. Albayrak, H. Celebi, A. Albayrak, ES. Can, V. Aslan, B. Onec, I. Coban", "publication_date": "2011-12-01", "keywords": "Chronic myelocytic leukemia (CML), Imatinib, Skin lesions"}, {"pubmed_id": "22119977", "title": "Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.", "authors": "MB. Rios, P. Ault", "publication_date": "2011-11-29", "keywords": ""}, {"pubmed_id": "22104358", "title": "Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.", "authors": "G. Sanguineti, MP. Sormani, S. Marur, GB. Gunn, N. Rao, M. Cianchetti, F. Ricchetti, T. McNutt, B. Wu, A. Forastiere", "publication_date": "2011-11-23", "keywords": ""}, {"pubmed_id": "22076388", "title": "Pulmonary toxicities from targeted therapies: a review.", "authors": "NA. Barber, AK. Ganti", "publication_date": "2011-11-15", "keywords": ""}, {"pubmed_id": "22068151", "title": "Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.", "authors": "I. S\u00e1nchez-Ortega, O. Servitje, M. Arnan, G. Ort\u00ed, T. Peralta, F. Manresa, RF. Duarte", "publication_date": "2011-11-10", "keywords": ""}, {"pubmed_id": "22067393", "title": "Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.", "authors": "D. Marin, AR. Ibrahim, C. Lucas, G. Gerrard, L. Wang, RM. Szydlo, RE. Clark, JF. Apperley, D. Milojkovic, M. Bua, J. Pavlu, C. Paliompeis, A. Reid, K. Rezvani, JM. Goldman, L. Foroni", "publication_date": "2011-11-10", "keywords": ""}, {"pubmed_id": "22028489", "title": "Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.", "authors": "RS. Finn, C. Bengala, N. Ibrahim, H. Roch\u00e9, J. Sparano, LC. Strauss, J. Fairchild, O. Sy, LJ. Goldstein", "publication_date": "2011-10-27", "keywords": ""}, {"pubmed_id": "21990409", "title": "Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.", "authors": "WT. Parker, RM. Lawrence, M. Ho, DL. Irwin, HS. Scott, TP. Hughes, S. Branford", "publication_date": "2011-10-13", "keywords": ""}, {"pubmed_id": "21976132", "title": "Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.", "authors": "JC. Araujo, P. Mathew, AJ. Armstrong, EL. Braud, E. Posadas, M. Lonberg, GE. Gallick, GC. Trudel, P. Paliwal, S. Agrawal, CJ. Logothetis", "publication_date": "2011-10-07", "keywords": ""}, {"pubmed_id": "21972208", "title": "Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.", "authors": "P. Valent", "publication_date": "2011-10-06", "keywords": ""}, {"pubmed_id": "21970091", "title": "Dasatinib: pulmonary arterial hypertension. French data.", "authors": "", "publication_date": "2011-10-06", "keywords": ""}, {"pubmed_id": "21942976", "title": "Clinically significant drug interactions with antacids: an update.", "authors": "R. Ogawa, H. Echizen", "publication_date": "2011-09-29", "keywords": ""}, {"pubmed_id": "21910796", "title": "Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.", "authors": "I. Amitay-Laish, SM. Stemmer, ME. Lacouture", "publication_date": "2011-09-14", "keywords": ""}, {"pubmed_id": "21903773", "title": "A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.", "authors": "EL. Mayer, JF. Baurain, J. Sparano, L. Strauss, M. Campone, P. Fumoleau, H. Rugo, A. Awada, O. Sy, A. Llombart-Cussac", "publication_date": "2011-09-10", "keywords": ""}, {"pubmed_id": "21902298", "title": "Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.", "authors": "PL. McCormack, SJ. Keam", "publication_date": "2011-09-10", "keywords": ""}, {"pubmed_id": "21901399", "title": "Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.", "authors": "D. Kim, HG. Goh, SH. Kim, BS. Cho, DW. Kim", "publication_date": "2011-09-09", "keywords": ""}, {"pubmed_id": "21897052", "title": "Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics.", "authors": "A. Hoshino-Yoshino, M. Kato, K. Nakano, M. Ishigai, T. Kudo, K. Ito", "publication_date": "2011-09-08", "keywords": ""}, {"pubmed_id": "21890201", "title": "Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.", "authors": "EM. Orlandi, B. Rocca, AS. Pazzano, S. Ghio", "publication_date": "2011-09-06", "keywords": ""}, {"pubmed_id": "21881918", "title": "Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.", "authors": "A. Argiris, TM. Feinstein, L. Wang, T. Yang, S. Agrawal, LJ. Appleman, RG. Stoller, JR. Grandis, AM. Egloff", "publication_date": "2011-09-02", "keywords": ""}, {"pubmed_id": "21876122", "title": "Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.", "authors": "L. Roy, C. Tomowiak, F. Guilhot", "publication_date": "2011-08-31", "keywords": ""}, {"pubmed_id": "21874302", "title": "The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.", "authors": "MA. Schwarzbich, M. Gutknecht, J. Salih, HR. Salih, P. Brossart, SM. Rittig, F. Gr\u00fcnebach", "publication_date": "2011-08-30", "keywords": ""}, {"pubmed_id": "21860001", "title": "Emerging therapies to prevent skeletal morbidity in men with prostate cancer.", "authors": "PJ. Saylor, RJ. Lee, MR. Smith", "publication_date": "2011-08-24", "keywords": ""}, {"pubmed_id": "21859733", "title": "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.", "authors": "AR. Ibrahim, RE. Clark, TL. Holyoake, J. Byrne, P. Shepherd, JF. Apperley, D. Milojkovic, R. Szydlo, J. Goldman, D. Marin", "publication_date": "2011-08-24", "keywords": ""}, {"pubmed_id": "21844872", "title": "Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.", "authors": "PJ. Shami, M. Deininger", "publication_date": "2011-08-17", "keywords": ""}, {"pubmed_id": "21828123", "title": "Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.", "authors": "DM. Ross, PA. Bartley, J. Goyne, AA. Morley, JF. Seymour, AP. Grigg", "publication_date": "2011-08-11", "keywords": ""}, {"pubmed_id": "21821988", "title": "[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].", "authors": "J. Imagawa, Y. Harada, T. Yoshida, M. Tarutani, A. Kimura, K. Matsumoto, K. Morita, H. Harada", "publication_date": "2011-08-09", "keywords": ""}, {"pubmed_id": "21810917", "title": "Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.", "authors": "CI. Herold, V. Chadaram, BL. Peterson, PK. Marcom, J. Hopkins, GG. Kimmick, J. Favaro, E. Hamilton, RA. Welch, S. Bacus, KL. Blackwell", "publication_date": "2011-08-04", "keywords": ""}, {"pubmed_id": "21794916", "title": "Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.", "authors": "J. Nakata, M. Okada, H. Tamaki, A. Satake, K. Kaida, S. Yoshihara, R. Kato, K. Ikegame, H. Ogawa", "publication_date": "2011-07-29", "keywords": ""}, {"pubmed_id": "21791426", "title": "Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.", "authors": "JC. Chomel, ML. Bonnet, N. Sorel, A. Bertrand, MC. Meunier, S. Fichelson, M. Melkus, A. Bennaceur-Griscelli, F. Guilhot, AG. Turhan", "publication_date": "2011-07-28", "keywords": ""}, {"pubmed_id": "21782241", "title": "Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.", "authors": "BL. Stein, BD. Smith", "publication_date": "2011-07-26", "keywords": ""}, {"pubmed_id": "21781226", "title": "Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.", "authors": "S. Takahashi, M. Miyazaki, I. Okamoto, Y. Ito, K. Ueda, T. Seriu, K. Nakagawa, K. Hatake", "publication_date": "2011-07-26", "keywords": ""}, {"pubmed_id": "21738539", "title": "Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood.", "authors": "HH. Koo", "publication_date": "2011-07-09", "keywords": "Acute lymphoblastic leukemia, Child, Philadelphia chromosome, Tyrosine kinase inhibitor"}, {"pubmed_id": "21719499", "title": "Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.", "authors": "D. Dumitrescu, C. Seck, H. ten Freyhaus, F. Gerhardt, E. Erdmann, S. Rosenkranz", "publication_date": "2011-07-02", "keywords": ""}, {"pubmed_id": "21705080", "title": "Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.", "authors": "R. Latagliata, M. Breccia, F. Castagnetti, F. Stagno, L. Luciano, A. Gozzini, S. Ulisciani, F. Cavazzini, M. Annunziata, F. Sor\u00e0, AR. Rossi, P. Pregno, E. Montefusco, E. Abruzzese, E. Cris\u00e0, P. Musto, M. Tiribelli, G. Binotto, U. Occhini, C. Feo, P. Vigneri, V. Santini, C. Fava, G. Rosti, G. Alimena", "publication_date": "2011-06-28", "keywords": ""}, {"pubmed_id": "21700550", "title": "[Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].", "authors": "X. Thomas", "publication_date": "2011-06-28", "keywords": ""}, {"pubmed_id": "21685471", "title": "Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.", "authors": "M. Breccia, R. Latagliata, F. Stagno, L. Luciano, A. Gozzini, F. Castagnetti, C. Fava, F. Cavazzini, M. Annunziata, A. Russo Rossi, P. Pregno, E. Abruzzese, P. Vigneri, G. Rege-Cambrin, S. Sica, F. Pane, V. Santini, G. Specchia, G. Rosti, G. Alimena", "publication_date": "2011-06-21", "keywords": ""}, {"pubmed_id": "21672900", "title": "Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.", "authors": "SF. Wong, H. Mirshahidi", "publication_date": "2011-06-16", "keywords": ""}, {"pubmed_id": "21672337", "title": "Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.", "authors": "J. Li, G. Xu, S. Yu, L. He, L. Guo", "publication_date": "2011-06-16", "keywords": ""}, {"pubmed_id": "21647156", "title": "Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.", "authors": "A. Kreutzman, K. Ladell, C. Koechel, E. Gostick, M. Ekblom, L. Stenke, T. Melo, H. Einsele, K. Porkka, DA. Price, S. Mustjoki, R. Seggewiss", "publication_date": "2011-06-08", "keywords": ""}, {"pubmed_id": "21646774", "title": "[Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase].", "authors": "Y. Sunami, E. Sato, K. Ichikawa, H. Yasuda, N. Komatsu", "publication_date": "2011-06-08", "keywords": ""}, {"pubmed_id": "21618517", "title": "Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.", "authors": "P. Ceppi, I. Rapa, M. Lo Iacono, L. Righi, J. Giorcelli, M. Pautasso, A. Bill\u00e8, F. Ardissone, M. Papotti, GV. Scagliotti", "publication_date": "2011-05-28", "keywords": ""}, {"pubmed_id": "21600381", "title": "Novel agents and future directions for refractory breast cancer.", "authors": "HJ. Burstein", "publication_date": "2011-05-27", "keywords": ""}, {"pubmed_id": "21605451", "title": "Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?", "authors": "JK. Hennigs, G. Keller, HJ. Baumann, F. Honecker, S. Kluge, C. Bokemeyer, TH. Br\u00fcmmendorf, H. Klose", "publication_date": "2011-05-25", "keywords": ""}, {"pubmed_id": "21598241", "title": "Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.", "authors": "A. Quint\u00e1s-Cardama, JE. Cortes, HM. Kantarjian", "publication_date": "2011-05-21", "keywords": ""}, {"pubmed_id": "21594763", "title": "Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.", "authors": "Y. Kobayashi, H. Sakamaki, S. Fujisawa, K. Ando, K. Yamamoto, M. Okada, K. Ishizawa, T. Nagai, S. Miyawaki, T. Motoji, N. Usui, S. Iida, M. Taniwaki, N. Uoshima, T. Seriu, R. Ohno", "publication_date": "2011-05-20", "keywords": ""}, {"pubmed_id": "21357665", "title": "Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.", "authors": "S. Harnicar", "publication_date": "2011-05-20", "keywords": ""}, {"pubmed_id": "21335443", "title": "NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.", "authors": "S. O'Brien, E. Berman, JO. Moore, J. Pinilla-Ibarz, JP. Radich, PJ. Shami, BD. Smith, DS. Snyder, HM. Sundar, M. Talpaz, M. Wetzler", "publication_date": "2011-05-20", "keywords": ""}, {"pubmed_id": "21575924", "title": "Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.", "authors": "F. Ravandi", "publication_date": "2011-05-18", "keywords": ""}, {"pubmed_id": "21565522", "title": "Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.", "authors": "G. Rosti, F. Castagnetti, G. Gugliotta, F. Palandri, M. Baccarani", "publication_date": "2011-05-14", "keywords": ""}, {"pubmed_id": "21556318", "title": "Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.", "authors": "DL. Deremer, K. Katsanevas, C. Ustun", "publication_date": "2011-05-11", "keywords": "adverse events, chronic myeloid leukemia, frontline therapy, nilotinib"}, {"pubmed_id": "21552992", "title": "Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.", "authors": "MR. Sharma, K. Wroblewski, BN. Polite, JA. Knost, JA. Wallace, S. Modi, BG. Sleckman, D. Taber, EE. Vokes, WM. Stadler, HL. Kindler", "publication_date": "2011-05-10", "keywords": ""}, {"pubmed_id": "21539969", "title": "Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.", "authors": "EY. Yu, C. Massard, ME. Gross, MA. Carducci, S. Culine, G. Hudes, EM. Posadas, CN. Sternberg, G. Wilding, GC. Trudel, P. Paliwal, K. Fizazi", "publication_date": "2011-05-05", "keywords": ""}, {"pubmed_id": "21538960", "title": "Talc crystals in pleurodesis-associated talc granuloma.", "authors": "MJ. Castro, J. Jessurun, SE. Pambuccian", "publication_date": "2011-05-04", "keywords": ""}, {"pubmed_id": "21534873", "title": "Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.", "authors": "SB. Patel, I. Gojo, ML. Tidwell, EA. Sausville, MR. Baer", "publication_date": "2011-05-04", "keywords": ""}, {"pubmed_id": "21531328", "title": "Novel nephrotoxins.", "authors": "N. Harbord", "publication_date": "2011-05-03", "keywords": ""}, {"pubmed_id": "21528941", "title": "Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.", "authors": "M. Breccia, G. Alimena", "publication_date": "2011-05-03", "keywords": ""}, {"pubmed_id": "21524239", "title": "Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.", "authors": "JE. Signorovitch, EQ. Wu, KA. Betts, K. Parikh, E. Kantor, A. Guo, VK. Bollu, D. Williams, LJ. Wei, DJ. DeAngelo", "publication_date": "2011-04-29", "keywords": ""}, {"pubmed_id": "21523765", "title": "Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.", "authors": "A. Quint\u00e1s-Cardama, H. Kantarjian, J. Shan, E. Jabbour, LV. Abruzzo, S. Verstovsek, G. Garcia-Manero, S. O'Brien, J. Cortes", "publication_date": "2011-04-28", "keywords": ""}, {"pubmed_id": "21523734", "title": "A phase 2 trial of dasatinib in advanced melanoma.", "authors": "HM. Kluger, AZ. Dudek, C. McCann, J. Ritacco, N. Southard, LB. Jilaveanu, A. Molinaro, M. Sznol", "publication_date": "2011-04-28", "keywords": ""}, {"pubmed_id": "21523723", "title": "Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.", "authors": "HD. Brooks, BS. Glisson, BN. Bekele, FM. Johnson, LE. Ginsberg, A. El-Naggar, KS. Culotta, N. Takebe, J. Wright, HT. Tran, VA. Papadimitrakopoulou", "publication_date": "2011-04-28", "keywords": ""}, {"pubmed_id": "21521831", "title": "Current status of SRC inhibitors in solid tumor malignancies.", "authors": "LN. Puls, M. Eadens, W. Messersmith", "publication_date": "2011-04-28", "keywords": ""}, {"pubmed_id": "21517814", "title": "Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.", "authors": "P. Gallipoli, P. Shepherd, D. Irvine, M. Drummond, T. Holyoake", "publication_date": "2011-04-27", "keywords": ""}, {"pubmed_id": "21479663", "title": "Stochastic dynamics of leukemic cells under an intermittent targeted therapy.", "authors": "N. Pizzolato, D. Persano Adorno, D. Valenti, B. Spagnolo", "publication_date": "2011-04-12", "keywords": ""}, {"pubmed_id": "21477076", "title": "Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.", "authors": "I. Novitzky-Basso, C. Craddock", "publication_date": "2011-04-12", "keywords": ""}, {"pubmed_id": "21454871", "title": "The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).", "authors": "G. Visani, M. Breccia, E. Montefusco, E. Morra, V. Santini, A. Isidori", "publication_date": "2011-04-02", "keywords": ""}, {"pubmed_id": "23556080", "title": "Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.", "authors": "N. von Bubnoff", "publication_date": "2011-04-01", "keywords": "CML, matinib, myeloid neoplasms"}, {"pubmed_id": "21442641", "title": "Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.", "authors": "A. Pardanani", "publication_date": "2011-03-29", "keywords": ""}, {"pubmed_id": "21442637", "title": "Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.", "authors": "SJ. Lee, CW. Jung, DY. Kim, KH. Lee, SK. Sohn, JY. Kwak, HJ. Kim, IH. Kim, S. Park, DH. Kim", "publication_date": "2011-03-29", "keywords": ""}, {"pubmed_id": "21438838", "title": "Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.", "authors": "T. Tachibana, A. Numata, M. Tanaka, K. Motohashi, S. Fujisawa, H. Fujita, R. Sakai, N. Tomita, A. Maruta, Y. Ishigatsubo, H. Kanamori", "publication_date": "2011-03-29", "keywords": ""}, {"pubmed_id": "21423276", "title": "Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity.", "authors": "H. Zhong, D. Wang, N. Wang, Y. Rios, H. Huang, S. Li, X. Wu, S. Lin", "publication_date": "2011-03-23", "keywords": ""}, {"pubmed_id": "21410427", "title": "Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?", "authors": "A. Br\u00f3zik, C. Heged\u00fcs, Z. Erdei, T. Hegedus, C. \u00d6zvegy-Laczka, G. Szak\u00e1cs, B. Sarkadi", "publication_date": "2011-03-18", "keywords": ""}, {"pubmed_id": "21406471", "title": "A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.", "authors": "MN. Fornier, PG. Morris, A. Abbruzzi, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, AD. Seidman, N. Sklarin, J. Chang, L. Norton, CA. Hudis", "publication_date": "2011-03-17", "keywords": ""}, {"pubmed_id": "21402714", "title": "Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.", "authors": "PC. Amrein, EC. Attar, T. Takvorian, EP. Hochberg, KK. Ballen, KM. Leahy, DC. Fisher, AS. Lacasce, ED. Jacobsen, P. Armand, RP. Hasserjian, L. Werner, D. Neuberg, JR. Brown", "publication_date": "2011-03-16", "keywords": ""}, {"pubmed_id": "21385851", "title": "Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.", "authors": "A. Mazharian, C. Ghevaert, L. Zhang, S. Massberg, SP. Watson", "publication_date": "2011-03-10", "keywords": ""}, {"pubmed_id": "21357709", "title": "Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.", "authors": "AE. Eskazan, T. Soysal, S. Ongoren, E. Gulturk, B. Ferhanoglu, Y. Aydin", "publication_date": "2011-03-02", "keywords": ""}, {"pubmed_id": "21353701", "title": "Nilotinib and dasatinib first-line: are we ready for imatinib replacement?", "authors": "M. Breccia, G. Alimena", "publication_date": "2011-03-01", "keywords": ""}, {"pubmed_id": "21333826", "title": "[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].", "authors": "A. de Masson, S. Bouvresse, T. Cl\u00e9rici, E. Mah\u00e9, P. Sa\u00efag", "publication_date": "2011-02-22", "keywords": ""}, {"pubmed_id": "21298759", "title": "Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.", "authors": "SL. Hobernicht, B. Schweiger, P. Zeitler, M. Wang, SP. Hunger", "publication_date": "2011-02-08", "keywords": ""}, {"pubmed_id": "21271862", "title": "A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.", "authors": "JJ. Powers, JA. Dubovsky, PK. Epling-Burnette, L. Moscinski, L. Zhang, S. Mustjoki, EM. Sotomayor, JA. Pinilla-Ibarz", "publication_date": "2011-01-29", "keywords": ""}, {"pubmed_id": "21263099", "title": "Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.", "authors": "R. Aplenc, SM. Blaney, LC. Strauss, FM. Balis, S. Shusterman, AM. Ingle, S. Agrawal, J. Sun, JJ. Wright, PC. Adamson", "publication_date": "2011-01-26", "keywords": ""}, {"pubmed_id": "21253680", "title": "[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].", "authors": "A. Burchert, A. Neubauer", "publication_date": "2011-01-22", "keywords": ""}, {"pubmed_id": "21252655", "title": "Navigating the road toward optimal initial therapy for chronic myeloid leukemia.", "authors": "RA. Okimoto, RA. Van Etten", "publication_date": "2011-01-22", "keywords": ""}, {"pubmed_id": "21252264", "title": "Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.", "authors": "N. Skoetz, S. Kluge, I. Monsef, K. Bauer, H. Siebert, KA. Kreuzer, A. Engert", "publication_date": "2011-01-22", "keywords": ""}, {"pubmed_id": "21234296", "title": "Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.", "authors": "M. Serpa, SS. Sanabani, I. Bendit, F. Seguro, F. Xavier, CB. Barroso, M. Conchon, PE. Dorlhiac-Llacer", "publication_date": "2011-01-15", "keywords": "adverse events, chronic myeloid leukemia, dasatinib/*administration & dosage, treatment outcome"}, {"pubmed_id": "21226671", "title": "Dasatinib: an anti-tumour agent via Src inhibition.", "authors": "A. Gnoni, I. Marech, N. Silvestris, A. Vacca, V. Lorusso", "publication_date": "2011-01-14", "keywords": ""}, {"pubmed_id": "21204748", "title": "The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.", "authors": "TJ. Kruser, AM. Traynor, DL. Wheeler", "publication_date": "2011-01-06", "keywords": ""}, {"pubmed_id": "23284261", "title": "Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.", "authors": "M. Conchon, CM. Freitas, MA. Rego, JW. Braga Junior", "publication_date": "2011-01-01", "keywords": "Clinical Trial, Drug interactions, Drug resistance, neoplasm, Drug toxicity, Gastrointestinal tract/drug effects, Interferonalpha/administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Piperazines/therapeutic use, Pyrimidines"}, {"pubmed_id": "22937303", "title": "Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.", "authors": "B. Uz, O. Bektas, E. Eliac\u0131k, H. Goker, Y. Erbilgin, M. Sayitoglu, N. Sayinalp, S. Aksu, Y. Buyukasik, O. Ozcebe, IC. Haznedaroglu", "publication_date": "2011-01-01", "keywords": ""}, {"pubmed_id": "21153679", "title": "Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.", "authors": "C. Lu-Emerson, AD. Norden, J. Drappatz, EC. Quant, R. Beroukhim, AS. Ciampa, LM. Doherty, DC. Lafrankie, S. Ruland, PY. Wen", "publication_date": "2010-12-15", "keywords": ""}, {"pubmed_id": "21108851", "title": "First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.", "authors": "G. Wei, S. Rafiyath, D. Liu", "publication_date": "2010-11-27", "keywords": ""}, {"pubmed_id": "21091149", "title": "Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.", "authors": "KR. Schultz, T. Prestidge, B. Camitta", "publication_date": "2010-11-26", "keywords": ""}, {"pubmed_id": "21062136", "title": "Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.", "authors": "EQ. Wu, A. Guerin, AP. Yu, VK. Bollu, A. Guo, JD. Griffin", "publication_date": "2010-11-11", "keywords": ""}, {"pubmed_id": "21042889", "title": "Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.", "authors": "N. Iwamoto, JH. Distler, O. Distler", "publication_date": "2010-11-03", "keywords": ""}, {"pubmed_id": "20973144", "title": "Second-generation BCR-ABL kinase inhibitors in CML.", "authors": "LP. Akard", "publication_date": "2010-10-26", "keywords": ""}, {"pubmed_id": "20968202", "title": "Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.", "authors": "H. Bumbea, AM. Vladareanu, I. Voican, D. Cisleanu, L. Barsan, M. Onisai", "publication_date": "2010-10-26", "keywords": ""}, {"pubmed_id": "20945321", "title": "Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.", "authors": "E. Jabbour, J. Cortes, H. Kantarjian", "publication_date": "2010-10-15", "keywords": ""}, {"pubmed_id": "20934998", "title": "Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.", "authors": "MT. Krauth, S. Herndlhofer, MT. Schmook, G. Mitterbauer-Hohendanner, E. Schl\u00f6gl, P. Valent", "publication_date": "2010-10-12", "keywords": ""}, {"pubmed_id": "20929406", "title": "Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.", "authors": "TD. Kim, M. Schwarz, H. Nogai, P. Grille, J. Westermann, U. Pl\u00f6ckinger, D. Braun, U. Schweizer, R. Arnold, B. D\u00f6rken, P. le Coutre", "publication_date": "2010-10-12", "keywords": ""}, {"pubmed_id": "20922786", "title": "Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.", "authors": "J. Pinilla-Ibarz, J. Cortes, MJ. Mauro", "publication_date": "2010-10-06", "keywords": ""}, {"pubmed_id": "20922699", "title": "[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].", "authors": "C. Rollino, G. Beltrame, M. Ferro, G. Quattrocchio, L. Tonda, F. Quarello", "publication_date": "2010-10-06", "keywords": ""}, {"pubmed_id": "20875552", "title": "Stem cell transplant for chronic myeloid leukemia in the imatinib era.", "authors": "J. Radich", "publication_date": "2010-09-30", "keywords": ""}, {"pubmed_id": "20875551", "title": "Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?", "authors": "E. Jabbour, H. Kantarjian, J. Cortes", "publication_date": "2010-09-30", "keywords": ""}, {"pubmed_id": "20864900", "title": "Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.", "authors": "S. Shayani", "publication_date": "2010-09-25", "keywords": ""}, {"pubmed_id": "20861918", "title": "Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.", "authors": "E. Jabbour, M. Deininger, A. Hochhaus", "publication_date": "2010-09-24", "keywords": ""}, {"pubmed_id": "20855820", "title": "Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.", "authors": "FM. Johnson, BN. Bekele, L. Feng, I. Wistuba, XM. Tang, HT. Tran, JJ. Erasmus, LL. Hwang, N. Takebe, GR. Blumenschein, SM. Lippman, DJ. Stewart", "publication_date": "2010-09-22", "keywords": ""}, {"pubmed_id": "20827202", "title": "Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis.", "authors": "JK. Gordon, RF. Spiera", "publication_date": "2010-09-10", "keywords": ""}, {"pubmed_id": "20824400", "title": "Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.", "authors": "Y. Ono, T. Mori, J. Kato, A. Yamane, T. Yajima, Y. Iwao, T. Hibi, S. Okamoto", "publication_date": "2010-09-09", "keywords": ""}, {"pubmed_id": "20824399", "title": "Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.", "authors": "Y. Ishida, K. Terasako, K. Oshima, K. Sakamoto, M. Ashizawa, M. Sato, M. Kikuchi, S. Kimura, H. Nakasone, S. Okuda, S. Kako, R. Yamazaki, J. Nishida, Y. Kanda", "publication_date": "2010-09-09", "keywords": ""}, {"pubmed_id": "20810928", "title": "Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.", "authors": "A. Haouala, N. Widmer, MA. Duchosal, M. Montemurro, T. Buclin, LA. Decosterd", "publication_date": "2010-09-03", "keywords": ""}, {"pubmed_id": "20805664", "title": "[Development of ABL tyrosine kinase inhibitors].", "authors": "S. Kimura", "publication_date": "2010-09-02", "keywords": ""}, {"pubmed_id": "20722490", "title": "Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.", "authors": "M. Breccia, G. Alimena", "publication_date": "2010-08-21", "keywords": ""}, {"pubmed_id": "20685771", "title": "Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.", "authors": "NM. Agostino, VM. Chinchilli, CJ. Lynch, A. Koszyk-Szewczyk, R. Gingrich, J. Sivik, JJ. Drabick", "publication_date": "2010-08-06", "keywords": ""}, {"pubmed_id": "20684746", "title": "Metabolism considerations for kinase inhibitors in cancer treatment.", "authors": "DR. Duckett, MD. Cameron", "publication_date": "2010-08-06", "keywords": ""}, {"pubmed_id": "20652453", "title": "Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "R. Ohno", "publication_date": "2010-07-24", "keywords": ""}, {"pubmed_id": "20640942", "title": "Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the \"best\" therapy?", "authors": "M. Agrawal, RJ. Garg, H. Kantarjian, J. Cortes", "publication_date": "2010-07-20", "keywords": ""}, {"pubmed_id": "20582584", "title": "Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.", "authors": "G. Gervasini, J. Ben\u00edtez, JA. Carrillo", "publication_date": "2010-06-29", "keywords": ""}, {"pubmed_id": "20564086", "title": "Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.", "authors": "G. Saglio, A. Hochhaus, YT. Goh, T. Masszi, R. Pasquini, F. Maloisel, P. Erben, J. Cortes, R. Paquette, MB. Bradley-Garelik, C. Zhu, H. Dombret", "publication_date": "2010-06-22", "keywords": ""}, {"pubmed_id": "20553275", "title": "Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.", "authors": "FP. Santos, H. Kantarjian, C. Fava, S. O'Brien, G. Garcia-Manero, F. Ravandi, W. Wierda, D. Thomas, J. Shan, J. Cortes", "publication_date": "2010-06-18", "keywords": ""}, {"pubmed_id": "20537386", "title": "BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.", "authors": "X. An, AK. Tiwari, Y. Sun, PR. Ding, CR. Ashby, ZS. Chen", "publication_date": "2010-06-12", "keywords": ""}, {"pubmed_id": "20529808", "title": "Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.", "authors": "E. Jabbour, A. Fullmer, JE. Cort\u00e9s, H. Kantarjian", "publication_date": "2010-06-10", "keywords": ""}, {"pubmed_id": "20525995", "title": "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.", "authors": "H. Kantarjian, NP. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z. Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boqu\u00e9, C. Chuah, E. Bleickardt, MB. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, M. Baccarani", "publication_date": "2010-06-08", "keywords": ""}, {"pubmed_id": "20473616", "title": "Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.", "authors": "H. Oweini, ZK. Otrock, RA. Mahfouz, A. Bazarbachi", "publication_date": "2010-05-18", "keywords": ""}, {"pubmed_id": "20471511", "title": "Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.", "authors": "N. Larsson, R. Billstr\u00f6m, H. Lilljebj\u00f6rn, C. Lassen, J. Richter, M. Ekblom, T. Fioretos", "publication_date": "2010-05-18", "keywords": ""}, {"pubmed_id": "20466853", "title": "First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.", "authors": "F. Ravandi, S. O'Brien, D. Thomas, S. Faderl, D. Jones, R. Garris, S. Dara, J. Jorgensen, P. Kebriaei, R. Champlin, G. Borthakur, J. Burger, A. Ferrajoli, G. Garcia-Manero, W. Wierda, J. Cortes, H. Kantarjian", "publication_date": "2010-05-15", "keywords": ""}, {"pubmed_id": "20463821", "title": "The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis.", "authors": "J. Stephens, KT. Carpiuc, M. Botteman", "publication_date": "2010-05-14", "keywords": "adverse events, cost, and cost analysis, dasatinib, imatinib, nilotinib, safety"}, {"pubmed_id": "20460883", "title": "Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse.", "authors": "BW. Kang, JH. Moon, YS. Chae, JG. Kim, SN. Kim, SK. Sohn", "publication_date": "2010-05-13", "keywords": ""}, {"pubmed_id": "20419513", "title": "Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?", "authors": "C. Beyer, JH. Distler, O. Distler", "publication_date": "2010-04-27", "keywords": ""}, {"pubmed_id": "20408871", "title": "Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.", "authors": "M. Giehl, A. Leitner, C. Haferlach, P. Duesberg, WK. Hofmann, R. Hofheinz, W. Seifarth, A. Hochhaus, A. Fabarius", "publication_date": "2010-04-23", "keywords": ""}, {"pubmed_id": "20405252", "title": "Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.", "authors": "Y. Nagata, K. Ohashi, S. Fukuda, N. Kamata, H. Akiyama, H. Sakamaki", "publication_date": "2010-04-21", "keywords": ""}, {"pubmed_id": "20399520", "title": "Cardiac side-effects of cancer chemotherapy.", "authors": "JJ. Monsuez, JC. Charniot, N. Vignat, JY. Artigou", "publication_date": "2010-04-20", "keywords": ""}, {"pubmed_id": "20386534", "title": "Reversible cardiotoxicity with tyrosine kinase inhibitors.", "authors": "J. Francis, MS. Ahluwalia, M. Wetzler, E. Wang, P. Paplham, S. Smiley, PL. McCarthy, IL. Cohen, E. Spangenthal, M. Battiwalla", "publication_date": "2010-04-14", "keywords": ""}, {"pubmed_id": "20379112", "title": "[Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].", "authors": "T. Hoshino, K. Tahara, K. Miyawaki, N. Hatsumi, S. Takada, S. Miyawaki, T. Sakura", "publication_date": "2010-04-10", "keywords": ""}, {"pubmed_id": "20375898", "title": "Pleural effusions due to dasatinib.", "authors": "AG. Brixey, RW. Light", "publication_date": "2010-04-09", "keywords": ""}, {"pubmed_id": "20375493", "title": "A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.", "authors": "M. Erkut, N. Erkut, S. Ersoz, M. Arslan, M. Sonmez", "publication_date": "2010-04-09", "keywords": ""}, {"pubmed_id": "20350280", "title": "The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.", "authors": "J. Chen, Z. Zheng, J. Shen, Y. Zhou", "publication_date": "2010-03-31", "keywords": ""}, {"pubmed_id": "20345830", "title": "Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.", "authors": "SM. Tinsley", "publication_date": "2010-03-30", "keywords": ""}, {"pubmed_id": "20331405", "title": "Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.", "authors": "F. Stagno, P. Vigneri, V. Del Fabro, S. Stella, A. Cupri, M. Massimino, C. Consoli, L. Tamb\u00e8, ML. Consoli, A. Antolino, F. Di Raimondo", "publication_date": "2010-03-25", "keywords": ""}, {"pubmed_id": "20310049", "title": "Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.", "authors": "H. Kantarjian, P. le Coutre, J. Cortes, J. Pinilla-Ibarz, A. Nagler, A. Hochhaus, S. Kimura, O. Ottmann", "publication_date": "2010-03-24", "keywords": ""}, {"pubmed_id": "20302388", "title": "Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.", "authors": "G. Rosti, F. Castagnetti, G. Gugliotta, F. Palandri, G. Martinelli, M. Baccarani", "publication_date": "2010-03-23", "keywords": ""}, {"pubmed_id": "20221270", "title": "Chronic myelogenous leukemia: treatment and monitoring.", "authors": "N. von Bubnoff, J. Duyster", "publication_date": "2010-03-12", "keywords": ""}, {"pubmed_id": "20191333", "title": "Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.", "authors": "Y. Nagata, S. Fukuda, T. Kobayashi, T. Yamashita, K. Ohashi, H. Sakamaki, H. Akiyama", "publication_date": "2010-03-02", "keywords": ""}, {"pubmed_id": "20142592", "title": "Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.", "authors": "EB. Haura, T. Tanvetyanon, A. Chiappori, C. Williams, G. Simon, S. Antonia, J. Gray, S. Litschauer, L. Tetteh, A. Neuger, L. Song, B. Rawal, MJ. Schell, G. Bepler", "publication_date": "2010-02-10", "keywords": ""}, {"pubmed_id": "20139391", "title": "Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.", "authors": "NP. Shah, DW. Kim, H. Kantarjian, P. Rousselot, PE. Llacer, A. Enrico, J. Vela-Ojeda, RT. Silver, HJ. Khoury, MC. M\u00fcller, A. Lambert, Y. Matloub, A. Hochhaus", "publication_date": "2010-02-09", "keywords": ""}, {"pubmed_id": "20131302", "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.", "authors": "MB. Lilly, OG. Ottmann, NP. Shah, RA. Larson, JJ. Reiffers, G. Ehninger, MC. M\u00fcller, A. Charbonnier, E. Bullorsky, H. Dombret, M. Brigid Bradley-Garelik, C. Zhu, G. Martinelli", "publication_date": "2010-02-05", "keywords": ""}, {"pubmed_id": "20113282", "title": "Acute renal failure under dasatinib therapy.", "authors": "S. Ozkurt, G. Temiz, MF. Acikalin, M. Soydan", "publication_date": "2010-02-02", "keywords": ""}, {"pubmed_id": "20113198", "title": "Dasatinib in solid tumors.", "authors": "LC. Kim, U. Rix, EB. Haura", "publication_date": "2010-02-02", "keywords": ""}, {"pubmed_id": "20108303", "title": "Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.", "authors": "FM. Johnson, S. Agrawal, H. Burris, L. Rosen, N. Dhillon, D. Hong, A. Blackwood-Chirchir, FR. Luo, O. Sy, S. Kaul, AA. Chiappori", "publication_date": "2010-01-29", "keywords": ""}, {"pubmed_id": "20087228", "title": "A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).", "authors": "AA. Miller, H. Pang, L. Hodgson, N. Ramnath, GA. Otterson, MJ. Kelley, RA. Kratzke, EE. Vokes, ", "publication_date": "2010-01-21", "keywords": ""}, {"pubmed_id": "20072833", "title": "Dasatinib.", "authors": "M. Lindauer, A. Hochhaus", "publication_date": "2010-01-15", "keywords": ""}, {"pubmed_id": "20062096", "title": "Development of severe sclerotic chronic GVHD during treatment with dasatinib.", "authors": "D. Pulanic, EW. Cowen, K. Baird, MR. Bishop, SZ. Pavletic", "publication_date": "2010-01-12", "keywords": ""}, {"pubmed_id": "20061946", "title": "Managing imatinib resistance in chronic myeloid leukaemia.", "authors": "M. Osborn, T. Hughes", "publication_date": "2010-01-12", "keywords": ""}, {"pubmed_id": "22791487", "title": "Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.", "authors": "S. Bayraktar, B. Morency, MP. Escal\u00f3n", "publication_date": "2010-01-01", "keywords": ""}, {"pubmed_id": "22282699", "title": "Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.", "authors": "LM. Lima, M. Arellano, S. Holloway, M. Shepard, S. McMillan, HJ. Khoury", "publication_date": "2010-01-01", "keywords": "dasatinib, outcomes, resistant CML"}, {"pubmed_id": "20001232", "title": "Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "W. Stock", "publication_date": "2009-12-17", "keywords": ""}, {"pubmed_id": "19959091", "title": "Management of drug toxicities in chronic myeloid leukaemia.", "authors": "MJ. Mauro, MW. Deininger", "publication_date": "2009-12-05", "keywords": ""}, {"pubmed_id": "19951880", "title": "Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.", "authors": "J. Pavl\u016f, D. Marin", "publication_date": "2009-12-03", "keywords": ""}, {"pubmed_id": "19924787", "title": "Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.", "authors": "K. Porkka, HJ. Khoury, RL. Paquette, Y. Matloub, R. Sinha, JE. Cortes", "publication_date": "2009-11-20", "keywords": ""}, {"pubmed_id": "19920908", "title": "Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.", "authors": "X. Huang, S. Patel, N. Ahmed, K. Seiter, D. Liu", "publication_date": "2009-11-19", "keywords": "chronic myeloid leukemia, imatinib, skin rash, tyrosine kinase inhibitor"}, {"pubmed_id": "19920114", "title": "Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.", "authors": "EY. Yu, G. Wilding, E. Posadas, M. Gross, S. Culine, C. Massard, MJ. Morris, G. Hudes, F. Calabr\u00f2, S. Cheng, GC. Trudel, P. Paliwal, CN. Sternberg", "publication_date": "2009-11-19", "keywords": ""}, {"pubmed_id": "19915358", "title": "[Clinical progress in chronic myelogenous leukemia].", "authors": "T. Matsunaga", "publication_date": "2009-11-17", "keywords": ""}, {"pubmed_id": "19909541", "title": "The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.", "authors": "D. Masiello, G. Gorospe, AS. Yang", "publication_date": "2009-11-17", "keywords": ""}, {"pubmed_id": "19890374", "title": "A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.", "authors": "U. Rix, LL. Remsing Rix, AS. Terker, NV. Fernbach, O. Hantschel, M. Planyavsky, FP. Breitwieser, H. Herrmann, J. Colinge, KL. Bennett, M. Augustin, JH. Till, MC. Heinrich, P. Valent, G. Superti-Furga", "publication_date": "2009-11-06", "keywords": ""}, {"pubmed_id": "19886867", "title": "Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.", "authors": "D. Mokhtari, N. Welsh", "publication_date": "2009-11-06", "keywords": ""}, {"pubmed_id": "19885746", "title": "Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.", "authors": "A. Czyz, K. Lewandowski, R. Kroll, M. Komarnicki", "publication_date": "2009-11-04", "keywords": ""}, {"pubmed_id": "19884523", "title": "Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.", "authors": "M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, RT. Silver, J. Goldman, R. Hehlmann, ", "publication_date": "2009-11-04", "keywords": ""}, {"pubmed_id": "19878083", "title": "Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.", "authors": "FP. Santos, M. Rodrigues, C. Mac-Donald Bley do Nascimento, FR. Kerbauy, AA. Ribeiro, J. Mauro Kutner, N. Hamerschlak", "publication_date": "2009-11-03", "keywords": ""}, {"pubmed_id": "19838099", "title": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "authors": "M. Goldblatt, JT. Huggins, P. Doelken, P. Gurung, SA. Sahn", "publication_date": "2009-10-20", "keywords": ""}, {"pubmed_id": "19833633", "title": "Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.", "authors": "D. Milojkovic, E. Nicholson, JF. Apperley, TL. Holyoake, P. Shepherd, MW. Drummond, R. Szydlo, M. Bua, L. Foroni, A. Reid, JS. Khorashad, H. de Lavallade, K. Rezvani, C. Paliompeis, JM. Goldman, D. Marin", "publication_date": "2009-10-17", "keywords": ""}, {"pubmed_id": "19822300", "title": "Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.", "authors": "AS. Stein, JM. Palmer, MR. O'Donnell, NM. Kogut, RT. Spielberger, ML. Slovak, NC. Tsai, D. Senitzer, DS. Snyder, SH. Thomas, SJ. Forman", "publication_date": "2009-10-14", "keywords": ""}, {"pubmed_id": "19798095", "title": "Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.", "authors": "E. Jabbour, A. Hochhaus, J. Cortes, P. La Ros\u00e9e, HM. Kantarjian", "publication_date": "2009-10-03", "keywords": ""}, {"pubmed_id": "19789325", "title": "Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.", "authors": "GD. Demetri, P. Lo Russo, IR. MacPherson, D. Wang, JA. Morgan, VG. Brunton, P. Paliwal, S. Agrawal, M. Voi, TR. Evans", "publication_date": "2009-10-01", "keywords": ""}, {"pubmed_id": "19757705", "title": "Old disease, new targets. Part-II, haematological malignancies.", "authors": "S. Kumar, N. Masood, SN. Adil", "publication_date": "2009-09-18", "keywords": ""}, {"pubmed_id": "19744571", "title": "Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).", "authors": "E. Klyuchnikov, N. Kr\u00f6ger, TH. Brummendorf, B. Wiedemann, AR. Zander, U. Bacher", "publication_date": "2009-09-12", "keywords": ""}, {"pubmed_id": "19744184", "title": "Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.", "authors": "C. Sillaber, H. Herrmann, K. Bennett, U. Rix, C. Baumgartner, A. B\u00f6hm, S. Herndlhofer, E. Tschachler, G. Superti-Furga, U. J\u00e4ger, P. Valent", "publication_date": "2009-09-12", "keywords": ""}, {"pubmed_id": "19734999", "title": "Cardiotoxicity induced by tyrosine kinase inhibitors.", "authors": "GS. Orphanos, GN. Ioannidis, AG. Ardavanis", "publication_date": "2009-09-08", "keywords": ""}, {"pubmed_id": "19708572", "title": "[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].", "authors": "OIu. Vinogradova, AG. Turkina, AV. Vorontsova, EIu. Chelysheva, GA. Gusarova, SV. Kuznetsov, SR. Goriacheva, MA. Sokolova, EM. Abakumov, OV. Stakhina, EV. Domracheva, AV. Misiurin, ND. Khoroshko", "publication_date": "2009-08-28", "keywords": ""}, {"pubmed_id": "19689244", "title": "Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.", "authors": "JT. Hartmann, M. Haap, HG. Kopp, HP. Lipp", "publication_date": "2009-08-20", "keywords": ""}, {"pubmed_id": "19679008", "title": "Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?", "authors": "A. Quint\u00e1s-Cardama, J. Cortes", "publication_date": "2009-08-15", "keywords": ""}, {"pubmed_id": "19657995", "title": "Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "T. Shimokaze, T. Mitsui, H. Takeda, T. Kawakami, T. Arai, M. Ito, A. Iwaba, H. Izumino, N. Takahashi, M. Kanno, D. Sendo, K. Hayasaka", "publication_date": "2009-08-07", "keywords": ""}, {"pubmed_id": "19640584", "title": "Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.", "authors": "A. Gafter-Gvili, R. Ram, U. Gafter, O. Shpilberg, P. Raanani", "publication_date": "2009-07-31", "keywords": ""}, {"pubmed_id": "19638722", "title": "[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].", "authors": "S. Kimura", "publication_date": "2009-07-30", "keywords": ""}, {"pubmed_id": "19603032", "title": "Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.", "authors": "T. Koreckij, H. Nguyen, LG. Brown, EY. Yu, RL. Vessella, E. Corey", "publication_date": "2009-07-16", "keywords": ""}, {"pubmed_id": "19546604", "title": "Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.", "authors": "F. Roszkiewicz, R. Garidi, I. Vaida, B. Royer, A. Parcelier, JP. Marolleau, G. Damaj", "publication_date": "2009-06-24", "keywords": ""}, {"pubmed_id": "19536906", "title": "Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).", "authors": "H. Kantarjian, R. Pasquini, V. L\u00e9vy, S. Jootar, J. Holowiecki, N. Hamerschlak, T. Hughes, E. Bleickardt, D. Dejardin, J. Cortes, NP. Shah", "publication_date": "2009-06-19", "keywords": ""}, {"pubmed_id": "19536317", "title": "Dasatinib in chronic myeloid leukemia: a review.", "authors": "DG. Aguilera, AM. Tsimberidou", "publication_date": "2009-06-19", "keywords": "BCR-ABL, chronic myeloid leukemia, dasatininb, tyrosine kinase inhibitor"}, {"pubmed_id": "19531657", "title": "Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.", "authors": "D. Verma, HM. Kantarjian, D. Jones, R. Luthra, G. Borthakur, S. Verstovsek, MB. Rios, J. Cortes", "publication_date": "2009-06-18", "keywords": ""}, {"pubmed_id": "19525190", "title": "Response dynamics in chronic-phase chronic myeloid leukemia.", "authors": "MJ. Mauro", "publication_date": "2009-06-16", "keywords": ""}, {"pubmed_id": "19517473", "title": "Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.", "authors": "A. Quint\u00e1s-Cardama, FP. De Souza Santos, H. Kantarjian, S. O'Brien, S. Faderl, A. Awais, G. Borthakur, J. Cortes", "publication_date": "2009-06-12", "keywords": ""}, {"pubmed_id": "19505856", "title": "Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.", "authors": "A. Haouala, B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, MA. Duchosal, HB. Ris, S. Leyvraz, N. Widmer, LA. Decosterd", "publication_date": "2009-06-10", "keywords": ""}, {"pubmed_id": "19502192", "title": "Practical management of dasatinib for maximum patient benefit.", "authors": "I. Galinsky, S. Buchanan", "publication_date": "2009-06-09", "keywords": ""}, {"pubmed_id": "19502190", "title": "A once-daily dasatinib dosing strategy for chronic myeloid leukemia.", "authors": "G. Bryant", "publication_date": "2009-06-09", "keywords": ""}, {"pubmed_id": "19496239", "title": "Dasatinib: for some difficult cases of adult leukaemia.", "authors": "", "publication_date": "2009-06-06", "keywords": ""}, {"pubmed_id": "19487385", "title": "Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.", "authors": "JF. Apperley, JE. Cortes, DW. Kim, L. Roy, GJ. Roboz, G. Rosti, EO. Bullorsky, E. Abruzzese, A. Hochhaus, D. Heim, CA. de Souza, RA. Larson, JH. Lipton, HJ. Khoury, HJ. Kim, C. Sillaber, TP. Hughes, P. Erben, J. Van Tornout, RM. Stone", "publication_date": "2009-06-03", "keywords": ""}, {"pubmed_id": "19468276", "title": "Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.", "authors": "MJ. Mauro", "publication_date": "2009-05-27", "keywords": ""}, {"pubmed_id": "19455391", "title": "Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.", "authors": "DW. Kim, YT. Goh, HH. Hsiao, PB. Caguioa, D. Kim, WS. Kim, T. Saikia, S. Agrawal, A. Roy, D. Dai, MB. Bradley-Garelik, J. Mukhopadhyay, S. Jootar", "publication_date": "2009-05-21", "keywords": ""}, {"pubmed_id": "19414863", "title": "Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.", "authors": "A. Quint\u00e1s-Cardama, X. Han, H. Kantarjian, J. Cortes", "publication_date": "2009-05-06", "keywords": ""}, {"pubmed_id": "19402798", "title": "Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.", "authors": "MJ. Taylor, PA. Scuffham", "publication_date": "2009-05-01", "keywords": ""}, {"pubmed_id": "19395585", "title": "Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.", "authors": "T. Eley, FR. Luo, S. Agrawal, A. Sanil, J. Manning, T. Li, A. Blackwood-Chirchir, R. Bertz", "publication_date": "2009-04-28", "keywords": ""}, {"pubmed_id": "19381453", "title": "Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.", "authors": "K. Kelly, R. Swords, D. Mahalingam, S. Padmanabhan, FJ. Giles", "publication_date": "2009-04-22", "keywords": ""}, {"pubmed_id": "19373652", "title": "Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.", "authors": "S. Ocheni, GB. Iwanski, P. Schafhausen, AR. Zander, F. Ayuk, E. Klyuchnikov, T. Zabelina, W. Fiedler, S. Schnittger, A. Hochhaus, TH. Br\u00fcmmendorf, N. Kr\u00f6ger, U. Bacher", "publication_date": "2009-04-18", "keywords": ""}, {"pubmed_id": "19370179", "title": "Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach.", "authors": "SK. Pal, RK. Gupta, G. Dosik, RA. Figlin", "publication_date": "2009-04-17", "keywords": "Imatinib, bevacizumab, chronic myelogenous leukemia, erlotinib, renal cell carcinoma"}, {"pubmed_id": "19369231", "title": "Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.", "authors": "H. Kantarjian, J. Cortes, DW. Kim, P. Dorlhiac-Llacer, R. Pasquini, J. DiPersio, MC. M\u00fcller, JP. Radich, HJ. Khoury, N. Khoroshko, MB. Bradley-Garelik, C. Zhu, MS. Tallman", "publication_date": "2009-04-17", "keywords": ""}, {"pubmed_id": "19363859", "title": "Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.", "authors": "A. Sun, RS. Akin, E. Cobos, J. Smith", "publication_date": "2009-04-15", "keywords": ""}, {"pubmed_id": "19357815", "title": "The toxicities of modern targeted therapies: learning from the price of progress.", "authors": "FJ. Giles", "publication_date": "2009-04-10", "keywords": ""}, {"pubmed_id": "19337199", "title": "Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.", "authors": "KL. McFarland, GA. Wetzstein", "publication_date": "2009-04-02", "keywords": ""}, {"pubmed_id": "19337197", "title": "Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.", "authors": "MJ. Mauro", "publication_date": "2009-04-02", "keywords": ""}, {"pubmed_id": "19336654", "title": "Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.", "authors": "T. Tyler", "publication_date": "2009-04-02", "keywords": ""}, {"pubmed_id": "19306355", "title": "First-line therapy for chronic myeloid leukemia: Past, present, and future.", "authors": "C. Pavlovsky, H. Kantarjian, JE. Cortes", "publication_date": "2009-03-24", "keywords": ""}, {"pubmed_id": "19296866", "title": "Protein kinase inhibitors: contributions from structure to clinical compounds.", "authors": "LN. Johnson", "publication_date": "2009-03-20", "keywords": ""}, {"pubmed_id": "19295545", "title": "Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.", "authors": "S. Mustjoki, M. Ekblom, TP. Arstila, I. Dybedal, PK. Epling-Burnette, F. Guilhot, H. Hjorth-Hansen, M. H\u00f6glund, P. Kovanen, T. Laurinolli, J. Liesveld, R. Paquette, J. Pinilla-Ibarz, A. Rauhala, N. Shah, B. Simonsson, M. Sinisalo, JL. Steegmann, L. Stenke, K. Porkka", "publication_date": "2009-03-20", "keywords": ""}, {"pubmed_id": "19280591", "title": "Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.", "authors": "A. Quint\u00e1s-Cardama, H. Kantarjian, F. Ravandi, S. O'Brien, D. Thomas, G. Vidal-Senmache, W. Wierda, S. Kornblau, J. Cortes", "publication_date": "2009-03-13", "keywords": ""}, {"pubmed_id": "19275507", "title": "New approved dasatinib regimen available for clinical use.", "authors": "DS. Snyder", "publication_date": "2009-03-12", "keywords": ""}, {"pubmed_id": "19263190", "title": "Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "H. Sakamaki, KI. Ishizawa, M. Taniwaki, S. Fujisawa, Y. Morishima, K. Tobinai, M. Okada, K. Ando, N. Usui, S. Miyawaki, A. Utsunomiya, N. Uoshima, T. Nagai, T. Naoe, T. Motoji, I. Jinnai, M. Tanimoto, Y. Miyazaki, K. Ohnishi, S. Iida, S. Okamoto, T. Seriu, R. Ohno", "publication_date": "2009-03-06", "keywords": ""}, {"pubmed_id": "19254885", "title": "Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.", "authors": "A. Quint\u00e1s-Cardama, JE. Cort\u00e9s, H. Kantarjian", "publication_date": "2009-03-04", "keywords": ""}, {"pubmed_id": "19236716", "title": "New dosing schedules of dasatinib for CML and adverse event management.", "authors": "SF. Wong", "publication_date": "2009-02-25", "keywords": ""}, {"pubmed_id": "19195046", "title": "Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.", "authors": "HJ. Khoury, F. Guilhot, TP. Hughes, DW. Kim, JE. Cortes", "publication_date": "2009-02-06", "keywords": ""}, {"pubmed_id": "19181650", "title": "Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?", "authors": "E. Jabbour, JE. Cortes, HM. Kantarjian", "publication_date": "2009-02-03", "keywords": ""}, {"pubmed_id": "21082998", "title": "Role of gene-expression profiling in chronic myeloid leukemia.", "authors": "S. Schmidt, D. Wolf", "publication_date": "2009-02-01", "keywords": ""}, {"pubmed_id": "19131559", "title": "Dasatinib induces a response in chronic lymphocytic leukemia.", "authors": "V. Pitini, C. Arrigo, G. Altavilla", "publication_date": "2009-01-10", "keywords": ""}, {"pubmed_id": "19104491", "title": "Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.", "authors": "D. Mattei, M. Feola, F. Orzan, N. Mordini, D. Rapezzi, A. Gallamini", "publication_date": "2008-12-24", "keywords": ""}, {"pubmed_id": "19101781", "title": "Chronic myeloid leukemia in Asia.", "authors": "WY. Au, PB. Caguioa, C. Chuah, SC. Hsu, S. Jootar, DW. Kim, IY. Kweon, WM. O'Neil, TK. Saikia, J. Wang", "publication_date": "2008-12-23", "keywords": ""}, {"pubmed_id": "19093165", "title": "Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.", "authors": "MR. de Mello Conchon, I. Bendit, P. Ferreira, W. Lima, C. Kumeda, L. Dias, D. de Alencar Fischer Chamone, PE. Dorlhiac-Llacer", "publication_date": "2008-12-19", "keywords": ""}, {"pubmed_id": "19092801", "title": "Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy.", "authors": "G. Martinelli, S. Soverini, I. Iacobucci, M. Baccarani", "publication_date": "2008-12-19", "keywords": ""}, {"pubmed_id": "19075651", "title": "Targeted drugs in chronic myeloid leukemia.", "authors": "J. Gora-Tybor, T. Robak", "publication_date": "2008-12-17", "keywords": ""}, {"pubmed_id": "19066329", "title": "Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.", "authors": "DH. Kim, S. Kamel-Reid, H. Chang, R. Sutherland, CW. Jung, HJ. Kim, JJ. Lee, JH. Lipton", "publication_date": "2008-12-11", "keywords": ""}, {"pubmed_id": "18986703", "title": "Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.", "authors": "C. Ustun, CL. Corless, N. Savage, W. Fiskus, E. Manaloor, MC. Heinrich, G. Lewis, P. Ramalingam, I. Kepten, A. Jillella, K. Bhalla", "publication_date": "2008-11-07", "keywords": ""}, {"pubmed_id": "18986702", "title": "Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.", "authors": "W. Rasheed, B. Flaim, JF. Seymour", "publication_date": "2008-11-07", "keywords": ""}, {"pubmed_id": "18978822", "title": "Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.", "authors": "A. Quint\u00e1s-Cardama, J. Cortes", "publication_date": "2008-11-04", "keywords": ""}, {"pubmed_id": "18956997", "title": "Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.", "authors": "A. Jarkowski, RP. Sweeney", "publication_date": "2008-10-30", "keywords": ""}, {"pubmed_id": "18835038", "title": "Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.", "authors": "SA. Holstein, JB. Stokes, RJ. Hohl", "publication_date": "2008-10-07", "keywords": ""}, {"pubmed_id": "18833925", "title": "[Management of chronic myeloid leukemia].", "authors": "Y. Kubuki", "publication_date": "2008-10-07", "keywords": ""}, {"pubmed_id": "18829412", "title": "[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].", "authors": "P. Cony-Makhoul, A. Bergeron, S. Corm, V. Dubruille, D. Rea, F. Rigal-Huguet, FE. Nicolini", "publication_date": "2008-10-03", "keywords": ""}, {"pubmed_id": "18818391", "title": "Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.", "authors": "E. Jabbour, HM. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, J. Cortes", "publication_date": "2008-09-27", "keywords": ""}, {"pubmed_id": "18761212", "title": "Dasatinib-induced lupus.", "authors": "D. Rea, A. Bergeron, C. Fieschi, D. Bengoufa, E. Oksenhendler, H. Dombret", "publication_date": "2008-09-02", "keywords": ""}, {"pubmed_id": "18754032", "title": "Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.", "authors": "J. Cortes, DW. Kim, E. Raffoux, G. Martinelli, E. Ritchie, L. Roy, S. Coutre, S. Corm, N. Hamerschlak, JL. Tang, A. Hochhaus, HJ. Khoury, TH. Br\u00fcmmendorf, M. Michallet, G. Rege-Cambrin, C. Gambacorti-Passerini, JP. Radich, T. Ernst, C. Zhu, JM. Van Tornout, M. Talpaz", "publication_date": "2008-08-30", "keywords": ""}, {"pubmed_id": "18753186", "title": "Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.", "authors": "SF. Wong", "publication_date": "2008-08-30", "keywords": ""}, {"pubmed_id": "18608866", "title": "Dasatinib-induced acute hepatitis.", "authors": "A. Bonvin, A. Mesnil, FE. Nicolini, L. Cotte, M. Michallet, J. Descotes, T. Vial", "publication_date": "2008-07-09", "keywords": ""}, {"pubmed_id": "18596746", "title": "Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.", "authors": "A. Shimoni, M. Leiba, M. Schleuning, G. Martineau, M. Renaud, M. Koren-Michowitz, E. Ribakovski, P. le Coutre, R. Arnold, F. Guilhot, A. Nagler", "publication_date": "2008-07-04", "keywords": ""}, {"pubmed_id": "18577747", "title": "Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.", "authors": "J. Wu, F. Meng, LY. Kong, Z. Peng, Y. Ying, WG. Bornmann, BG. Darnay, B. Lamothe, H. Sun, M. Talpaz, NJ. Donato", "publication_date": "2008-06-26", "keywords": ""}, {"pubmed_id": "18559612", "title": "Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.", "authors": "S. Verstovsek, A. Tefferi, J. Cortes, S. O'Brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, H. Kantarjian", "publication_date": "2008-06-19", "keywords": ""}, {"pubmed_id": "18541900", "title": "Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.", "authors": "NP. Shah, HM. Kantarjian, DW. Kim, D. R\u00e9a, PE. Dorlhiac-Llacer, JH. Milone, J. Vela-Ojeda, RT. Silver, HJ. Khoury, A. Charbonnier, N. Khoroshko, RL. Paquette, M. Deininger, RH. Collins, I. Otero, T. Hughes, E. Bleickardt, L. Strauss, S. Francis, A. Hochhaus", "publication_date": "2008-06-11", "keywords": ""}, {"pubmed_id": "18518762", "title": "Current status of therapy for chronic myeloid leukemia: a review of drug development.", "authors": "S. Padmanabhan, S. Ravella, T. Curiel, F. Giles", "publication_date": "2008-06-04", "keywords": ""}, {"pubmed_id": "18472616", "title": "Management of patients with resistant or refractory chronic myelogenous leukemia.", "authors": "A. Quint\u00e1s-Cardama, J. Cortes", "publication_date": "2008-05-14", "keywords": ""}, {"pubmed_id": "18465678", "title": "Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.", "authors": "A. Quint\u00e1s-Cardama, J. Cortes", "publication_date": "2008-05-10", "keywords": ""}, {"pubmed_id": "18463676", "title": "Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.", "authors": "G. Caocci, S. Atzeni, N. Orr\u00f9, L. Azzena, L. Martorana, R. Littera, A. Ledda, G. La Nasa", "publication_date": "2008-05-09", "keywords": ""}, {"pubmed_id": "18462793", "title": "Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.", "authors": "A. Bajel, S. Bassili, JF. Seymour", "publication_date": "2008-05-09", "keywords": ""}, {"pubmed_id": "18452422", "title": "Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.", "authors": "M. Sonmez, U. Cobanoglu, E. Ovali, SB. Omay", "publication_date": "2008-05-03", "keywords": ""}, {"pubmed_id": "18346528", "title": "Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.", "authors": "FJ. Giles, DJ. DeAngelo, M. Baccarani, M. Deininger, F. Guilhot, T. Hughes, M. Mauro, J. Radich, O. Ottmann, J. Cortes", "publication_date": "2008-05-03", "keywords": ""}, {"pubmed_id": "18348294", "title": "Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.", "authors": "E. Jabbour, JE. Cortes, HM. Kantarjian", "publication_date": "2008-03-19", "keywords": ""}, {"pubmed_id": "18331365", "title": "Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.", "authors": "H. de Lavallade, S. Punnialingam, D. Milojkovic, M. Bua, JS. Khorashad, IH. Gabriel, A. Chaidos, E. Olavarria, JM. Goldman, JF. Apperley, D. Marin", "publication_date": "2008-03-12", "keywords": ""}, {"pubmed_id": "18252160", "title": "[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].", "authors": "OW. Bjerrum, IH. Dufva, J. Stentoft, HC. Hasselbalch", "publication_date": "2008-02-07", "keywords": ""}, {"pubmed_id": "18223208", "title": "Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.", "authors": "M. Brave, V. Goodman, E. Kaminskas, A. Farrell, W. Timmer, S. Pope, R. Harapanhalli, H. Saber, D. Morse, J. Bullock, A. Men, C. Noory, R. Ramchandani, L. Kenna, B. Booth, J. Gobburu, X. Jiang, R. Sridhara, R. Justice, R. Pazdur", "publication_date": "2008-01-29", "keywords": ""}, {"pubmed_id": "18215092", "title": "Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "SJ. Keam", "publication_date": "2008-01-25", "keywords": ""}, {"pubmed_id": "18158072", "title": "Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.", "authors": "M. Steinberg", "publication_date": "2007-12-26", "keywords": ""}, {"pubmed_id": "18067026", "title": "Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).", "authors": "R. Garc\u00eda-Mu\u00f1oz, A. Galar, C. Moreno, P. Rodr\u00edguez-Otero, E. Panizo-Morgado, M. Ponz-Sarvis\u00ea, M. Fernandez-Alonso, M. Rubio, J. Merino, B. Cuesta, C. Panizol, F. Prosper", "publication_date": "2007-12-11", "keywords": ""}, {"pubmed_id": "18067004", "title": "Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?", "authors": "HA. Torres, RF. Chemaly", "publication_date": "2007-12-11", "keywords": ""}, {"pubmed_id": "18056932", "title": "Targeted chronic myeloid leukemia therapy: Seeking a cure.", "authors": "C. Fausel", "publication_date": "2007-12-11", "keywords": ""}, {"pubmed_id": "18056929", "title": "Leukemia. Q&A highlights.", "authors": "D. Frame, J. Sessions, C. Fausel", "publication_date": "2007-12-11", "keywords": ""}, {"pubmed_id": "18056928", "title": "Chronic myeloid leukemia. Introduction.", "authors": "D. Frame", "publication_date": "2007-12-11", "keywords": ""}, {"pubmed_id": "18035968", "title": "Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.", "authors": "A. Hochhaus", "publication_date": "2007-11-27", "keywords": ""}, {"pubmed_id": "18034600", "title": "Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.", "authors": "J. Brandwein", "publication_date": "2007-11-24", "keywords": ""}, {"pubmed_id": "18024653", "title": "Medical management of CML.", "authors": "NP. Shah", "publication_date": "2007-11-21", "keywords": ""}, {"pubmed_id": "18020922", "title": "Management of Bcr-Abl-positive leukemias with dasatinib.", "authors": "A. Hochhaus", "publication_date": "2007-11-21", "keywords": ""}, {"pubmed_id": "17964981", "title": "[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].", "authors": "X. Thomas", "publication_date": "2007-10-30", "keywords": ""}, {"pubmed_id": "17824574", "title": "What's blasting off in CML?", "authors": "P. Oestreicher", "publication_date": "2007-09-11", "keywords": ""}, {"pubmed_id": "17761974", "title": "Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.", "authors": "A. Quint\u00e1s-Cardama, H. Kantarjian, S. O'brien, G. Borthakur, J. Bruzzi, R. Munden, J. Cortes", "publication_date": "2007-09-01", "keywords": ""}, {"pubmed_id": "17720881", "title": "Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.", "authors": "U. Rix, O. Hantschel, G. D\u00fcrnberger, LL. Remsing Rix, M. Planyavsky, NV. Fernbach, I. Kaupe, KL. Bennett, P. Valent, J. Colinge, T. K\u00f6cher, G. Superti-Furga", "publication_date": "2007-08-28", "keywords": ""}, {"pubmed_id": "17694781", "title": "Drugs offer new hope for patients with CML who are resistant to imatinib.", "authors": "P. Oestreicher", "publication_date": "2007-08-19", "keywords": ""}, {"pubmed_id": "17684099", "title": "The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.", "authors": "O. Hantschel, U. Rix, U. Schmidt, T. B\u00fcrckst\u00fcmmer, M. Kneidinger, G. Sch\u00fctze, J. Colinge, KL. Bennett, W. Ellmeier, P. Valent, G. Superti-Furga", "publication_date": "2007-08-09", "keywords": ""}, {"pubmed_id": "17665323", "title": "American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.", "authors": "K. Walker, A. Kibble, J. Shumoogam", "publication_date": "2007-08-01", "keywords": ""}, {"pubmed_id": "17634461", "title": "BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.", "authors": "CA. Schiffer", "publication_date": "2007-07-20", "keywords": ""}, {"pubmed_id": "17600277", "title": "Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.", "authors": "A. Bergeron, D. R\u00e9a, V. Levy, C. Picard, V. Meignin, J. Tamburini, H. Bruzzoni-Giovanelli, F. Calvo, A. Tazi, P. Rousselot", "publication_date": "2007-06-30", "keywords": ""}, {"pubmed_id": "17510013", "title": "New drugs: paliperidone, dasatinib, and decitabine.", "authors": "DA. Hussar", "publication_date": "2007-05-19", "keywords": ""}, {"pubmed_id": "17496201", "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.", "authors": "O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, RA. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, AM. Apanovitch, A. Gollerkeri, S. Coutre", "publication_date": "2007-05-15", "keywords": ""}, {"pubmed_id": "17496200", "title": "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.", "authors": "T. O'Hare, CA. Eide, MW. Deininger", "publication_date": "2007-05-15", "keywords": ""}, {"pubmed_id": "17426060", "title": "The role of Src in prostate cancer.", "authors": "K. Fizazi", "publication_date": "2007-04-12", "keywords": ""}, {"pubmed_id": "17382019", "title": "Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.", "authors": "E. Atallah, H. Kantarjian, J. Cortes", "publication_date": "2007-03-27", "keywords": ""}, {"pubmed_id": "17373201", "title": "A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.", "authors": "N. Scheinfeld", "publication_date": "2007-03-22", "keywords": ""}, {"pubmed_id": "17264298", "title": "Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.", "authors": "F. Guilhot, J. Apperley, DW. Kim, EO. Bullorsky, M. Baccarani, GJ. Roboz, S. Amadori, CA. de Souza, JH. Lipton, A. Hochhaus, D. Heim, RA. Larson, S. Branford, MC. Muller, P. Agarwal, A. Gollerkeri, M. Talpaz", "publication_date": "2007-02-01", "keywords": ""}, {"pubmed_id": "17220814", "title": "Dasatinib (Sprycel) for CML and Ph + ALL.", "authors": "", "publication_date": "2007-01-16", "keywords": ""}, {"pubmed_id": "17185463", "title": "Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.", "authors": "J. Cortes, P. Rousselot, DW. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, O. Ottmann, N. Shah, P. Erben, S. Branford, P. Agarwal, A. Gollerkeri, M. Baccarani", "publication_date": "2006-12-23", "keywords": ""}, {"pubmed_id": "17138817", "title": "Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.", "authors": "A. Hochhaus, HM. Kantarjian, M. Baccarani, JH. Lipton, JF. Apperley, BJ. Druker, T. Facon, SL. Goldberg, F. Cervantes, D. Niederwieser, RT. Silver, RM. Stone, TP. Hughes, MC. Muller, R. Ezzeddine, AM. Countouriotis, NP. Shah", "publication_date": "2006-12-02", "keywords": ""}, {"pubmed_id": "17106016", "title": "Novel treatment strategies for chronic myeloid leukemia.", "authors": "CA. Fausel", "publication_date": "2006-11-16", "keywords": ""}, {"pubmed_id": "16990603", "title": "MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.", "authors": "FJ. Giles, J. Cortes, D. Jones, D. Bergstrom, H. Kantarjian, SJ. Freedman", "publication_date": "2006-09-23", "keywords": ""}, {"pubmed_id": "16990591", "title": "Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.", "authors": "A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, J. Cortes", "publication_date": "2006-09-23", "keywords": ""}, {"pubmed_id": "16957155", "title": "Dasatinib in chronic myelogenous leukemia.", "authors": "SK. Kathula", "publication_date": "2006-09-08", "keywords": ""}, {"pubmed_id": "20425345", "title": "Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.", "authors": "JA. Zonder, CA. Schiffer", "publication_date": "2006-09-01", "keywords": ""}, {"pubmed_id": "16840219", "title": "Dasatinib-related alveolar pneumonia responsive to corticosteroids.", "authors": "F. Radaelli, S. Bramanti, NN. Fantini, G. Fabio, I. Greco, G. Lambertenghi-Deliliers", "publication_date": "2006-07-15", "keywords": ""}, {"pubmed_id": "16775249", "title": "Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.", "authors": "S. Assouline, P. Laneuville, C. Gambacorti-Passerini", "publication_date": "2006-06-16", "keywords": ""}, {"pubmed_id": "16775234", "title": "Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.", "authors": "M. Talpaz, NP. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'Brien, C. Nicaise, E. Bleickardt, MA. Blackwood-Chirchir, V. Iyer, TT. Chen, F. Huang, AP. Decillis, CL. Sawyers", "publication_date": "2006-06-16", "keywords": ""}, {"pubmed_id": "16542059", "title": "Dasatinib: BMS 354825.", "authors": "", "publication_date": "2006-03-18", "keywords": ""}, {"pubmed_id": "16304378", "title": "Loss of response to imatinib: mechanisms and management.", "authors": "NP. Shah", "publication_date": "2005-11-24", "keywords": ""}, {"pubmed_id": "16235580", "title": "Chronic myelogenous leukemia.", "authors": "J. D'Antonio", "publication_date": "2005-10-21", "keywords": ""}, {"pubmed_id": "15751154", "title": "Oral BMS-354825 rescues Gleevec-resistant CML.", "authors": "", "publication_date": "2005-03-09", "keywords": ""}, {"pubmed_id": "15450235", "title": "New generation leukaemia drugs are on their way.", "authors": "L. Nelson", "publication_date": "2004-09-29", "keywords": ""}]}